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 Summary	  Abstract	  
Background: 
Type 2 diabetes mellitus (T2DM) is characterised by increased rates of morbidity and 
mortality, much of which is related to cardiovascular disease. T2DM is considered to be 
a non-communicable disease, with its cause and aetiology linked to a number of genetic 
factors, which are influenced by dietary behaviours and lifestyle. Diet has a significant 
role to play in the prevention and management of T2DM. Both in vitro and in vivo 
studies suggest that plant flavanols may have beneficial effects for people with diabetes, 
including potentially those found in cocoa and chocolate. 
Cesar Fraga suggested in 2005 that perhaps we should eat more chocolate to prevent 
and manage diabetes, following a study of just 15 healthy individuals, which 
demonstrated improvements in insulin sensitivity and blood pressure. Despite this 
remark seven years ago, almost no work has been published outside of that presented in 
this thesis has investigated the effect of chocolate containing only its native flavanols 
(predominantly epicatechins) on glycaemic control and markers of cardiovascular risk 
in T2DM. 
 
Methodology: 
An exploratory review of the literature suggested that the effect of chocolate might be 
greater than that seen with cocoa. This thesis considered the published literature to 
ascertain whether chocolate provides greater efficacy over cocoa supplementation using 
a meta-analysis. This led into a series of clinical trials aimed at testing chocolate 
supplementation at levels which provide an adequate dose of flavanols without leading 
to excess energy or sugar intake. The first of the three studies consisted of a proof of 
concept study feeding 45g of chocolate over eight weeks in a double-blinded 
randomised crossover design (n=12). The second, using 13.5g again used a double-
blinded randomised crossover design to assess the acute effects of flavanols rich 
chocolate over a three-hour period in individuals with T2DM with an induced transient 
hyperglycaemia caused by a 75g oral glucose load (n=10). The final clinical trial was a 
three-arm randomised double-blinded parallel study aimed to investigate the effects 
over a 12-week period of milk chocolate enriched with flavanols in an attempt to 
maximise palatability. 
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Results: 
The exploratory review with meta-analysis demonstrated that chocolate 
supplementation resulted in significantly greater reduction in blood pressure (both 
systolic and diastolic, sub-group analysis, p<0.05) compared to cocoa supplementation. 
Cocoa was significantly more effective at reducing LDL cholesterol (p=0.02). The key 
difference between studies which used chocolate (38.8±13.1%) and those which used 
cocoa (68.2±13.8%) was the chocolate used in trials appeared to have significantly 
lower percentage energy from carbohydrate  (p<0.001). 
The pilot study provided 45g of chocolate for 8 weeks, had no adverse effects on weight 
or glycaemia despite it providing an additional daily energy content of 1.03Mj 
(246kcal). HDL cholesterol improved following consumption of high flavanols 
chocolate (p=0.05) with HDL cholesterol: total cholesterol significantly falling 
(p=0.04). 
The provision of 13.5g of flavanols rich chocolate prior to a 75g oral glucose load, 
resulted in improved endothelial function, measured by Reactive Hyperaemia- 
Peripheral Artery Tonography (RH-PAT) as a functional measure and adhesion 
molecules (P>0.05). This effect was accompanied by a simultaneous reduction in 
urinary 15-F2t-isoprostane (a marker of oxidative stress). 
The final study using a milk chocolate and lower doses of epicatechin did not have an 
adverse effect on weight or glycaemia after 12 weeks, with participants actually gaining 
weight in the four weeks immediately after the completion of the study (p=0.002). No 
clear beneficial effects of any one chocolate were seen.  
 
Conclusion: 
The work in this thesis finally provides evidence to support Fraga’s suggestion, that 
there are benefits in terms of improved lipid profile and endothelial function with 
chocolate supplementation for individuals with T2DM. The equivocal results from the 
final study which used a chocolate containing about a third of the epicatechin dose of 
the first two studies, suggest that the dose required for benefit may be at least that 
accepted as being beneficial with respect of endothelial function (EFSA, 2012a) at 
200mg of flavanols in the general population for individuals with T2DM.
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Chapter	  One:	  Introduction	  -­‐	  Metabolic	  Syndrome	  in	  Type	  2	  
Diabetes	  Mellitus	  and	  its	  Nutritional	  Management	  
This thesis considers the potential benefits and risks of consuming chocolate rich in 
flavanols for individuals with type 2 diabetes mellitus (T2DM). In 2005 Cesar Fraga in 
the American Journal of Clinical Nutrition suggested that we should consume more 
cocoa and chocolate to reduce the burdens of hypertension and diabetes (Fraga, 2005). 
This article was an editorial reporting on a small study of 15 healthy individuals by 
Grassi et al. (2005a). This represented the emergence of a hypothesis, which fuelled a 
body of work that has suggested chocolate may reduce blood pressure. This began with 
a study by Taubert et al. (2003) which suggested a beneficial effect upon blood pressure 
and culminated with a series of meta-analyses (Taubert, Roesen & Schomig, 2007; 
Ding, Hutfless, Ding & Girotra, 2006; Ried et al., 2010a; Desch et al., 2010a; Shrime et 
al., 2011; Hooper, et al., 2012) which have been consistent in their support of the theory 
that cocoa and chocolate have beneficial effects upon blood pressure, lipid profile and 
potentially insulin resistance. However, with respect to the effects of chocolate and 
cocoa in individuals with diabetes, there have been very few studies (Balzer et al., 2008; 
Curtis et al., 2012).  
This chapter will initially describe the condition, of T2DM and then develop the case 
for the use of chocolate as part of a dietary regimen for this patient group. With the 
longest intervention including chocolate being one year in duration, there are no data 
with respect to hard clinical endpoints, including death or myocardial infarctions. Data 
from a variety of biomarkers or surrogate endpoints will be used to assess the effects of 
chocolate and cocoa interventions. In addition to the effect of these biomarkers on 
future risk, in terms of safety, the measures used in the clinical management of diabetes 
will also be considered. 
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Overview	  of	  Chapter	  
Aims and Scope of Chapter: 
• To consider T2DM as a chronic condition, including its diagnosis and its 
implications to the individual and in terms of public health. 
• To review nutritional management of T2DM. 
• To consider the evidence for the potential benefits of cocoa and chocolate as part 
of the nutritional management of individuals with diabetes mellitus by 
considering the underlying potential mechanisms, epidemiology and clinical trial 
data. 
To address these aims, this chapter is split into five sections: 
1.1 – An introduction to T2DM as a clinical condition, including its 
 definition and the burden it represents on global health. 
1.2 – Review of the evidence for the nutritional management of diabetes 
 mellitus, with a particular focus upon the dietary influences on 
 cardiovascular disease risk. 
1.3 – The history and potential health benefits of cocoa and chocolate, 
 including a review of the biological effects of polyphenols.  
1.4 – A review using systematic methodologies of the evidence from in 
vitro experiments, epidemiological data, clinical trials in publication and 
print until the end of June 2012 (an exploratory review with meta-
analysis of these data will form Chapter Three). 
1.5 – The aims, objectives and hypothesis of the experimental work of 
 the thesis. 
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1.1–	  Type	  2	  Diabetes	  Mellitus	  	  
1.1.1	  -­‐	  Global	  Burden	  of	  Diabetes	  Mellitus	  and	  Metabolic	  Syndrome	  
Diabetes Mellitus is the first non-communicable disease to obtain a United Nations 
(UN) resolution to grant its own global day, akin to communicable diseases including 
HIV/AIDS (UN Resolution 61/225) (United Nations 2007, Silink 2007). This was in 
response to the increasing burden and epidemic of diabetes globally. According to the 
latest International Diabetes Federation (IDF) Diabetes Atlas (IDF, 2011), diabetes was 
responsible for 4.6 million deaths annually worldwide, or one death every seven 
seconds. Approximately half of these deaths were also associated with cardiovascular 
disease, the most common complication of diabetes. This has led to the view that 
diabetes could potentially lead to a failure to achieve the Millennium Development 
goals, and could lead to a global failure of public health (Silink, 2007).  
In an attempt to reduce the burden of cardiovascular disease in England attributable to 
diabetes, the National Health Service through its contractual system with primary care 
clinicians has set a number of cardiovascular associated targets (Information Centre, 
2011). Attached to these are financial incentives linked to their implementation (Simon, 
2008). The current system is an example of the evolution of care over the last decade. 
Initially, care objectives were based upon the National Service Framework (NSF) for 
Diabetes (Department of Health, 2001). These have since evolved based upon best 
practice recommendations and guidelines developed through the National Institute for 
Health and Clinical Excellence (NICE) including Clinical Guidance 66 (NICE, 2008). 
This has latterly been supported by NHS Diabetes, in conjunction with the Yorkshire 
and Humber Public Health Observatory who are the national lead for diabetes (NHS 
Diabetes, 2012). 
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Further support for the development of clinical targets in the management of diabetes 
mellitus, has been associated with evidence of reduced cardiovascular disease if these 
targets are achieved (Perk et al., 2012). In practice, targets focus on the assessment of a 
small number of biomarkers, which are acknowledged as accounting for a large 
proportion of the risk.  
The most commonly assessed markers include hyperglycaemia (raised plasma glucose 
and glycosylated haemoglobin (HbA1c)), hypertension (raised blood pressure) and the 
biochemical assessment of lipids (plasma fat levels), especially cholesterol 
(dyslipidaemia). Chronic hyperglycaemia (UKPDS Group 1998a; 1998b) and 
hypertension (UKPDS Group 1998b) are associated with increased risk of 
cardiovascular morbidity and mortality. This relationship is extended to cholesterol, 
with a level above the 80th centile being associated with a 52% excess risk compared to 
the bottom quintile (Michael et al., 1986). 
The abnormal changes in these risk factors are a common feature of T2DM (Turner et 
al., 1998), but are not exclusive to diabetes (Alberti, Zimmet, Shaw & Grundy, 2006). 
When not associated with T2DM, the clustering together of these risk factors has been 
labelled as the metabolic syndrome (also described as Syndrome X, Cardio-metabolic 
syndrome, Pre-diabetes and Reaven’s Syndrome) (Alberti & Zimmet 1998; Alberti et al. 
2006;  Alberti et al. 2009; Grundy et al. 2004; Reaven, 1991).	  	  
1.1.2	  -­‐	  Diagnosis	  and	  Classification	  of	  Diabetes	  Mellitus	  
A number of classifications of diabetes have been developed, accepted and then revised 
based upon the emergence of new evidence over the past fifty years (John, 2012). The 
universal characteristic of all types of diabetes mellitus is persistent hyperglycaemia; the 
definitions of which have been revised over time in line with emergence of new data. 
The derivation of the name of the condition comes from the Greek and can literally be 
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translated as “honey syphon”; a reference to the glycosuria often seen as a feature of 
diabetes, which, in ancient times was diagnosed by tasting the urine of the patient. 
The most widely accepted diagnostic criteria were these set out by the World Health 
Organisation (WHO) and IDF consultation in 2006 (WHO/IDF, 2006). The WHO 
diagnostic criteria (table 1.1.2), define the stages of glycaemia from normal, through 
impaired and intermediate states to diabetes although, additionally it is now 
acknowledged that HbA1c > 48mmol/l (6.5%) is emerging as a new diagnostic criteria 
for diabetes (WHO, 2011; John, 2012). However HbA1c below this level do not 
exclude diabetes diagnosed using glucose levels (WHO, 2011), so interpretation needs 
to be undertaken with caution. Moreover, as the recruitment to the interventional studies 
presented in this thesis was completed prior to the suggested new diagnostic criteria, 
elevated glucose will be the focus of this discussion. 
Table 1.1.2: WHO/IDF classifications of normoglycaemia, intermediate hyperglycaemia and 
diabetes mellitus. (WHO/ IDF, 2006). 
Definition Fasting Glucose (mmol/l) 
2 hour reading following a 75g 
glucose load  (Oral Glucose 
Tolerance Test) 
Normal/ 
Normoglycaemia 
ADA - <5.5mmol/l 
WHO - <6.0 mmol/l 
ADA and WHO - <7.8 mmo/l 
Impaired 
Fasting Intermediate 
glycaemia 
ADA - 5.5-6.9 mmol/l 
WHO – 6.0-6.9 mmol/l 
ADA and WHO - <11.1mmol/l 
May also include impaired glucose 
tolerance 
Impaired 
Glucose 
Tolerance 
ADA and WHO - <7.0 mmol/l 
May also include impaired 
fasting glucose 
ADA and WHO – 7.8-11.1mmol/l 
Diabetes Mellitus ADA and WHO ≥7.0 mmol/l ADA and WHO ≥ 11.1 mmol/l 	  
There has been a gradual evolution in the diagnostic criteria of diabetes mellitus, 
possibly representative of a shift in clinical focus over that time. This has seen a move 
from the aim of reducing the risk of developing diabetic retinopathy (Kadowaki et al., 
1984),  towards a focus upon reducing cardiovascular risk (Coutinho, Gerstein, Wang & 
Yusuf, 1999). The move from microvascular to macrovascular risk has also led to the 
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shift in diagnostic criteria for diabetes mellitus, from a fasting glucose of ≥7.8mmol/l to 
≥7.0mmol/l in the 1997 Report of the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus (1997).   
It is apparent that hyperglycaemia is responsible for many of the acute features and 
symptoms associated with diabetes mellitus, including thirst polyuria and acute 
complications including infections (e.g. balanitis and thrush). This has led to the 
suggestion that the principle pathology in T2DM is hyperglycaemia. However, 
hyperglycaemia is likely to represent the tangible effect of a more fundamental 
pathology related metabolic incompetence, which in turn is associated with insulin 
resistance (Taylor, 2012). The insulin resistance results from a range of associated 
genetic and possibly epigenetic factors which are ‘activated by’ environmental factors, 
the most prominent of these being an obese or overweight phenotype (Weyer, 
Bogardus, Mott & Pratley, 1999) . 
1.1.2.1	  -­‐	  Classification	  of	  glycaemia	  
The WHO avoided classifying any level glycaemia as being the normal range 
(WHO/IDF, 2006). This was based upon the principle that dysglycaemia is merely the 
routinely measurable manifestation of the underlying metabolic abnormality. Instead the 
WHO chose to suggest a point at which risk of developing T2DM and cardiovascular 
risk is considered at its lowest. The alternate perspective may be that this is a reflection 
of the true lack of consensus from the literature of what a normal level of glycaemia 
might truly be. This perspective could be considered for the global aspects of the other 
risk factors for cardiovascular disease. It not only apply to glycaemia, in that the norms 
are defined for blood pressure, lipids or weight, are those where in epidemiology or 
intervention trials the rates of cardiovascular disease were seen at there lowest (Perk et 
al., 2012).  
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Beyond the upper limit of ‘normal’, exist states defined as intermediate 
hyperglycaemia: the level of glycaemia not elevated sufficiently to be considered 
diabetes mellitus (table 1.1.2). These states can be sub-divided into the classifications of 
‘impaired fasting glucose’ (IFG) and ‘impaired glucose tolerance’ (IGT). It is highly 
plausible that ‘IFG and IGT are conditions which may be linked, but represent different 
manifestations of underlying metabolism (Unwin, Shaw, Zimmet & Alberti, 2002).  
Abnormal glucose metabolism based upon fasting criteria suggests an inability of the 
body, either to regulate glucose metabolism in the fasted state and/or a failure to return 
to fasting state metabolism. Thus, implying that endogenous glucose production 
predominantly from the liver (with modest contribution from the kidneys) (Gerich, 
Meyer, Woerle & Stumvoll, 2001) with subsequent exportation into the circulation is 
not adequately regulated. Raised fasting glucose is often associated with excess central 
or visceral adiposity (Gautier et al., 2010) leading to the hypothesis that excess visceral 
adipose tissue has the feature of being metabolically active and contributes to the 
pathology of insulin resistance (Wajchenberg, Nery, Cunha & Silva, 2009).  
The metabolic activity of this adipose tissue may contribute to the futile cycling of 
nutrients and metabolically active compounds which is acknowledged as primary 
feature of insulin resistance (Macfarlane, Forbes & Walker, 2008). This may result in 
ectopic fat deposition in the liver (Taylor, 2008) and pancreas (Lim et al., 2011) adding 
to the insulin resistance and ultimately the dysfunction and decline in insulin 
production, thus linking the genetic and environmental risk factors to dysfunction, 
pathology and ultimately T2DM (Taylor, 2012). 
When the insulin resistance cannot be matched by insulin secretion from the beta cells 
in the Islets of Langerhans’s within the pancreas, elevated glucose levels occur. This 
leads to a states of intermediate hyperglycaemia which then ultimately progresses 
towards diabetes mellitus (Nathan et al., 2007). It is unclear if the dysfunction of control 
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of fasting glucose is entirely linked to a relative lack of insulin, or to an excess of 
counter-regulatory hormones, especially glucagon (Moller, 2001). 
Postprandial glucose, which is most typically defined by a 2 hour plasma measurement 
following an oral glucose load of 75g of anhydrous glucose in 300ml of water (Oral 
Glucose Tolerance Test (OGTT)) can be used to demonstrate the inability of an 
individual to handle an exogenous load of carbohydrate. For this reason, the OGTT is 
the recommended test for impaired fasting glucose and in some cases diabetes (WHO 
/IDF, 2006).  This suggests that in the presence of exogenous glucose, there is an 
inability of the beta cells to respond adequately to an oral load or meal. This may be the 
result of insulin resistance, insulin deficiency or a combination of the two leading to a 
reduction in tissue uptake of glucose by muscle and other tissues. An extension of this 
view is that the pancreas is unable to secrete either adequate or appropriately timed 
levels of insulin in response to a glucose load in the circulating plasma (Weyer et al., 
1999), resulting in dysregulation of post-prandial glucose metabolism. 
1.1.2.2	  -­‐	  Classification	  of	  diabetes	  	  
Diabetes mellitus falls into 4 broad categories as suggested by WHO /IDF (2006): 
   Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
“Other specific types” 
Gestational diabetes mellitus (diabetes first presenting in pregnancy).  
Type 1 diabetes (T1DM) is typified by an absolute lack of insulin, which therefore 
needs replacement therapy, although there may be a temporary period when this 
requirement ceases (known as the “honeymoon period”). Type 1 diabetes mellitus can 
present with ketosis (high levels of ketone bodies in the urine and blood) due to the 
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absolute lack of insulin, which may in turn lead to ketoacidosis, a potentially life 
threatening condition requiring emergency medical intervention.  
Type 2 diabetes mellitus is characterised by its insulin resistance as previously 
described (Section 1.1.2). Despite, two clearly different pathologies, types 1 and 2 
diabetes mellitus are associated with macrovascular and microvascular complications 
(Holman et al. 2008; Nathan 1993). 
The predominant macrovascular complications seen in T1DM and T2DM are those of 
the cardiovascular system. In T1DM these may largely be linked to the degree of 
hyperglycaemia (Nathan et al., 2005). However with T2DM this association may not be 
clearly linked with hyperglycaemia, instead being a complex interaction between 
glycaemia, blood pressure and blood lipids (especially cholesterol and triglycerides). 
This triad of risk factors in turn appear to be influenced by a range of emerging risk 
factors (Anderssohn et al., 2010). These include endothelial dysfunction (Heitzer et al., 
2001), oxidative stress (Ceriello & Motz, 2004; Brownlee, 2001) and pro-inflammatory 
markers (Pfützner & Forst, 2006). These risk factors may be categorised as either 
established or emerging. There has been much debate about whether new risk factors 
add any additional diagnostic or predictive value beyond that provided by the routine 
clinical assessments of glycaemia, lipids and blood pressure (Shishehbor et al., 2008).  
1.1.3	  	  -­‐	  Summary	  of	  the	  Classification	  of	  Type	  2	  Diabetes	  Mellitus	  
Obesity and particularly central obesity (the excess of body fat around the organs of the 
abdomen), are associated with metabolic dysfunction including T2DM (Wannamethee 
& Shaper 1999; Power & Thomas 2011). It is clear that lifestyle factors, especially 
nutrition have a causative function, through ‘over-nutrition’, and are crucial to 
management in the form of dietetic and public health interventions. 
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1.2-­‐	  Nutritional	  Interventions	  Aimed	  at	  Reducing	  Cardiovascular	  
Risk	  in	  Type	  2	  Diabetes	  	  
Type 2 diabetes mellitus, results in a two-fold increased cardiovascular risk in men and 
three-fold increased risk in women (Wilson, 1998). This may in part be managed via the 
manipulation of intake of a range of nutritional factors (He et al., 1999; Ness & Powles, 
1997). For example, cardiovascular disease risk is thought to decrease with a lower 
intake of fat and especially saturated fatty acids and trans-fatty acids (Hunter, Zhang & 
Kris-Etherton, 2010; Mozaffarian et al., 2006). 
Epidemiological evidence suggests that a reduction in refined carbohydrates and in 
particular non-milk extrinsic sugars improves dysglycaemia (Malik et al., 2010). This 
may be in part by the moderation of weight gain and ideally facilitating weight loss, 
thus resulting in lower levels of obesity and a reduction in hypertriglyceridaemia (Malik 
et al., 2010). The nutritional effects of sugar metabolically in individuals with diabetes, 
has arguably been unduly influenced by the work of Peters, Davidson and Eisenberg 
(1990) who suggested that an isocalorific substitution of chocolate cake for potato had 
no effect on glycaemia in individuals with T1DM. This led to a trend within clinical 
practice, which appears to be based on the unsubstantiated extrapolation of this single 
study, lacking direct experimental evidence or mechanism as its basis. In its application 
in T2DM, it ignores the fundamental differences between the underpinning pathologies 
of type 1 and type 2 diabetes mellitus. Where T1DM, is typified by its absolute 
deficiency of insulin; and T2DM is an insulin resistant state with increased counter 
regulation (excess glucagon) leading to increased de novo gluconeogenesis (Jiang & 
Zhang, 2003). 
The effect of this misplaced approach to treatment has resulted in a generation of people 
with diabetes being encouraged to consume foods rich in sugar, such as chocolate, only 
as part of a meal. This piece of advice was based upon the assumption that the starches 
Chapter	  One	  –	  Introduction	  and	  Literature	  Review	  
	  27	  
and fibre in the meal were able to help moderate the hyperglycaemic effects of the sugar 
in the chocolate (Gillespie, 1996). Opinion on the effect of sugars on glycaemia 
dramatically changed with the introduction of the concept of the glycaemic index, and 
of glycaemic loads of carbohydrate containing foods (Jenkins et al., 1981). This concept 
has resulted in the realisation that foods high in carbohydrate and in particular, sugars, 
may have a more modest effect upon blood glucose than might be expected. With the 
National Diet and Nutrition Survey (NDNS, 2012), suggesting that British adults 
consumed 46.5% of the energy intake from carbohydrate, of which 11.4% was in the 
form of non-milk extrinsic sugar (NMES) or added sugar.  This methodology is derived 
from the area under the curve compared to ‘complex carbohydrate’ rich foods, which 
are high in starch and fibre including potatoes and bread, which are also low in sugar 
with foods high in sugar. The methodology compares 50g of carbohydrate from the test 
food with 50g of glucose. This is then used to estimate the relative area under the curve 
compared as a percentage of the area under the curve for glucose. Figure 1.2 shows the 
glycaemic response curve, the glycaemic index is estimated by calculating the area 
under this curve using a trapezoid methodology (Brouns et al., 2005).  
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Figure 1.2: The evaluation of the incremental rise of blood glucose (area under curve) after 
ingestion of a food that contains 50g of carbohydrates, as a percentage of the same amount of 
carbohydrate from a reference food (50g glucose) and absorbed by the same person. The green 
line represents a high glycaemic food and the blue a low glycaemic index food (the dashed red line 
shows the baseline which is taken as the fasting glucose measurement). The area under the blue 
line indicates the area under the curve, this is represented as a percentage of the area under the 
curve of 50g glucose, which is calculated using the trapezoid methodology as described by 
Brouns et al. (2005) 
1.2.1	  –	  Recommendations	  for	  the	  Nutritional	  Management	  of	  Type	  2	  
Diabetes	  Mellitus	  
A recent review of the nutritional management of both type 1 and type 2 diabetes 
mellitus in the United Kingdom was undertaken by the Diabetes UK Nutrition Working 
Group (Dyson et al., 2011), which was in part designed to update the 2003 
recommendations (Connor et al., 2003) and move to a systematic approach in line with 
evidence based practice as is used by the American Dietetic Association (Franz et al., 
2008). The Diabetes UK Nutrition Working Group was composed of dietitians and 
potentially may have led to a bias in their interpretation of the literature. This is 
highlighted by the emphasis placed on use of structured education as a mode of delivery 
which may have represented a professional interest (Deakin, Cade, Williams & 
Greenwood, 2006; Davies et al., 2008). These guidelines included recommendations for 
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the management of diabetes and the cardiovascular risk in T2DM, of which the primary 
focus was weight management. It was noticeable that there were no recommendations 
were made with respect to what the optimal quantities or percentage energy from each 
of the macronutrients including saturated fatty acids and sugars should be, beyond those 
recommended to the general population in the Eat Well Plate (Deptartment of Health, 
2011) (Figure 1.2.1). 
The guidelines also distinguished between the nutritional management of type 1 and 
type 2 diabetes mellitus, which was a change for UK guidelines. These evidence-based 
guidelines actually took account of the lack of insulin in T1DM and assumed that 
hyperglycaemia is the result of abnormalities associated with T2DM. These generally 
recommend a low fat, high carbohydrate diet, which currently is considered to be the 
best way for adults to reduce their risk of nutrition related diseases including 
cardiovascular disease (Department of Health, 1991). 
Figure 1.2.1: Eat Well Plate, Reproduced with acknowledgment of Dept. of Health (2011). 
Reproduced with permission. 
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Table 1.2.1: Current United Kingdom recommendations for macronutrient intakes (excluding 
protein which is expressed as grams per kilogram body weight) from the Report of the Panel on 
Dietary Reference Values of the Committee on Medical Aspects of Food Policy (COMA) 
(Department of Health, 1991) 
Dietary Recommendations 
Total Fat No more than 35% of food energy 
Saturated Fatty 
Acids No more than 11% of food energy 
Total 
Carbohydrate Approximately 50% of food energy 
Sugars 
(Added or NMES) No more than 11% of food energy 
Dietary Fibre 
(Non Starch 
Polysaccharides) 
Average intake of dietary fibre to 18g per day 
Alcohol 
Should not provide more than 5% of energy in the diet. 
Women – should not regularly drink more than 2-3 units of alcohol/day 
Men – should not regularly drink more than 4-5 units of alcohol/day 	  
Weight loss was proposed to be the strongest predictor of a reduction in the risk of 
developing T2DM in individuals who had been identified as being at high risk of 
developing the disorder across a wide range of population groups (Pan et al., 1997; 
Lindstrom et al., 2003; Ramachandran et al., 2006; Orchard et al., 2005). Weight loss of 
5-7% was shown to reduce the risk of progressing to diabetes from impaired glucose 
tolerance by 57%; this was far effective than treatment with metformin (31% reduction 
in risk) (Knowler et al., 2002). The benefits of weight management in individuals who 
are overweight or obese with T2DM (over 90% of cases) are clearly evident.  
The new Diabetes UK guidelines recommend weight management as the primary 
strategy to improve glycaemic control (HbA1c) along with additional improvements in 
reduction of cardiovascular disease risk (Ray et al., 2009). The approach to weight loss 
should be via overall energy reduction, rather than restricting any one macronutrient 
(carbohydrate, fat or protein). However, there were no recommendations for the use of 
supplements or functional foods, except for stanol and sterol esters, which met the 
threshold for evidence with respect to reduction in cholesterol with proven effects upon 
diabetes control or reduction in cardiovascular risk (Dyson et al., 2011). This was likely 
to be the effect of the substantial amount of clinical trial data reporting the effects of 
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stanol and sterol esters (Katan et al., 2003; Abumweis, Barake & Jones, 2008; 
Baumgartner, Messink & Platt, 2011). 
1.2.2	  -­‐	  Potential	  Beneficial	  Effects	  of	  Functional	  Foods	  in	  Type	  2	  Diabetes	  
Although there is no evidence for a functional benefit of foods beyond their nutrient 
composition, this has not stopped a number of foods companies seeking health claims 
related to functionality of nutraceutical qualities. The term nutraceuticals can be traced 
back to the 1980s (Kalra, 2003). The originator of the term appears to be Dr Stephen 
DeFelice, who combined the words ‘nutrition’ and ‘pharmaceutical’ in 1989. The word 
has developed into the accepted international term to describe a food or a food 
component with potentially health improving properties that go beyond those normally 
expected from a food or ingredient. These effects can may be associated with nutrients, 
which have already been defined and accepted as essential for health, or as in most 
cases a bioactive compound, typically a secondary plant metabolite, which have health 
improving benefits.  
The initial difficulty was that there were no regulations or a legal definition for the 
meaning of the term nutraceuticals or the effect which is expected to be seen (Zeisel, 
1999). Subsequently in many countries across the World a number of regulatory 
procedures have been put in place. Within the European Union a range of legislation has 
been passed to create what has come to be known as Article 13, 13.5 and 14 health 
claims for foods (EFSA, n.d.).  
1.2.3	  -­‐	  Methods	  of	  Assessing	  the	  Effect	  of	  Nutritional	  Interventions	  upon	  
Cardiovascular	  Risk	  
Mann (2006), in a review of the evidence supporting lifestyle management of diabetes, 
suggested a number of surrogate markers which could be used to evaluate the strength 
of the evidence reported in nutritional studies for their effect in populations of 
individuals with diabetes. The effect of this was to produce a more concise and 
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clinically focused approach compared to the earlier work of the Process for the 
Assessment of Scientific Support for Claims on Foods (PASSCLAIM) group (Riccardi 
et al., 2004) formed in Europe by the International Life Sciences Institute (ILSI) and 
funded by the European Commission. This work reflected upon the wider aspects of 
body weight regulation and insulin resistance along with diabetes. These 
recommendations have been further developed and updated by the Dietetic Products, 
Nutrition and Allergies (NDA) panel of the European Food Safety Agency (EFSA) 
(EFSA, n.d.). These align with the European Society of Cardiology guidelines (Perk et 
al., 2012) for cardiovascular risk reduction, United Kingdom Diabetes Prevention Study 
(UKPDS) risk engine (Mount, 2007) and the IDF standard and platinum definition of 
metabolic syndrome (Alberti, Zimmet, Shaw & Grundy 2006) (with the addition of 
oxidative stress (Brownlee, 2001; Ceriello & Motz, 2004) which include assessments 
of: 
• Blood Pressure 
• Lipids 
• Insulin resistance and glycaemia  
• Endothelial dysfunction 
• Oxidative Stress 
• Inflammation 
The challenge of nutritional studies, compared with pharmaceutical studies, is often one 
of power, duration and population size. This creates a number of potential 
considerations. Firstly, the surrogate markers, which may be sensitive for larger scale 
pharmaceutical studies, may not have the level of sensitivity or specificity for smaller 
scale studies, which is often the case with nutritional intervention studies. The 
variability of food might also mean that the concept of dose in pharmaceutical studies 
cannot be easily transcribed across. Therefore this can mean that due to the often-
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limited numbers in nutritional interventions, systematic review and meta-analysis 
methodologies are often required to meet the demand for statistical power and 
confidence in the generalizability of the findings of studies. However these may not be 
robust due to the high level of heterogeneity between studies. This can be associated 
with the design, study population or the intervention used.  
Therefore it is clear that there is a need to assess how foods and dietary components 
affect aspects of diabetes and cardiovascular risk. The following section of this thesis 
considers the effects of chocolate rich in polyphenols, especially the flavanols, 
epicatechins, on the six areas of diabetes and cardiovascular risk proposed on the 
previous page. For the purpose of this thesis, polyphenols will initially be discussed as 
the class of compounds. However to reduce the risk of mixed terminology; flavanols 
will be used as the generic term for the polyphenols found in chocolate and cocoa, with 
epicatechin being used when relevant to the literature and data being discussed.   
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1.3-­‐	  Cocoa	  and	  Chocolate;	  History,	  Composition	  and	  Biologically	  
Active	  Compounds	  
1.3.1	  -­‐	  Introduction	  
The Latin name for the cacao tree (Theobroma cacao) the source of cocoa, is widely 
thought to mean 'tree of the Gods'. As such it has been used as a key part of Central 
American culture for over a millennium. This is highlighted by the Mayans who thought 
the gods discovered this tree, which led to its use in religious ceremonies. During this 
time its consumption was highly restrictive, being reserved for the ruling classes and 
priesthood (Dillinger et al., 2000).  
Christopher Columbus first introduced cocoa beans to Europe, where they were thought 
to be mouldy almonds. It was not until later in the 16th and 17th centuries, with the 
increasing colonisation of Central America by the Spanish conquistadors that a greater 
understanding of these practices became apparent. The new colonialists brought monks 
with them, who conducted rudimentary ethnographic studies of the Native Americans 
and chronicled their findings. These documents developed into what have become 
known as codex; they list many potential health benefits of cocoa including an aid to 
digestion, resisting fatigue, helping reduce malnutrition and weakness along with being 
a therapy for cough and possible consumption (tuberculosis) (Pucciarelli & Grivetti, 
2008). This is described below in the following quotation:  
   "The divine drink, which builds up resistance and fights fatigue.  A cup of this 
precious drink [cocoa] permits man to walk for a whole day without food''.  
Aztec Emperor Montezuma II (born c.1480 reigned 1502-1520)  
In (Corti, Flammer, Hollenberg & Luscher, 2009) 
Despite the reported benefits of cocoa, as a foodstuff, it has developed a somewhat 
negative profile in Europe. The cocoa houses of London during the reign of Charles II 
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were seen as places of 'sedition', and equally, in France, attempts were made to ban it as 
a dangerous drug! These legal attempts are suggestive of a biological activity beyond 
what might be expected in a normal food (Mehrinfar & Frishman, 2008). 
The development of chocolate dramatically altered the desire of the general public to 
consume cocoa. The effects of industrialisation and its accompanying inventions has 
allowed the conversion of a bitter, unstable grit containing drink which often had a fatty 
beer-like 'head', to become the smooth sweet, melt in the mouth, solid chocolate seen 
today. This has led to the addition of other ingredients including sugar and dried milk, 
along with varying the quantities of saturated fatty acid rich, cocoa butter. The end 
result could be considered as a product, which is not compatible with dietary 
recommendations, being a rich source of saturated fatty acids and sugar. 
Table 1.3.1: The typical composition of chocolate (Food Standards Agency, 2002) compared to 
dietary recommendations, EFSA (2010a; 2010b) and Department of Health (1991) 
 Typical ‘dark’ 
chocolate 
McCance and 
Widdowson 6th Ed. 
(FSA 2002) (per 100g) 
‘Dark’ 
Chocolate 
Percentage 
energy  
UK Recommendations 
(Health, 1991) 
Male (19-50 years) 
Total energy and 
percentage energy  
EFSA  
Recommendations 
(EFSA, 2010a; 
2010b) 
Percentage energy 
Energy   2050Kj  10600Kj  
Sugar  59g 49% <11%* <10% 
Fat  26g 47% 33% 20-35% 
Saturated 
Fatty Acid  
16.2g 29% 11%* 
* Assuming no 
consumption of alcohol 
As low as possible 
	  
So, with the potential negative nutritional effects of cocoa in the form of chocolate 
based on its high energy content (contributed to by the large amounts of saturated fatty 
acids and sugar), the data available from epidemiological and interventional studies 
were reviewed to assess the potential effect in humans. A review of PubMed (accessed 
30th June 2012) (see Chapter 3 for methodology of literature search and Appendix I for 
the list of search terms) suggested that pre-1990 the focus of the literature was on 
assessing potentially harmful aspects of chocolate, with respect to allergies, 
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theobromine (the caffeine like stimulant), effects of sugar on dental health and negative 
aspects of its saturated fatty acid content. 
From the middle of the 1990s a major change of perspective in the literature is apparent, 
with the research community becoming increasingly interested in investigating the 
potential health benefits of cocoa and cocoa containing products. A review following 
systematic methodologies of the clinical trial data is presented later in this chapter 
(section 1.5), with the data being incorporated into the exploratory review with meta-
analysis, which forms Chapter Three of this thesis. 
1.3.2	  -­‐	  In	  Vitro	  Evidence	  for	  the	  Beneficial	  Effects	  of	  Cocoa	  and	  Chocolate	  
The antioxidant theory as a potential mechanism for the prevention of disease grew in 
prominence through the late 20th century. This was associated with epidemiological 
evidence including the World Cancer Research Fund (WCRF) systematic review of the 
effects of diet on risk of cancer, which suggested high intakes of fruit and vegetables may 
reduce disease risk (WCRF, 2011). This had the net effect that many foods were 
investigated in the laboratory to assess their antioxidant capacity. This was often measured 
using a number of assays, with ORAC (Oxygen Radical Absorbance Capacity) deemed the 
standard assessment although still with considerable methodological limitations (Ou et al., 
2002; Huang et al., 2002). Table 1.4.2 highlights the antioxidant capacity of commonly 
available foods based on data previously available via the United States Department for 
Agriculture website (USDA, 2012). 
Table 1.3.2: Antioxidant capacity of common foods adapted from (USDA, 2010) 
Food ORAC, Trolox equiv., mcmol per 100 g 
Raw unprocessed Cocoa bean 28,000 
Red kidney bean 13,259 
Blueberry 9,019 
Cranberry 8,983 
Blackberry 7,701 
Raspberry 6,058 
Strawberry 5,938 
Red Delicious apple 5,900 
Granny Smith apple 5,381 
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The theory appeared to match the clinical study data from in vivo investigations. In that 
many of the observations being apparently mediated via an antioxidant mechanism. 
These include data suggesting reduced oxidation of low density lipoprotein (LDL) 
cholesterol (Frankel et al., 1993), reduction in measures of oxidative stress and reactive 
oxygen species determination (Scalbert, Johnson & Saltmarsh, 2005).  
However in 2012, the USDA withdrew publication of ORAC values from its Nutrient 
Data Laboratory website. This decision was based on mounting data suggesting that 
there was no link between the antioxidant capacity of foods and how they might reduce 
chronic disease risk (USDA, 2012). This is in concordance with the review of Hollman 
et al. (2011) which considered whether the cardiovascular benefits associated with 
polyphenols could be attributed to their in vitro antioxidant properties or whether 
alternative mechanisms are responsible for any in vivo effects. Using the PASSCLAIM 
criteria, which are the basis for European Food Safety Agency (EFSA) health claims 
approved by the panel on Dietetic Products, Nutrition and Allergies (NDA), the authors 
found that any reduction in cardiovascular risk could not be attributed to the antioxidant 
effects of the polyphenol containing food (Hollman et al., 2011). This publication 
followed on from the scientific opinion of the NDA panel of EFSA in 2010, which 
found that a causal relationship could not be demonstrated. The panel also stated that 
any beneficial, psychological effect (as with physiological effects) could not be linked 
to the foods antioxidant activity, content or properties (EFSA, 2010c). 
Therefore, despite the in vitro antioxidant potential, and even though the flavanols in 
cocoa and chocolate, being predominantly epicatechins are relatively bioavailable 
compared to many of the other polyphenols (Manach et al., 2005b; Williamson & 
Manach, 2005), this mechanism appears not to be of clinical relevance. This position is 
further supported by data comparing the normal concentration of polyphenols in the 
blood and those following supplementation, with the key physiological antioxidants in 
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the form of vitamin E, vitamin C and urate (Wayner et al., 1987; Nieto et al., 2000). In 
this context polyphenols make up less than one percent of circulating antioxidants in 
plasma supporting the hypothesis that other mechanisms must be at work which may 
allow the lower concentrations observed to be able to exert biological activity and 
explain their mode of action in reducing disease risk (Hollman et al., 2011).  
1.3.3	  -­‐	  Flavanols	  and	  Cardiovascular	  Disease	  Risk	  
Polyphenols (including flavanols) have been described as the most abundant 
antioxidants in the human diet (Scalbert, Johnson & Saltmarsh, 2005; Manach et al., 
2005). It has been suggested that dietary intakes can be as high as 1g per day in a typical 
Western diet, being approximately 10 times higher than the intake of vitamin C and 
about 100 times higher than intakes of vitamin E and carotenoids (Scalbert and 
Williamson, 2000; Manach et al., 2005; Williamson & Manach, 2005). As a result of 
their abundance this led to phytochemicals being associated with a reduction in risk of a 
number of diseases over the last decade. It is also possible these compounds may have 
effects in preserving foods (Li, Henning, Zhang & Zerlin, 2010; Mellor et al., 2010a) or 
even intestinal roles by acting as prebiotics,  with the action of intestinal bacteria upon 
these compounds resulting in reduced cardiovascular risk (Tzounis et al., 2011). 
Despite the lack of evidence for the antioxidant hypothesis in vivo, there are large 
numbers of studies reporting a beneficial effect of polyphenols in reducing 
cardiovascular disease risk, carcinogenesis and osteoporosis, along with potential to 
assist in the prevention of neurodegenerative diseases and diabetes mellitus (Scalbert et 
al., 2005). However global consensus is still being sought, with the World Health 
Organisation (FAO/WHO, 2003), suggesting that the risk reduction of cardiovascular 
disease by polyphenols was “possible” but that “insufficient” data were available to 
support a claim for risk reduction of cancers. This research field has subsequently 
moved forward rapidly over the last decade, therefore a systematic review of the 
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literature pertaining to chocolate and cocoa is therefore presented later in Section 1.5 in 
this chapter. 
1.3.3.1	  –	  Polyphenols	  as	  a	  potential	  nutrient	  
Polyphenols are a group of the biologically active food components, which appear to 
have a large and rapidly expanding evidence base for their beneficial effects upon 
human health. For the purpose of this thesis, polyphenols are not considered as true 
nutrients as they are not currently deemed to be essential for human health and survival. 
A review of their bioavailability (Manach et al., 2005) defined polyphenols as an 
‘abundant dietary micronutrient’. In terms of clear effects upon health it could be argued 
that polyphenols are a nutrient, through this opinion is yet to be universally accepted. 
However there is no evidence of harm of dietary intakes, which totally exclude 
polyphenols, only potential benefits of increased intake. The argument that to be 
defined as a nutrient, the compound must be essential and de novo synthesis cannot 
occur, does not hold true, as in theory humans could synthesise all the carbohydrate 
needed. This is also the case for niacin and vitamin D both of which can also be 
synthesised in humans. Unlike glucose, niacin and vitamin D, polyphenols as secondary 
plant metabolites are not synthesised by humans, and therefore consumption may 
provide additional benefits when compared to dietary exclusion. Supporting the initial 
assertion that polyphenols are a nutrient, originally being described as vitamin P (Mobh, 
1939). 
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There is a growing volume of evidence to support the hypothesis that polyphenols may 
be beneficial in moderating the risk of developing T2DM, and reducing the risk from 
the cardiovascular risks associated with T2DM. These effects were categorised by 
Williamson and Manach (2005) as follows: 
• Reduced blood pressure 
• Improved lipid profile 
• Improved vascular health 
• Reduced oxidative stress 
• Reduce insulin resistance 
These have been associated with cardiovascular risk and morbidity associated with 
T2DM, and along with inflammation will be the key areas of focus for this thesis. 
1.3.4	  -­‐	  Classification	  of	  Polyphenols	  
It is important, prior to considering the wide distribution of polyphenols found in the 
typical human diet, to consider their chemistry. In terms of their chemical structure 
polyphenols are phenolic compounds, containing more than one aromatic ring (benzene) 
in conjunction with one or more alcohol group (hydroxyl). Polyphenols are responsible 
for many of the organoleptic properties of foods and beverages derived from plants. 
Along with their proposed health benefits, they are particularly important flavour and 
colour compounds in many plant-based foodstuffs. It has been proposed that many of 
the health benefits linked to fruit and vegetable consumption along with tea and wine 
are an effect of their constituent polyphenols. Although polyphenols have been 
purported to have beneficial effects upon health they have been poorly described and 
defined in the literature possibly due to the difficulties in assaying all compounds in a 
food, with many studies having tended to focus on the small number of characterised 
molecules. It is additionally plausible that the activity of these polyphenols may be via a 
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synergistic effect with other components within the carrier food matrix. A further 
important consideration is that polyphenols also change physically, in terms of their 
chemical structure, in terms of bioavailability and in concentration within foods post-
harvest under the influence of numerous enzymic pathways within the foodstuff, and the 
effects of food storage and processing. These factors are complex and difficult to define 
and operate prior to the effects of gut microflora, the ability of the human 
gastrointestinal tract to absorb polyphenols and their post-absorption metabolism and 
half-life (Setchell, Brown & Lydeking-Olsen, 2002; Tzounis et al., 2011). Overall, the 
complex nature of the original molecules, their wide distribution in foods, how they 
behave prior to consumption, and individual variations in metabolic potential, make it 
impossible with any degree of certainty to be sure how these molecules have their 
effects. 
The term ‘polyphenols’ refers to the overarching class of molecules (figure 1.3.4.1.1), 
which include the flavonoids and several classes of non-flavonoids. The non-flavonoids 
are considered as having simpler structures and include: 
 Hydroxybenzoic acids 
 Hydroxycinnamic acids 
 Stillbenes 
 Gallotanins  
Lignans 
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Figure 1.3.4.1.1: Chemical structures of polyphenols showing both flavonoid and non-flavonoid 
polyphenol structures. Produced with permission from Manach et al. (2005)  
These non-flavonoids, are typically less well defined than the flavonoids, and there is 
some suggestion that they are less bioavailable than the flavonoids (Williamson & 
Holst, 2008) 
The flavonoids can also be classified into a number of different groups: 
 Flavonols 
Flavanols 
Isoflavonols 
Anthocyanins 
Proanthocyanins 
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Figure 1.3.4.1.2: Chemical structures of flavonoids showing. Produced with permission from 
Manach et al. (2005)  
In total, more than 4000 flavonoid compounds have been identified in plants, at least in 
part due to the way the skeleton of the compounds can have groups substituted, e.g. 
hydroxyl, methoxyl and glycosyl switched or glycosylated (glycone) or aclyated to 
provide more complex structures.  
1.3.4.1	  -­‐	  Flavonols	  
The major flavonol in the diet is quercetin (figure 1.3.4.1.2), which is found in many 
foods, and is particularly found in high concentrations in apples, broccoli, onions, red 
wine and tea. It is also a component of the nutritional supplement Ginkgo biloba. This is 
significant as the Ginkgo biloba also contains another potential bioactive compounds in 
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the form of terpenoids. This suggests a number of strategies that can be employed to 
investigate the effects of polyphenols in foods. The investigator can choose to look at 
the effects of the pure compound, as a food extract, or the whole food. In the future it is 
possible that polyphenols with demonstrable bioactivity will be isolated and formulated 
into compounds, which are then reintroduced into a food matrix to provide a novel 
functional food. 
Demonstrating the effectiveness of flavonols represents a considerable challenge. There 
is clear evidence of quercetin effects in vitro, but in vivo studies have not shown 
consistent effects. The probable reason for the lack of effect of quercetin in clinical 
trials, is perhaps its poor absorption (Manach et al., 2005).  
1.4.4.2	  -­‐	  Flavanols	  (Flavan-­‐3-­‐ols)	  
The catechins are the most common group of compounds classified as flavanols (figure 
1.3.4.1.2). They are widely distributed in plant-based foods and are further sub 
classified into five groups: 
 (+) - Catechin 
(-) - Epicatechin 
(-) - Epigallocatechin 
(-) - Epicatechin gallate 
(-) - Epigallocatechin gallate 
(+) - Catechins are especially found at highest concentration in broad beans (fava 
beans), dark skinned grapes, apricots and strawberries. (-) – Epicatechins along with 
their high abundance in broad beans and dark skinned grapes, are also found in apples, 
blackberries, cherries, chocolate, cocoa, pears and raspberries. The gallates and 
gallocatechins are found almost exclusively in tea, especially green tea (Williamson & 
Manach, 2005). 
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Proanthocyanidins, is a term often used to describe polymeric chains of other 
flavonoids; it was initially known as vitamin P by chemists in the 1930s and 40s (Mobh, 
1939; Carpenter, 2003) . This further highlights the wide variety of molecules, which 
make up this group. As well as being antioxidants, these compounds are considered to 
have the biological effect of being bitter, as a survival mechanism to reduce palatability 
of the plant to herbivores. As proanthocyanidins are polymeric flavonoids, their 
distribution is similar to that as described for the flavanols above (also figure 1.3.4.1.2). 
1.3.4.3	  -­‐	  Isoflavonols	  
Much polyphenols research has focused upon isoflavones. These have been studied both 
in the short term (a period of weeks), often seen as a limitation of the studies 
investigating isoflavonols, as well as in a small number of studies of up to 1 year in 
duration. The majority of the studies investigated the effects of isoflavones have been 
linked to their effects on biomarkers of bone mineral density. It was proposed that the 
potential to reduce bone mineral loss in women was linked to hormonal changes 
following the menopause, the mechanism being that isoflavonols have weak effects via 
their binding to oestrogen receptors, and supplement falling endogenous oestrogen 
levels in post-menopausal women (Mei, 2001; Atkinson et al., 2004). This effect might 
help explain changes seen in lipid profiles since increases with High Density 
Lipoprotein (HDL) cholesterol and decreases in LDL cholesterol levels and the 
susceptibility of LDL cholesterol to oxidation, are known to be affected adversely by 
the menopause (Derby et al., 2009). 
The effects of isoflavones have been investigated using either soy or red clover as their 
source (Hamilton-Reeves et al., 2010; Hooper et al., 2009), with most of the literature 
reporting the effects of soy, either in whole beans, protein extracts (which may have 
been supplemented with isoflavones) or pure isoflavones. As with flavonols, 
isoflavones are found in soy mostly in the conjugated glycoside form (glycine), which 
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can be converted to the free form (aglycone) when the soy is fermented. However the 
aglycone isoflavones need to be in the glycoside form to be absorbed at the maximum 
level. This is often considered to be a function of the gut microflora, with some 
individuals being more efficient than others with respect to this, which in turn results in 
responders and non-responders to soy supplementation (Rowland et al., 2000). The 
most abundant isoflavone glycosides in soy are genistin (genistein being the aglycone, 
which has lower bioavailability) and diadzin (together with it less available aglycone 
daidzein).  
As with the flavonols, isoflavonols have been shown to have activity in vitro, some of 
which is linked to their pseudo-hormonal action, with other observed effects, 
historically ascribed to an antioxidant mechanism. These effects are potentially difficult 
to distinguish, as described earlier, from which it may be inferred that these compounds 
act via a range of pathways, which appear to mimic an antioxidant function, thus 
making it difficult to be certain of the precise biological effects of these compounds. In 
postmenopausal women with T2DM, Jayagopal et al. (2002) demonstrated that 
supplementation of soy protein with isoflavones can reduce insulin resistance along 
with modest improvements in measures of glycaemic control. Whole soy nuts have also 
been shown to be beneficial in T2DM (Azadbakht et al., 2003, 2007). However, pure 
isoflavones in the form of the aglycone isoflavones were shown not to have any effects 
(González et al., 2007). This might be due to the form in which the isoflavones were 
provided or to a synergistic relationship between isoflavones and soy proteins. 
1.3.4.4	  -­‐	  Anthocyanidins	  	  
These are related compounds, and probably the least well studied of the flavanol 
compounds both chemically and in terms of effects on human health (Williamson & 
Holst, 2008). Anthocyanidins can exist in glycosylated forms, known as anthocyanins, 
and produce the deep red and purple pigments in plants. Plants use these properties to 
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attract pollinators and seed distributors along with their antioxidant role, which includes 
defending the plant from ultra violet radiation. However it is considered that these 
compounds have biological activity in foods, both in terms of food preservation (Mellor 
et al., 2010a), and potentially in vivo, following consumption by man. 
1.3.5	  -­‐	  Bioavailability	  
A considerable barrier to polyphenols achieving biological efficacy in humans is their 
low bioavailability (Williamson & Manach, 2005; Manach et al., 2005). Polyphenols 
are not all absorbed to the same extent.  Bioavailability data assumes, as stated in the 
reviews of Williamson and Manach (2005) and Manach et al. (2005), that polyphenols 
must be absorbed and bioavailable in order that beneficial effects can be observed.  
However in a recent study by an Italian group (Villaño et al., 2010), benefits in terms of 
a reduction in oxidative stress were reported, but no plasma aspalathin or nothofagin 
(the dominant polyphenol in the investigational product) were detected. Other groups 
have detected these polyphenols in plasma, so this might have been a problem with the 
assay rather than the compounds true bioavailability (Breiter et al., 2011). 
Of all the polyphenols, the epicatechins, especially those found in cocoa show the 
greatest bioavailability with a maximal plasma concentration detected after two hours. 
Approximately 20% of the total epicatechin consumed is excreted in the urine (Manach 
et al., 2005). This might explain in part why cocoa polyphenols have been amongst the 
most studied of this group of compounds.  
1.3.5.1	  –	  Inhibitors	  of	  polyphenol	  availability	  
A range of dietary factors is known to influence the availability of polyphenols. Perhaps 
the most relevant to dietary intake in the UK, is the influence of milk and dairy produce. 
This assumption appears to have been derived from epidemiological studies where tea 
does not appear to have beneficial effects in British populations, the conclusion being 
that this is a reflection of the British habit of having milk with tea, thus reducing the 
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availability of the polyphenols (Frei & Higdon, 2003). However data from 
bioavailability studies using cocoa and milk, suggest that although urinary epicatechins 
are reduced by the addition of milk, plasma levels are not adversely affected. It is 
plausible that the fatty acid composition of milk may enhance the absorption of 
epicatechins. In fact this mechanism is exploited to enhance uptake of a number of 
pharmaceutical agents (Anderberg, Lindmark & Artursson, 1993; Lindmark, Kimura & 
Artursson, 1998). 
A final potential issue regarding polyphenols is their stability within foods post-harvest. 
In the case of anthocyanidins, instability can be seen when foods including red cabbage 
are cooked, when a drop in pH alters its structure, and hence the colour from red to blue. 
Bąkowska, Kucharska and Oszmiański, (2003), also demonstrated the lack of stability 
of polyphenols when exposed to ultra violet light. However this is not the case for all 
polyphenols or food matrices. For example, the polyphenols in chocolate have been 
shown to be stable for up to two years (Hurst, Payne, Miller & Stuart, 2009). 
1.3.6	  -­‐	  Observed	  Health	  Effects	  of	  Polyphenols	  
1.3.6.1	  -­‐	  Reduction	  in	  blood	  pressure	  
A number of polyphenolic compounds have been reported to lower blood pressure, both 
in animal models and in clinical trials in human participants. A study using wine 
polyphenols in rats, (Diebolt, Bucher & Andriantsitohaina, 2001), was the first to 
propose not only a reduction in blood pressure, but increase in the expression of a  
number of genes suggesting the potential for an epigenetic effect. The genes whose 
expression is enhanced appear to be associated with endothelial function via increased 
nitric oxide and prostaglandin production, which result in reduced blood pressure. More 
recently, studies supplementation with cocoa in humans has been shown to lead to an 
inhibition of angiotensin converting enzyme, a key step in the pathway which leads to a 
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reduction in the synthesis of angiotensin, which could lead to a reduction in blood 
pressure (Persson, Persson, Hägg & Andersson, 2011). 
1.3.6.2	  	  -­‐	  Improved	  lipid	  profile	  
Polyphenols have been associated with the beneficial effects of dyslipidaemias. This 
might also explain why diets rich in plant-derived foods and polyphenols have been 
associated with a reduction in cardiovascular risk (Jenkins et al., 2003). Data from mice 
models of diabetes, suggest that polyphenols might act via hepatocellular AMP-
activated protein kinase (AMPK) along with its downstream target, acetyl-CoA 
carboxylase. The effect of polyphenols also appeared to be approximately 200 times 
more potent than that of metformin in their effect upon lipid metabolism (Zang et al., 
2006). This work also linked AMPK to the pathogenesis of the dyslipidaemia in an 
animal model of diabetes. As with the case of blood pressure there are a number of 
alternate mechanisms, with a further possibility for lipid modification being via 
modulation of the ATP Cassette Binding protein, which may also improve lipid profile 
(Noe et al., 2004). In data from human studies improvements in lipid profiles have been 
seen in populations with diabetes (Mursu et al., 2004), with increased HDL cholesterol 
levels. Other research in populations without diabetes have suggested that polyphenols 
may reduce the oxidation of LDL cholesterol (Hudthagosol et al., 2011). 
1.3.6.3	  -­‐	  Reduction	  in	  insulin	  resistance	  	  
The mechanism, by which insulin resistance may be modified by polyphenols, has been 
suggested to be via a similar mechanism to the improvement in lipid profiles, the 
AMPK pathway, although in the case of insulin resistance, the AMPK pathway needs to 
be activated in both skeletal muscle and liver (Hegarty, Turner, Cooney & Kraegen, 
2009; Zang et al., 2006). 
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1.3.6.4	  -­‐	  Improved	  endothelial	  function	  
In many of the studies which demonstrated a reduction in blood pressure the effect of 
polyphenols has been attributed to endothelial function (Diebolt, Bucher & 
Andriantsitohaina, 2001). It has been suggested that the improvement in endothelial 
function derives from an increase in redox sensitive activation of the 
phosphatidylinositol 3-kinase/Akt pathway, which results in activation of endothelial 
nitric oxide synthase (eNOS). This is thought to be via an increase in intracellular free 
calcium concentration and activation of oestrogen receptors (Schini-Kerth et al., 2010).  
These changes appear to go beyond just nitric oxide, as polyphenols may act on other 
endothelium factors.  
1.3.6.5	  -­‐	  Reduced	  oxidative	  stress	  
Although in vitro studies suggest powerful effects of polyphenols in terms of their 
abilities to scavenge free radicals, the data from in vivo participants are considered to be 
‘confusing and equivocal’ (Halliwell, Rafter & Jenner, 2005; Halliwell, 2007). However 
it can be challenging to assess oxidative stress in vivo, as a number of assays measuring 
damage to genetic material can be insensitive to dietary manipulation (Collins, 2005). 
Also the potential difficulties presented by poor absorption of polyphenols, suggest that 
any effects are likely to go beyond just their antioxidant capabilities and likely act via 
multiple mechanisms (Williamson, 2009). It is highly plausible that other aspects of 
polyphenol action might be supported by their antioxidant capabilities, but this is not 
their primary beneficial effect. It is a logical hypothesis that the beneficial effect of 
polyphenols upon endothelium by increasing the synthesis of endothelium derived 
factors such as nitric oxide and prostaglandins, which have additional free radical 
scavenging capabilities, and would enhance the pool of these beneficial compounds. 
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1.3.6.6	  -­‐	  Other	  potential	  effects	  of	  polyphenols	  
The effects on endothelial function may extend into other aspects of vascular health. 
Polyphenols have been demonstrated to inhibit platelet aggregation (Demrow, Slane & 
Folts, 1995; Freedman et al., 2001), the potential mechanism which may be by a 
decrease in the production of superoxide anions and an increase in nitric oxide synthesis 
(Freedman et al., 2001). A further potential effect, which polyphenols may have on 
health, is as ‘an anti-nutrient’ or chelating agent. This apparently ‘negative effect’ could 
potentially have beneficial effects in the gastrointestinal tract, and potentially in vivo by 
binding metal ions, which could otherwise be pro-oxidants. Although such an effect has 
been hypothesised as beneficial, it could as a potentially increase the risk of mineral 
deficiencies, especially iron deficiency anaemia (Samman et al., 2001). It appears likely 
that polyphenols have a range of effects. It is likely that the comment of Williamson 
(2009) is correct, in that polyphenols have a ‘multitude of methods of action, with the 
mechanisms discussed above often interacting and overlapping in their action’. 
1.3.7	  -­‐	  Summary	  of	  the	  Polyphenols	  and	  their	  Potential	  Effects	  
Polyphenols are a diverse group of plant-derived compounds which have been shown to 
have dramatic antioxidant actions in vitro, but which it is difficult to replicate in humans. 
The effects of polyphenols potentially in enhancing health are hampered by their lack of 
bioavailability and stability/poor shelf life. Although polyphenols are abundant in many 
foods, and widely consumed in Western diets, it is a challenge to select a potential source 
for food supplementation, as the foods need to be palatable, provide a rich source of 
polyphenols, and be stable and well absorbed. The polyphenol most likely to fulfil these 
requirements are epicatechins from cocoa, with the caveat for individuals with diabetes, 
cocoa and chocolate may present other nutritional challenges, where potential benefit of 
polyphenols might be negated by other nutritional factors (especially the high energy, 
saturated fat and sugar content) within the final food product.	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1.4	  Systematic	  Review	  of	  the	  Effects	  of	  Cocoa	  and	  Chocolate	  on	  
Cardiovascular	  Risk	  
1.4.1	  -­‐	  Epidemiological	  Evidence	  for	  Beneficial	  Effects	  of	  Cocoa	  and	  
Chocolate	  
The case for potential benefit has been described in section 1.3. The purpose of this 
section is to consider critically the evidence and need for further work based on the 
published data. The approach will be using the structure of an inverted pyramid of 
evidence. The review aims to critique the literature, with Chapter Three summarising 
the data and presenting an exploratory review with meta-analysis comparing chocolate 
to cocoa in its effects on the six biomarkers of cardiovascular risk and glycaemia 
control defined previously in Section 1.2.3. 
	  
Figure 1.4.1: Inverted pyramid of evidence, highlighting the hierarchy of clinical evidence in 
reverse, with registered clinical studies currently as adding to the data.  The position of meta-
analyses is cited as having greater power of showing the effect than randomised controlled trials, 
but also linking into the design of current studies.  	  
Work on the Kuna Indians, an indigenous population who inhabit islands near Panama, 
provided initial insight into the health effects of cocoa (Hollenberg et al., 1997; 
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Hollenberg, 2006; McCullough et al., 2006). This ethnic group have little age-related 
increase in blood pressure or associated hypertension. However, when members of this 
ethnic group move to the urban environment of Panama City, they lose this protection 
and revert to the expected levels of hypertension. This could be said to represent the 
classic ‘migration type’ study suggesting a lack of a genetic effect, and that the increase 
in hypertension must be attributed solely to environmental influences. The island-
dwelling Kuna consume large quantities of cocoa daily, both as drinks (up to 5 cups a 
day) and as an ingredient in cooking. Those living in Panama City have a very low 
consumption of cocoa. Moreover, the island dwelling Kuna have a 3-fold higher level of 
nitric oxide metabolites in their urine compared to the city dwellers (Hollenberg et al., 
1997; McCullough et al., 2006). This epidemiological study clearly suggested an 
association between cocoa flavanols and improved vascular function as suggested in 
section 1.4.2.4 and warrants investigation via clinical trials to quantify the effect and 
assess causality. 
Epidemiological evidence on the effect of chocolate have largely been derived from 
studies in which the data collection was initially undertaken as part of other studies, and 
the effect of cocoa or chocolate consumption examined as a post hoc analysis. The 
majority of the data were derived from European prospective study data sets (Buijsse, 
Feskens, Kok & Kromhout, 2006; Buijsse et al., 2010; Janszky et al., 2009) with 
contributions from studies undertaken in the USA (Djoussé, Hopkins & Arnett, 2011) 
and Spain (Recio-Rodríguez et al., 2012). These later two studies were cross-sectional 
in design, and lack the predictive power of the European cohort studies. The European 
studies also had the strength of reporting the hard endpoints of death or myocardial 
infarction, suggesting that chocolate consumption is associated with a reduction in rates 
of mortality.  
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1.4.1.1	  –	  European	  epidemiological	  data	  
Data from the Zutphen Elderly study (Buijsse et al., 2006) reported the effects of the 
consumption of foods containing cocoa in 470 elderly men. The initial data was 
collected in 1985 and the outcome data analysed 15 years later. Buijsse et al. (2006) 
found no association between sugar confectionary consumption and mortality (p=0.54), 
but did demonstrate a significant inverse association between habitual cocoa containing 
food intake and cardiovascular mortality rates (as well as all-cause mortality rates). This 
was in agreement with the cross-sectional data collected in 1985, which suggested a 
significant inverse association between blood pressure and habitual intake of foods 
containing cocoa. These data were subsequently confirmed by an analysis of the 
Potsdam cohort from the European Prospective Investigation into Cancer (EPIC). 
Chocolate consumption and blood pressure were assessed at baseline and were found to 
be inversely associated in 19357 participants aged 35-65. The follow up data suggested 
that the highest intake of chocolate had a significantly lowered risk of myocardial 
infarction and stroke than the lowest consumers (RR=0.61 (95% confidence interval 
0.44-0.87) p=0.014 for trend), with 12% (95% confidence interval 3-36%) of this effect 
explained by the effect of chocolate on blood pressure after a mean follow up of eight 
years (Buijsse et al., 2010).  
This inverse relationship gained further support from the data presented in the 
Stockholm Heart Epidemiology Program (Janszky et al., 2009), which reported the 
outcomes of a population of 1169 patients who had survived their first acute myocardial 
infarction. At the point of diagnosis, patients reported their intake of chocolate over the 
preceding 12 months, and were then followed up for eight years. As previously seen, 
there was a strong inverse association between chocolate consumption and cardiac 
mortality rates. The highest quartile of consumers had an adjusted hazard ratio of 0.34 
(95% confidence interval 0.17-0.70) when compared to non-consumers. Also in keeping 
Chapter	  One	  –	  Introduction	  and	  Literature	  Review	  
	  55	  
with the Zutphen cohort (Buijsse et al., 2006) there was a weak inverse association with 
total mortality and chocolate consumption. 
These three studies have been included in the systematic reviews of Buitrago-Lopez et 
al. (2011) and Khawaja, Gaziano and Djoussé (2011) who both acknowledged that the 
evidence from prospective cohort studies suggests a strong association between 
cardiovascular mortality and cocoa/chocolate consumption. However, this type of data 
does not equate to ‘evidence of causality’ and it is necessary to undertake experimental 
work, such as randomised controlled trials in order to elucidate a cause and effect. 
Khawaja, Gaziano and Djoussé (2011) also suggested that further work is required to 
elucidate the underlying mechanisms of action, which in view of the widespread 
abandonment of the antioxidant hypothesis, due to a lack of evidence and low plasma 
concentrations (Hollman et al., 2011; EFSA, 2010c; USDA, 2012) is logical and 
compatible with the evidence supporting mechanisms linked to nitric oxide synthase, 
ATP binding cassette proteins, AMP kinase or Angiotensin Converting Enzyme. 
Cross-sectional studies, which can only suggest an association with incidence, have 
suggested an inverse link between chocolate consumption and calcified atherosclerotic 
plaque (Djoussé, Hopkins & Arnett, 2011) but not with cocoa consumption. Recio-
Rodríguez, et al. (2012) undertook a smaller cross-sectional study in Spain, finding no 
association between cocoa consumption and arterial stiffness. The study by Djoussé et 
al., (2011) considered data from 2217 individuals with increased risk of cardiovascular 
disease from the NHLBI Family Heart Study cohort, and later, 351 middle aged Spanish 
adults. These mixed results might have been an artefact of the study design and the 
population selected for the Spanish study (Recio-Rodríguez, et al., 2012), where by its 
nature the work of Djoussé, Hopkins and Arnett (2011) with a larger cohort, was 
potentially sensitive enough to detect an effect and by its nature behaving akin to a 
retrospective cohort study.  
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A final series of data worthy of consideration were presented in three studies from the 
USA; one cross-sectional study of a statin cohort (Golomb, Koperski & White, 2012)  
and two analyses of the NHANES data collected between 1999-2004. Golomb, 
Koperski and White (2012), found that chocolate consumption was negatively related to 
body weight. This perspective was given further support by the NHANES data in adults, 
teenagers and children (O’Neil, Fulgoni & Nicklas, 2011a; 2011b), which considered 
the relationship between chocolate and confectionary intake and body weight (body 
mass intake), cholesterol, blood pressure and C-reactive protein (O’Neil, Fulgoni & 
Nicklas, 2011a). This study found a significant inverse association between chocolate 
intake and body weight (p=0.0096) and waist circumference (p=0.0067). For the 
biomarkers assessed, the data suggested a significant positive association between 
chocolate intake and HDL cholesterol (p=0.0187) and a significant negative association 
with C-reactive protein (p=0.0174). Thus, in a population of 15023 adults (over 19 
years old) it suggested that higher chocolate consumption is associated with a lower risk 
of metabolic syndrome (O’Neil, Fulgoni & Nicklas, 2011a), potentially supporting the 
case for chocolate intake being beneficial in T2DM. This study together with the data 
from other epidemiological studies, excluding that of Recio-Rodríguez et al. (2012) 
suggest there is a reduced cardiovascular mortality and risk associated with chocolate 
consumption.  
Overall it is clear from the epidemiological data that there is a very strong association 
between chocolate consumption and improved cardiovascular risk which warrants 
interventional clinical trials to elucidate this effect further and assess the potential causal 
beneficial effects of chocolate. 
1.4.2	  -­‐	  Systematic	  Review	  of	  Clinical	  Trials	  
The systematic review of the data was undertaken following Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Liberati et al., 2009) 
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with a review of the literature being undertaken at the end of June 2012. The review will 
focus upon studies reporting primary outcomes related to the effects of chocolate and 
cocoa supplementation in the six areas set out below, and described in Section 1.2.3 and 
1.3.3. 
 Blood pressure 
 Lipids 
 Insulin resistance and diabetes control 
 Endothelial function 
 Oxidative Stress 
 Inflammation 
In addition, weight change was also included, based upon the findings of Golomb, 
Koperski and White (2012) and O’Neil, Fulgoni and Nicklas (2011a; 2011b) to see if 
similar neutral or postive effects on weight are reported in clinical trials. 
1.4.2.1	  -­‐	  Clinical	  trials	  data:	  blood	  pressure	  
Many trials investigating the effects of cocoa or chocolate consumption on health have 
included blood pressure as either a primary or secondary outcome. The first report to 
suggest beneficial health effects of chocolate consumption was published as a research 
letter in the Journal of the American Medical Association (Taubert et al., 2003). This 
small study selected thirteen elderly participants with isolated systolic hypertension, and 
in a crossover design, gave them either 100g of dark chocolate following seven days 
without chocolate for 14 days or 90g of white chocolate, then after a seven day wash out 
participants were crossed over. The dark chocolate was said to contain 500mg of 
polyphenols and the white chocolate was said to be polyphenol free. There are no 
details of how the polyphenols were analysed. Daily blood pressures were measured, 
and from day nine to fourteen there was a significant reduction in systolic blood 
pressure (for diastolic blood pressure, this was seen from day ten onwards). The 
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reduction in blood pressure was 5.4± 2.4/1.8±2.0 mmHg, which was clinically 
significant and equivalent to the effect seen when increasing habitual physical activity 
to the recommended levels (Arroll & Beaglehole, 1992). 
This protocol was repeated by Grassi et al. (2005a), using healthy participants with the 
additional assessment of insulin resistance (determined by Homeostatic Model 
Assessment (HOMA)). This was based upon the hypothesis that improved insulin 
sensitivity mediates an increase in nitric oxide, which has the additional benefit of 
improving insulin-mediated glucose uptake. This study produced a reduction in systolic 
blood pressure after 15 days supplementation (107.5±8.6 compared with 113.9±8.4 
mmHg, P<0.05) with no effect on diastolic blood pressure and a significant reduction in 
insulin resistance as measured by both the HOMA and the quantitative insulin 
assessment of insulin resistance (QUICKI) methodologies. Both these assessments are 
based on measurements of insulin and glucose levels, both assessed in the fasting state 
(Matthews et al.,1985; Wallace & Matthews, 2002; Matsuda & DeFronzo, 1999). 
Although of potential clinical benefit, this effect does not appear to fit with the 
hypothesis of insulin-mediated glucose uptake. The study reported the assessments of 
insulin sensitivity only and demonstrated just an improvement in the fasting state. These 
data would perhaps be better expressed as an area under the curve analysis to assess 
glucose removal effectively. However, the reduction in HOMA, which may be partially 
through nitric oxide, may be of relevance when considering feeding chocolate to 
participants with T2DM. 
The potential disadvantage of these initial studies, apart from design considerations, is 
the large quantity of chocolate used. At 100g this represents an energy intake of 480kcal 
(2020Kj), which represents almost 25% of the recommended requirements for an adult 
(SACN, 2011). In an attempt to address this, (Taubert et al., 2007) investigated the 
effects of 6.3g of chocolate, providing only 30kcal (126kj) of energy, using a parallel 
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study design, but over a longer timescale of 18 weeks. This study as with this group’s 
earlier work demonstrated a significant improvement in this healthy middle-aged (56-73 
years) population with prehypertension. Systolic blood pressure was reduced by 
2.9±1.6mmHg (p<0.001) and diastolic blood pressure by 1.9±1.0 mmHg. This study 
suggested there were no other effects on weight or glucose; the blood pressure reduction 
was associated with an increase in S-nitroglutathione and the appearance of cocoa 
polyphenols in plasma and implied that in prehypertension, a small dose of chocolate 
(providing 5.1mg epicatechin) may still impart an improvement in blood pressure, in 
individuals with this condition but no other risk factors of cardiovascular disease. 
Despite the data suggesting potential benefits of relatively small amounts of chocolate 
(approximately ½ a square), it should be noted that these data were from relatively 
healthy participants, where blood pressure was only moderately elevated. Grassi et al. 
(2008) published data demonstrating the effects of 100g of dark chocolate in glucose 
intolerant hypertensive participants. This study employed the same dose of chocolate 
and similar protocol as Taubert et al. (2003) and Grassi et al. (2005a; 2005b), The 
findings also concurred with those of this group in healthy participants; an improvement 
in fasting measures of insulin resistance and blood pressure (systolic blood pressure 
reducing by 3.82±2.40 mmHg and diastolic blood pressure by 3.92±1.9 mmHg). In this 
study data for the 120 minutes time point was reported, showing a significant 
improvement following 15 days of dark chocolate (p=0.035), but again no dynamic 
assessment of area under the curve for glucose or insulin was reported. 
Although early clinical trials showed a common effect: improvements in systolic blood 
pressure, further questions remain unanswered. Ried, Frank and Stocks (2009) 
attempted to compare high polyphenol dark chocolate supplementation with capsules of 
lycopene. This study did not show any blood pressure lowering effect over an eight-
week period, but did suggest that participants found it difficult to comply with 
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consuming 50g of dark chocolate at the time of the study. This supports the model that 
smaller quantities of chocolate or alternative formulations may be warranted. 
A criticism of much of these data is the nature of the placebo or control used (often 
white chocolate), in that it is clearly different visibly but also in terms of other 
biologically active compounds, namely caffeine and theobromine. To try and address 
this, van den Bogaard et al. (2010) using a cocoa supplement, matched the flavanol 
content but varied the dose of theobromine and the results, suggested that higher doses 
of theobromine could increase systolic blood pressure, but acutely reduce central blood 
pressure (assessed by the measurement of brachial pulse wave form). However no 
improvement in blood pressure was seen with the natural theobromine cocoa, which still 
provided 305 mg flavanols compared to the placebo in this group of healthy individuals 
participating in this crossover study. 
In other words, the dose and form of the supplement appear not to have been adequately 
defined. In studies which had primary outcomes associated with blood pressure, those 
using chocolate as the intervention had a consistent blood pressure lowering effect 
Desch et al. (2010b) described a two-dose study using 6g per day of dark chocolate 
(based on Taubert et al. (2007)) compared to 25g per day. This study did not have a 
control group, but did suggest a significant reduction in blood pressure in both arms. 
The higher dose of chocolate did lead to slightly more weight gain (0.8kg), but the lack 
of control limited the value of this study. A more systematic range of flavanol doses 
was tested by Davison et al. (2010); using a control with 33mg flavanols compared with 
cocoa drinks with 372, 712 and 1052mg in a parallel designed study, using healthy 
participants over a 6 week period. This study showed no effect on blood pressure when 
measured in the clinic room, but 24-hour ambulatory measurements showed mean 
improvement in systolic (5.1±5.1mmHg; p=0.001) and diastolic (3.0±3.2mmHg; 
p=0.002) at the highest dose only. No dose response effect was seen, suggesting that 
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more research is needed to explore the apparent difference in results between cocoa and 
chocolate, since the matrix or nutrient composition of the supplemental formula may 
have an influence. 
Further support for the hypothesis that chocolate may have a superior effect on blood 
pressure, was reported by Sudarma, Sukmaniah and Siregar (2011) who compared the 
effect of 30g dark chocolate with 25g white chocolate. This study only reported an 
approximate energy content of the chocolates and no information about the 
carbohydrate content or the flavanol content or type was given. Despite these 
limitations, after 15 days, this population of prehypertensive participants had a 
significant reduction in systolic blood pressure (difference between groups not reported; 
p=0.001), which was accompanied by an increase in serum nitric oxide levels (assessed 
by measuring the sum of nitrites and nitrates) (difference between groups not reported; 
p=0.001). This study supports the hypothesis that reduction in blood pressure is 
mediated via nitric oxide and that improved endothelial function might accompany this 
change. 
1.4.2.2	  -­‐	  Clinical	  trials	  data:	  lipid	  profile 
One of the first clinical trials of the effect of cocoa and dark chocolate investigated the 
effects of the addition of both of these compounds upon LDL cholesterol. This study, by 
Wan et al. (2001), found an increase in total serum antioxidant capacity as measured by 
Oxygen Radical Absorbance Capacity (ORAC), a measure which subsequently has been 
rejected as a marker of relevance to human health (USDA, 2012; Lotito & Frei, 2006; 
Hollman et al., 2011). Potentially of greater interest was the apparent protection by 
chocolate and cocoa supplementation of LDL cholesterol from oxidation, despite a 
reduction in HDL cholesterol. This trial was a parallel design in healthy participants 
lasting for four weeks, but may be criticised because the two arms of the study were 
combined together at baseline, making critical assessment of the data difficult. 
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However, the findings were potentially confirmed by a trial which lacked a control arm 
by Osakabe et al. (2001) who fed healthy participants 36g of cocoa, and after two weeks 
found similar changes in plasma antioxidant status and increased resistance in LDL 
cholesterol to oxidation. Mathur, Devaraj, Grundy and Jialal (2002) used a similar 
protocol, with a six week feeding intervention and a slightly larger dose of cocoa and 
chocolate (36.9g dark chocolate and 20.95g of cocoa powder, compared to 16g dark 
chocolate and 22g cocoa (Wan et al., 2001). However instead of a control group, 
Mathur et al. (2002) utilised a washout period. This could be argued to be a source of 
potential bias, along with the lack of any restrictions regarding other dietary flavanols in 
the protocol. However, a reduction in LDL cholesterol was still seen with the data of 
Mathur et al. (2002) without seeing a change in plasma antioxidant capacity. 
The first clinical trial to investigate the effects of chocolate alone (rather than in 
conjunction with cocoa) upon lipid profile was by Mursu et al. (2004), which 
investigated healthy individuals, found that supplementation led to a reduction in LDL 
cholesterol. Unlike Mathur et al. (2002) and Wan et al. (2001), Mursu et al. (2004) who 
used a parallel study design in their population of 45 participants in response to eating 
either 75g white chocolate, dark chocolate or high polyphenol chocolate, all groups 
demonstrated an increased resistance to LDL cholesterol. Mursu et al. (2004) then 
suggested that this might be a property of the fatty acids in cocoa. However they did 
report an increase in HDL cholesterol with the dark (11.4%) and high polyphenol dark 
chocolates (13.7%), implying a potential role for flavanols too. It was also of note that 
the white chocolate group lost -1.1 ±2.7kg bodyweight over the three-week intervention 
period of the study. This was the first study to report a change in a routinely measured 
marker of lipid metabolism, which is inversely related to cardiovascular mortality 
(Wilson, Abbott & Castelli, 1988). 
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Subsequently an increase in HDL cholesterol has been reported in healthy participants 
(Nanetti et al., 2008) given 50g of flavanol rich chocolate, but the value of this work 
was limited by the lack of a control group. Hamed et al. (2008) demonstrated an 
increase in HDL cholesterol of 9% and a reduction of LDL cholesterol of 6%, but again 
this study, which used 70g of 70% cocoa dark chocolate and was limited by the lack of 
a control arm.  
The three studies that used chocolate alone (Mursu et al., 2004; Nanetti et al., 2008; 
Hamed et al., 2008) all suggested an increase in HDL cholesterol in healthy participants. 
Studies that utilised cocoa, however only reported increased resistance to oxidation of 
LDL cholesterol. This position was partly challenged by the data of Baba et al. (2007) 
who claimed in a parallel study of 160 participants fed either placebo or one of three 
doses of cocoa (providing trace, 64.5, 96.7 or 129mg per day epicatechin) but HDL  
cholesterol was increased, along with a reduction in oxidation of LDL cholesterol. 
However, the analysis of variance did not reach significance (p=0.055) for HDL 
cholesterol. This was partially the result of all of the chocolate arms significantly 
demonstrating an increase in HDL cholesterol and suggesting that these findings may 
not be as valid as those of Baba et al. (2007) who felt there was a high risk of type 1 
error. Therefore, it appears as with blood pressure the effect of the matrix or formulation 
of the chocolate or cocoa warrants further investigation. This was considered partially 
by Khan et al. (2011) who in a population with increased cardiovascular risk, 
demonstrated that cocoa in milk when compared to milk alone in a crossover design of 
only four weeks in length can increase HDL cholesterol (p=0.008). This effect was 
accompanied by the appearance of urinary cocoa metabolites. It is clear that a crossover 
study, that the study would not be blinded and this might have been a source of 
confounding. Moreover, the population was not well defined; it included individuals 
with diabetes and/or three cardiovascular risk factors and did not control for medication. 
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The exploration of varied matrices or formulations of cocoa and chocolate, along with 
the effect of matrix on the action of polyphenols was investigated in a study which used 
a base control of cocoa cream with added cocoa polyphenols, hazelnut cream and plant 
sterols in one of four combinations (Solà et al., 2012). This study, in hypertensive 
participants, demonstrated a reduction in blood pressure with the cocoa cream alone, 
which was meant to be the control (P<0.05) and the effect was further enhanced for 
diastolic blood pressure by the addition of cocoa polyphenols. It was claimed that LDL 
cholesterol was reduced by the combination of cocoa with hazelnut cream, but this was 
estimated using the Friedewald equation (Friedewald, Levy & Fredrickson, 1972), so 
care needs to be taken with its interpretation, as this can be adversely influenced by 
changes in triglyceride levels. 
It therefore appears that cocoa polyphenols may help to protect lipids from oxidation, 
and that chocolate may perhaps increase HDL cholesterol. However many of these 
studies were lacking with respect to their design, with either no control, or one which 
was not matched in terms of appearance, taste, energy content or carbohydrate load.  
1.4.2.3	  -­‐	  Clinical	  trials	  data:	  insulin	  resistance	  and	  glycaemia	  
In three studies Grassi et al. (2005a; 2005b; 2008) investigated the effects of 
administration of 100g of dark chocolate for 15 days, and found that measures of fasting 
insulin and glucose metabolism improved in healthy individuals, those with 
hypertension and those with impaired glucose tolerance. However these measures were 
secondary to effects on blood pressure.  Only two further studies both by Almoosawi 
(Almoosawi, Fyfe, Ho & Al-Dujaili, 2010; Almoosawi et al., 2012) investigated the 
effects of chocolate on glycaemia as one of their primary outcomes. Their first study 
compared the effect of a 500mg polyphenol content chocolate with a 1000mg 
polyphenol content chocolate on fasting plasma glucose (Almoosawi et al., 2010), but 
did not measure insulin and the plasma glucose measurement was made using a near 
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patient testing meter (Accutrend GC, Roche Diagnostics, Burgess Hill, West Sussex, 
UK), a method which lacks the validity to be acceptable for diagnostic purposes due to 
a high coefficient of variance. Despite the limitations of a lack of a control, fasting 
glucose was seen to decrease in this population of healthy overweight and obese 
individuals along with a significant reduction in blood pressure after two weeks of 
supplementation. These reductions were seen in both the 500mg and 1000mg 
polyphenol chocolates. In their follow up to this study, Almoosawi et al., (2012), 
compared the 500mg polyphenol chocolate with a placebo chocolate with negligible 
polyphenol content over a four-week period in a crossover design with two-week 
washout. This study also stratified the women into overweight and lean based on their 
BMI being above or below 25kgm-2. Of note, no effects on lipid profile were seen, but 
blood pressure was significantly decreased in both lean and overweight participants 
(p<0.001), and plasma glucose significantly decreased in overweight participants 
(p=0.007) but not in lean participants. The difference in fasting insulin and HOMA 
(Homeostatic Model Assessment, to assess insulin resistance) appeared to be linked to 
an increase in fasting insulin in the placebo group (p=0.001). In this study, the glucose 
was measured in a laboratory using a hexokinase assay, which is considered to be more 
robust (Slein, 1963). 
It is therefore possible that modest effects on glucose and insulin metabolism may occur 
with chocolate consumption. However, it is unclear if this extends beyond healthy, 
overweight and impaired glucose tolerant participants, to individuals with T2DM.  
1.4.2.4	  -­‐	  Clinical	  Trials	  Data:	  endothelial	  function	  
Endothelial function or dysfunction has been a major area of interest as a primary 
outcome of cocoa research. To the end of June 2012 (the cut off point for the data 
collection for the exploratory review with meta-analysis) there have been twenty-three 
publications reporting effects of cocoa on endothelial function. Since this may be one of 
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the earliest manifestations of cardiovascular disease (Quyyumi, 1998; Vita & Keaney, 
2002) it is a biomarker of potential interest and significance for nutritional intervention 
studies. When considering the literature, four aspects warrant consideration. Firstly the 
methodology, the two predominate methodologies reported in the literature are Flow 
Mediated Dilation (FMD) and Reactive Hyperaemia-Peripheral Artery Tonometry (RH-
PAT). Using sildenafil (an inhibitor of cGMP-phosphodiesterase type 5, which 
enhances the effects of nitric oxide) to induce an improvement in these two functional 
assessments of endothelial function, Aversa et al. (2008) concluded that although 
related, these two functional measurements might represent different aspects of 
endothelial function. Secondly, along with the functional measures, biomarkers can be 
used, commonly in the form of adhesion molecules found on endothelial cells and 
circulating platelets. Thirdly, there are aspects of endothelial mechanism linked to 
inhibition or assessment of nitric oxide metabolism. Finally, the experimental design is 
open to question; whether the study protocol tended to assess change following acute 
ingestion (2-6 hours), after several days of feeding or both, as it is plausible that the 
short-term mechanisms of endothelial function improvement may differ to any chronic 
effects. 
The first clinical trial used RH-PAT to assess the role of nitric oxide on the potential 
effect of cocoa in 27 healthy volunteers (Fisher et al., 2003). This study fed 821mg of 
flavanols in a cocoa beverage for five days (only seven individuals underwent the 
placebo). This non-randomised trial demonstrated that a flavanol rich cocoa beverage 
could improve endothelial function acutely, and to greater effect, after 4 days. These 
findings appeared to be associated with nitric oxide, as this effect could be completely 
reversed by injecting NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide 
synthase. This association was also demonstrated using FMD and nitric oxide 
metabolites following a single dose of 176mg flavanol containing cocoa beverage 
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(Heiss et al., 2003) in 20 participants in a crossover study. The study included two 
participants with diabetes amongst a population with and without cardiovascular disease 
risk but who were not particularly obese. Heiss et al. (2005) extended these findings 
with similar cocoa formulations to a small sample of eleven smokers and found that a 
single dose could acutely reverse the endothelial dysfunction often seen with smoking. 
This effect in smokers was further supported by a chocolate supplementation study, 
where increases in serum nitrates and nitrites were observed along with improved flow-
mediation dilation 2 hours after ingestion (Loffredo et al., 2011). 
The benefits seen in endothelial function measured by FMD were not limited to young 
and middle aged participants.  Monahan et al. (2011), in a crossover design study, 
acutely tested a range of five energy matched doses of cocoa from 0g to 26g (flavanol 
doses 0.0, 9.3, 25.8, 66.6 and 146 mg) in 23 healthy older adults (63±2 years old). 
Monahan et al. (2011) additionally demonstrated a dose dependent increase in FMD.     
Engler et al. (2004) undertook the first study to investigate the effects of chocolate 
rather than the cocoa drinks used in earlier work on endothelial function, and were also 
the first to measure fasting endothelial function following two weeks of chocolate 
consumption. In a parallel-randomised study, healthy participants were fed 46g of 
chocolate with either 46mg epicatechin (213mg flavanols) or only a trace of these 
compounds. Engler et al. (2004) concluded that in their study population, a significant 
improvement of endothelial function was seen which coincided with an increase in 
serum epicatechins. These authors also suggested that this was independent of any 
improvement in oxidative stress or lipid profile, which does not concur with the 
conclusions of other researchers. To elucidate the potential mechanisms, Schroeter et al. 
(2006) reported data from five investigation which suggested that the significant 
improvements in FMD seen with cocoa can be produced by supplementing with the 
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flavanol epicatechin. Both of these supplements can also increase nitric oxide 
metabolites, which can be demonstrated in ex vivo models. 
Grassi et al. (2005b), studied individuals with untreated hypertension who were fed 
100g of dark chocolate using largely the same protocol as in their previous study with 
healthy participants (Grassi et al., 2005a) and then later in individuals with impaired 
glucose tolerance (Grassi et al., 2008). The dark chocolate was stated as containing 
65.97 mg epicatechin by their determination, but had no reference to the 500mg claimed 
in their previous work. In this crossover design study, twenty participants showed an 
11.9±7.7/8.5±5.0 mmHg reduction in blood pressure, which is a large change and 
comparable to many pharmaceutical agents! Along with this, improved insulin 
resistance, insulin sensitivity index and endothelial function, were also seen suggesting, 
that despite the caveat that this was a large amount of dark chocolate (100g) eaten over 
a short period of time (15 days) the effects on multiple aspects of cardiovascular risks 
are dramatic and of potential clinical significance. Before incorporating regular 
consumption of dark chocolate into public health messages, long term the effects of its 
high energy density and saturated fatty acid content need to be investigated and 
considered. These data were developed by Vlachopoulos et al. (2005), who showed that 
three hours after consuming 100g of chocolate, 17 healthy volunteers demonstrated 
improved endothelial function without altering aortic stiffness. This was despite the 
potential sources of confounding created by the control being sham feeding, which did 
not match the participant experience or energy and macronutrients intake. This effect 
was further supported by the data of Hermann et al. (2006) in a parallel design study, 
with 20 participants, where the intervention was a lower dose of 40g of dark chocolate. 
In addition to improved endothelial function after two hours this showed an 
improvement in shear stress dependent platelet function.  
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In a complex four arm study design (Kurlandsky & Stote, 2006), which combined 
interventions including chocolate with almonds in a population of healthy women over 
six weeks in a parallel design it was suggested, that it is also possible to show a 
significant improvement in adhesion molecules with 41g of chocolate alone (p=0.03), 
together with a decrease in circulating intercellular adhesion molecule-1 (ICAM-1). 
This observation was not replicated in the groups where chocolate was in combination 
with almonds. Although ICAM-1 did not change, in a study supplementing 32 
postmenopausal women with a cocoa beverage containing 446mg of flavanols over 6 
weeks, an improvement in flow mediated dilation and vascular capillary adhesion 
molecule (VCAM) were seen (Wang-Polagruto et al., 2006). These data suggest that 
individual assays of biomarkers are not perhaps valid in isolation. It may be preferable 
for trials to consider using multiple markers of endothelial function to enhance the 
validity of any findings. Further evidence was presented by Monagas et al. (2009) 
despite what could be suggested as an inadequate control, in the form of milk, with the 
active ingredient being cocoa in milk, which would therefore mean participants, would 
not be blinded. In a study of 42 high risk participants using a parallel study following 4 
weeks of cocoa supplementation, Monagas et al. (2009) reported a significant 
improvement in biomarkers of endothelial function, including a reduction in expression 
of markers from monocytes (very-late antigen (VLA-4), CD40 and CD36 all p<0.05) 
and reductions in p-selectin and ICAM-1 (p=0.007 for both markers). In addition to 
improvements in adhesion molecules, Vázquez-Agell et al. (2011) in an acute cocoa 
supplementation study in healthy participants (n=18) in milk or water, compared with 
milk alone, found improvements in ICAM-1 and e-selectin, but not VCAM which 
accompanied a decrease in NF-κB activation in mononuclear cells. These data of 
Vázquez-Agell et al. (2011) further support the position that to be assured of an effect 
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of cocoa or chocolate upon endothelial function, more than one marker should be 
reported as improving following supplementation. 
As regards the mechanisms for improvements in endothelial function, although acute 
responses are well described being mostly associated with nitric oxide metabolism, but 
the beneficial effects seen in longer-term studies might be different. Heiss et al. (2010), 
in a study using a 30-day supplementation period in a crossover study with 16 
participants with coronary artery disease found that cocoa rich in flavanols can mobilize 
early endothelial progenitor cells. These cells have been linked to endothelial repair, 
thus providing a plausible mechanism for acute and prolonged improvements in 
endothelial function (Shantsila, Watson & Lip, 2007). 
The first study which failed to find an effect of either acute or chronic ingestion of 
chocolate and cocoa upon markers of endothelial function was by Farouque et al. 
(2006). A parallel study of 40 individuals with cardiovascular disease also showed no 
effect of supplementation (Farouque et al., 2006). This lack of effect might be an 
artefact of significantly higher total and LDL cholesterol values in the high flavanol 
group, which may have acted as a source of confounding, with the populations not 
appearing to be adequately matched.  
The first study to investigate the effects of cocoa supplementation in individuals with 
T2DM was reported by Balzer et al. (2008). These data considered the effect of cocoa 
beverages following both acute (after 2 hours) and 30 days supplementation. This study 
used a 963mg flavanols per day dose (split into 3 doses) in a parallel designed study of 
41 medicated participants with T2DM to produce a 30% (p<0.0001) increase in fasting 
flow-mediated dilation. This was seen despite the additional 159 kcal (668Kj) and 15 
grams of sugar consumed suggesting that there is potential for cocoa/chocolate 
supplementation in T2DM. This study represents one of only two studies reporting the 
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effects of cocoa flavanols in populations defined by their T2DM prior to my work, 
which is reported in this thesis. 
The effect of the sugar and carbohydrate content given acutely was partially explored by 
Faridi et al. (2008) with further data from a six week feeding study reported by Njike et 
al. (2011). Both studies emphasised the comparison of cocoa rich in polyphenols with 
and without sugar and its effect upon endothelial function and both concluded that 
flavanol rich cocoa improved endothelial function, which maybe attenuated by sugar, 
and that sugar-free preparations may augment these effects. This was despite Faridi et 
al. (2008) reporting the first phase of their work, which included an equivalent dose of 
flavanols from chocolate as that given in the cocoa phase. No statistical comparisons of 
these data were reported. It is plausible that high sugar might inhibit the benefits of 
cocoa flavanols, however whether cocoa or chocolate is the optimal delivery vehicle 
was not investigated, despite the potential of having the data to address this question. 
The favoured mechanism for improved endothelial function appears well elucidated. 
Current consensus is that this is via the up regulation of nitric oxide; however 
potentially the data of Grassi et al. (2005b) suggests that insulin-mediated pathways 
may have a role in addition to nitric oxide. This mechanism is likely also to be 
influenced by the carbohydrate/sugar content of the cocoa or chocolate, which via a 
hyperinsulinaemic effect may inhibit the size of the bioavailable pool of nitric oxide 
(Dworakowski et al., 2008; Munzel et al., 2008).  
Muniyappa et al. (2008) in a 2-week supplementation trial using cocoa, demonstrated an 
improvement in insulin-mediated vasodilation, using the gold standard insulin clamp 
methodology (Matsuda & DeFronzo, 1999), instead of the simpler and cheaper HOMA 
or QUICKI reported by other groups who have reported improvements in insulin 
resistance with cocoa or chocolate. Muniyappa et al. (2008) did not observe an 
improvement in insulin resistance, as seen by Grassi et al. (2005b; 2008). This suggests 
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that the more robust methodology used in this cohort of twenty individuals taking part 
in a crossover study for a 2 week supplementation study with a one week washout 
period, means that changes in insulin resistance may not be a primary effect of cocoa 
flavanols, whilst maintaining support for an insulin mediated effect on the 
bioavailability of nitric oxide. This has significant implications for cocoa flavanols 
intervention trials, as formulations need to potentially minimise their carbohydrate 
content, whilst maintaining palatability to achieve maximal efficacy with respect to 
improved endothelial function. 
The effects of cocoa supplementation do not appear to be limited to the rested or 
inactive state. Berry et al. (2010), found that consumption of 701mg of cocoa flavanols 
(compared with 22mg of cocoa flavanols) reduced the rise in blood pressure in response 
to exercise associated with improved endothelial function. This suggests a beneficial 
effect of combining cocoa polyphenols with physical activity. The potentially adverse 
effects of night shift working on endothelial function and cardiovascular risk is known 
(Amir et al., 2004; Su et al., 2008), and has been shown to be reduced by 
supplementation with flavanol rich chocolate, however these data are potentially 
confounded by the lack of a control group (Kim et al., 2012).  
Westphal and Luley (2011) investigated the effect of feeding fat in combination with 
cocoa flavanols in a placebo controlled, double blind crossover study of 18 healthy 
participants. They combined cocoa rich in flavanols (918mg) or cocoa poor in flavanols 
with a meal consisting of whipping cream (3ml per kg, consisting of 33% fat). The data 
from this study, suggested that cocoa flavanols have the potential to reduce the 
metabolic stress, which results in endothelial dysfunction in the post-prandial state. 
Despite these data the effects of cocoa polyphenols on a carbohydrate load have not 
been tested. 
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1.4.2.5	  -­‐	  Clinical	  trials	  data:	  oxidative	  stress	  and	  inflammation	  
A few studies have focused on inflammation as a primary outcome while some have co-
reported markers including C-reactive protein (CRP) (Hamed et al., 2008). ‘Oxidative 
stress’ is often seen as the biologically relevant equivalent of antioxidant capacity 
measured in food. This is however a controversial area, as many potential biomarker 
compounds have been suggested; but as in the case of ORAC, a number of these 
including malondialdehyde (MDA) also referred to as 2-thiobarbituric acid reactive 
substances (TBARS). Both of which have been challenged in terms of their biological 
validity. Although widely used in studies and therefore the published literature, TBARS 
have been rejected as a valid marker of nutritional influence upon oxidative stress 
(Mensink et al., 2003). Despite these limitations, this review will consider all markers 
reported; but these will not included as part of the exploratory review with meta-
analysis, where only isoprostanes will be considered is reported in Chapter Three, as 
this has been acknowledged as a valid marker of oxidative stress (Mensink et al., 2003). 
Much of the initial data in this field was published at a time when the scientific 
community favoured the antioxidant hypothesis and the biological relevance of ORAC. 
Rein et al. (2000a) reported work linking a rise in plasma epicatechin following 
ingestion of 80g of dark chocolate, with an increase in plasma antioxidant capacity and 
TBARS. These data also demonstrated a non-significant increase in uric acid after 
giving flavanol rich chocolate. Uric acid is the primary antioxidant in plasma and was 
still present in greater than a thousand fold concentration than the peak epicatechin 
level. Perhaps of more relevance are markers of oxidative damage, in the form of 
damaged in vivo molecules. The PASSCLAIM group (Mensink et al., 2003) proposed 
isoprostanes, as a suitable surrogate measure of oxidative stress. These molecules are 
the free radical catalysed product of peroxidation of arachidonic acid and other long 
chain polyunsaturated fatty acids. These are relatively stable and are solely formed by in 
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vivo synthesis (Lawson et al., 1998), unlike MDA and they have become preferred 
measures of oxidative stress. Wang, Schramm and Holt (2000) demonstrated a rise in 
plasma levels of flavanols results in decreased levels of 8-isoprostane, along with the 
increase in antioxidant capacity and TBARS. The acute beneficial effects of cocoa upon 
F2-isoprostanes were also reported in healthy volunteers by Wiswedel et al. (2004) and 
in smokers (Carnevale et al., 2012). Few chocolate supplementing studies have focused 
on oxidative stress as a primary outcome. A study by Fraga et al. (2005) examined 
oxidative stress and demonstrated that high polyphenol milk chocolate (105g, 168 mg 
flavanols) consumption in young footballers for 14 days reduced MDA and uric acid, 
along with improvements in lipid profile and blood pressure. 
The value of isoprostane levels as a reflection of, cocoa flavanols, might relate flavanol 
chocolate increasing plasma prostacyclin (32% p<0.05) and decreasing plasma 
leukotrienes (29% p<0.04), both in an in in vivo crossover study in humans and in vitro 
work (Schramm et al., 2001), with data suggesting an effect upon eicosanoid 
metabolism as a result of the supplementation with chocolate. The eicosanoids have a 
role as endothelial derived factors, and thus an inter-relationship with nitric oxide, 
which reduces endothelial dysfunction. It is also plausible, that this mechanism might 
explain, in part, the effect of cocoa flavanols on isoprostanes (a breakdown product of 
eicosanoids). This hypothesis might suggest reductions in isoprostanes may not be via 
improved antioxidant status or reduced oxidative stress.  
Additionally cocoa flavanols have been shown to reduce erythrocyte susceptibility to 
damage by peroxide acutely (Zhu et al., 2005), and increase the resistance of DNA to 
damage by oxidative stress despite no change in total antioxidant activity (Spadafranca 
et al., 2010). These data further support the hypothesis of an alternative mechanism to 
the antioxidant preposition. The protective effects on reducing markers of oxidative 
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stress have also been demonstrated in exercise, which is known to increase circulating 
free radicals (Davison et al., 2012; Allgrove et al., 2011). 
1.4.2.6	  -­‐	  Clinical	  trials	  data:	  cardiovascular	  risk	  
Composite or combined cardiovascular risk estimates have been the focus of a number 
of studies, the rationale being the exploratory nature of these studies or that since data 
on individual markers may not demonstrate the necessary power to reach significance. 
In addition reducing cardiovascular risk, dark chocolate has been shown to inhibit 
collagen-induced platelet aggregation (Innes et al., 2003). These effects may relate to 
interactions in eicosanoid metabolism or pathways associated with adhesion molecules. 
This theory was partly explored by Flammer et al. (2007), in an acute feeding study of 
22 heart transplant patients who were fed 40g of dark (70% cocoa) chocolate in a 
double blind protocol. These data demonstrated an increase in endothelium-dependent 
coronary vasomotion and reduced platelet adhesion. In addition the isoprostanes and 
antioxidant capacity of plasma were improved (Flammer et al., 2007). More recently 
these effects were also demonstrated in healthy participants (Shiina, Funabashi & Lee, 
2009). 
Davison, Coates, Buckley and Howe (2008) reported an improvement in the composite 
measure of improved endothelial function, insulin resistance and blood pressure in 
overweight and obese participants following supplementation with 902mg flavanols in 
cocoa. These benefits were not further enhanced when combined with exercise. When 
combined with sterol esters, cocoa flavanols in chocolate appeared to demonstrate a 
positive effect upon cholesterol and blood pressure reduction (Allen et al., 2008; 
Polagruto et al., 2006; Solà et al., 2012). However, these studies lacked the ability to 
attribute those effects to specifically the flavanols or sterol ester component of the 
intervention. 
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Cardiovascular effects of flavanol rich chocolate alone were investigated by Flammer et 
al. (2011) in patients with heart failure. In 20 patients, the acute (over 2-hours) and four 
week effects were assessed. No effects on blood pressure were seen, perhaps a 
reflection of the high degree of antihypertensive poly-pharmacy in the study population. 
Endothelial function improved and platelet adhesion both decreased (Flammer et al., 
2011). In a study of 93 post-menopausal women with T2DM all treated with HMG-co-
ase inhibitors or ‘statins’, were given 1 years supplementation with a combination of 
flavanols and isoflavones given in chocolate (Curtis et al., 2012). There was a reduction 
in the level of LDL cholesterol (calculated from Friedewald (Friedewald, Levy & 
Fredrickson, 1972)), total cholesterol: HDL cholesterol: total cholesterol ratio and 
insulin resistance was reported (Curtis et al., 2012). This supplement might not be 
considered to be ‘chocolate’ in line with EU law (European Union, 2004), and it was 
difficult in this study as with the studies combining cocoa flavanols with sterol esters 
(Allen et al., 2008; Polagruto et al., 2006; Solà et al., 2012) to assess the proportion of 
the effect due to the cocoa or the other potentially active ingredients. Curtis et al. (2012) 
also postulated that supplementing with cocoa flavanols and isoflavones reduced the 
estimated 10-year risk of cardiovascular disease, in fact the data indicated there was no 
net increase for the active compared to a 1.1% increase for the placebo. 
1.4.2.7	  -­‐	  Clinical	  trials	  data:	  other	  biological	  markers	  	  
Chocolate and cocoa rich in flavanols have also been assessed for their effects on other 
markers of health. These have included the ability to protect the skin from UV damage, 
(Williams, Tamburic & Lally, 2009) and the emerging area of cognitive function in the 
elderly (Crews  Jr., Harrison & Wright, 2008), who additionally reported reductions in 
cardiovascular risk. Further effects were a reduced risk of dementia (Desideri et al., 
2012) and stroke (cerebral vascular accidents (CVA)) (Larsson, Virtamo & Wolk, 
2012). Effects of cocoa flavanols upon changes in muscle function at a structural level 
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were reported (Taub et al., 2012) in a very small and uncontrolled study, along with the 
potential to enhance muscle recovery following exercise (Gilson et al., 2010). 
There is also emerging data to suggest that cocoa polyphenols may have effects upon 
the gastrointestinal tract flora, with increases in bifidobacteria and lactobacilli (both 
p<0.05) along with decreases in potential pathogens (Tzounis et al., 2011). These 
effects were seen in conjunction with simultaneous decreases in C-reactive protein and 
triglycerides. This provides a further potential mode of action for cocoa flavanols as 
prebiotics, this might in turn influence enterocyte metabolism and result in systemic 
reductions in disease risk (Lomax & Calder, 2009). 
1.4.2.8	  -­‐	  Systematic	  reviews	  and	  meta-­‐analyses	  
Over thirty standard reviews, systematic reviews and meta-analyses have been 
published on the health effects of cocoa and chocolate up to the end of June 2012. 
However, only 11 of these reviews along with a costing study undertaken by Zomer et 
al. (2012) have followed a systematic methodology, and only these will be considered in 
this Chapter. Two of these have already been discussed in section 1.5.1, as part of the 
epidemiological data on the effects of cocoa on health, where they were, the only 
reviews to report hard endpoints, including death or myocardial infarction (Buitrago-
Lopez et al., 2011; Khawaja, Gaziano & Djoussé, 2011). 
The first systematic review on the effects of chocolate in the prevention of 
cardiovascular disease was published by Ding, Hutfless, Ding and Girotra (2006),  and 
considered both short term feeding trials along with in vitro and epidemiological data. 
This review focused upon stearic acid, which is found in cocoa butter. The data on this 
saturated fatty acid suggested it was at least neutral in its effects upon cardiovascular 
risk, while the flavanols in chocolate were likely to be beneficial, with a crude estimate 
that 50g chocolate might reduce cardiovascular risk by 10.5% (95% confidence interval 
7.0-13.5%). However, this estimate included the caveat that it was based on a number of 
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extrapolations. This was followed up by the meta-analysis of Taubert, Roesen and 
Schomig (2007) who considered cocoa and tea intake. The conclusion was that although 
cocoa may reduce blood pressure, tea intake had no effect. This is despite the significant 
reduction in blood pressure seen with cocoa (p<0.01 for both systolic and diastolic 
blood pressure), but not for tea. However, although the cocoa and tea studies were 
analysed separately, no formal subgroup analysis was undertaken. 
A rigorous review by Hooper et al. (2008) considered the effects upon cardiovascular 
risk of a range of flavonoid-rich foods which include cocoa flavanols. This again found 
that chocolate improved endothelial function (both acutely and chronically) and reduced 
blood pressure. A range of similar beneficial effects were also described for soy protein 
isolates and both green and black teas. 
Increased interest of the effects of cocoa and chocolate developed in 2010, 
demonstrated through the publication of three meta-analyses; two focused on blood 
pressure (Desch et al., 2010a; Ried et al., 2010a) and one on lipid profile (Jia et al., 
2010). Ried et al. (2010a) suggested that normotensive individuals did not see a 
significant improvement in blood pressure, in response to cocoa and chocolate where 
Desch et al. (2010a) reported a more global improvement was seen across the 10 studies 
analysed. The meta-analysis assessing the effects of cocoa consumption on lipid profile 
suggested that although total cholesterol was reduced, improvement in LDL cholesterol 
was only seen in studies of a lower quality (lower Jadad score (Jadad et al., 1996) and 
there were no changes in HDL cholesterol (Jia et al., 2010). The meta-analysis of Jia et 
al. (2010) was also limited by the lack of studies investigating participants with 
increased cardiovascular risk including T2DM, and therefore an atherosclerotic profile. 
This pattern of publication was repeated in 2011, with four further studies; two as 
previously discussed, focused on the epidemiological data (Buitrago-Lopez et al., 2011; 
Khawaja, Gaziano & Djoussé, 2011). The other two studies reported the effects on lipid 
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profile (Tokede, Gaziano & Djoussé, 2011) and multiple cardiovascular risk factors 
(Shrime et al., 2011). Tokede Gaziano and Djoussé (2011) reported the same benefits 
following cocoa and chocolate supplementation as Jia et al. (2010) but did not consider 
study quality across the 10 studies they selected. Shrime et al. (2011) suggested that the 
data from cocoa consumption studies gave short-term significant improvements in 
endothelial function, blood pressure, lipid profile and insulin resistance. However this 
paper had a number of methodological errors, for example the inclusion of data from 
trials that did not meet the reviewers own exclusion criteria.  
The high interest in systematic reviews and meta-analyses continued into 2012 (data 
collection for the review concluded 30 June 2012), with Zomer et al. (2012) suggesting 
that chocolate supplementation might prove to be a cost effective intervention in 
reducing cardiovascular disease. Ellinger, Reusch, Stehle and Helfrich (2012) using a 
nonlinear regression model with a Bayesian approach demonstrated in 16 randomised 
controlled trials there was a significant reduction in blood pressure with 25mg dose of 
epicatechin. This methodology attempted to consider dose effects, which many of the 
other systematic reviews did not explore. However, it did not address the effect of the 
formulation of the supplement, whether consuming chocolate is preferential to cocoa.  
Hooper et al. (2012) followed up their previous work of 2008 (Hooper et al., 2008) 
focusing solely upon chocolate and cocoa. This confirmed previous findings showing an 
improvement in endothelial function being improved. Additionally, the authors claimed 
it to be the first published meta-analysis of improvements in insulin and insulin 
resistance despite the work of Shrime et al. (2011). Hooper et al. (2012) also suggested 
that larger, long-term studies were needed which were independent of the cocoa and 
confectionary industries, to investigate the cardiovascular benefits of cocoa flavanols 
thoroughly. The overall conclusion of both Shrime et al. (2011) and Hooper et al. 
(2012) is that the optimal effect of cocoa and chocolate appeared to be in interventions 
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containing 500mg of polyphenols. This is the same dose that has recently been accepted 
by EFSA as having a significant effect upon maintaining healthy endothelial function 
(EFSA, 2012a). 
1.4.3	  -­‐	  Summary	  of	  Review	  
The history of this area of scientific exploration is less than twenty years old, from the 
initial in vitro work of Waterhouse, Shirley and Donovan (1996), to the first human 
studies being reported in 2000 (Wang et al., 2000, Rein et al., 2000a; 2000b). During 
this time, the beneficial effects of cocoa and chocolate have been demonstrated on a 
number of health markers. These include antioxidant status, which has been largely 
discredited as a false and simplistic mode of action to alternative mechanisms and 
oxidative stress/improved eicosanoid metabolism, lipid profile and resistance to 
oxidative damage, blood pressure and possibly insulin resistance. Most of these studies 
have been in healthy individuals, some with cardiovascular disease or risks. Only two 
studies have been undertaken in individuals with T2DM (although three others included 
some individuals as part of a high risk group). Of these two studies, one used cocoa as 
the intervention (Balzer et al., 2008) and did not assess effects upon diabetes, focusing 
on endothelial function, and the other used an interventional product with at least two 
potentially biologically active compounds (isoflavones in addition to cocoa flavanols) in 
a chocolate like formulation (Curtis et al., 2012). Thus there are no published data on 
the effect of chocolate upon measures of cardiovascular risk in T2DM (outside that 
presented in this thesis). 
The data systematically reviewed, suggest that many of the studies lack rigour in their 
design, being at risk of confounding to either a lack of control arm, inadequate controls 
(not matched for appearance, energy content or macronutrients) or randomisation and 
the concealment of the blinding.  In their personal review of the first decade of research 
into cocoa and health Cooper, Donovan, Waterhouse and Williamson (2008) 
Chapter	  One	  –	  Introduction	  and	  Literature	  Review	  
	  81	  
summarised and proposed an 11 point checklist for the planning of future trials; these 
included the design of the trials, the need to consider the matrix or formulation used; the 
use of chocolate in preference to cocoa (this will be considered in the exploratory 
review with meta-analysis presented in Chapter Three), transparency; both in terms of 
independency of the trial from industry and the need to register human trials publically, 
careful selection of biomarkers; especially those assessing antioxidant effects and 
finally, publication of null or negative results.  
This introduction has considered the potential of cocoa flavanols, administered both in 
cocoa and chocolate as being beneficial to health. The claim has been accepted by the 
NDA panel of EFSA as a health claim relating to endothelial function (EFSA 2012a). 
The literature and currently registered studies leave highlighted six areas proposed in 
Chapter One, of benefit: 
 Blood pressure 
 Lipid profile 
 Insulin resistance and glycaemia 
 Endothelial function 
 Oxidative stress (rather than antioxidant capacity) 
 Inflammation 
These six aspects of cardiovascular risk; three established and routinely used in clinical 
care, and three emerging risk factors will be examined through the exploratory review 
with meta-analysis and experimental studies which comprise the original data presented 
in this thesis. 
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1.5	  Aims	  and	  Objectives	  of	  Experimental	  Work	  
The comments of Fraga (2005), published eight years ago, suggested clear beneficial 
effects of cocoa and chocolate in diabetes. However, despite this, no systematic clinical 
trials have been undertaken to investigate the effects of chocolate in T2DM. 
1.5.1	  Aim	  of	  Thesis:	  
Systematically investigate the effects of chocolate on the cardiovascular risk and 
glycaemic control of individuals with T2DM. 
1.5.1.1	  Objectives:	  
• Investigate the effect of the matrix (either chocolate or cocoa) on markers of 
cardiovascular risk and glycaemic control using an exploratory review with a 
meta-analysis methodology. 
• Investigate the modulating effects of chocolate on cardiovascular risk over a 
two-month period. 
• Investigate the acute effects of chocolate in individuals with T2DM during 
transient hyperglycaemia. 
• Investigate the potential of milk chocolate to reduce cardiovascular risk in 
T2DM over a three-month period. 
1.5.2	  Hypothesis:	  
Primary hypothesis 
Null Hypothesis:  Chocolate rich in cocoa flavanols does not reduce  
  cardiovascular risk in individuals with T2DM and 
  leads to weight gain as part of a clinical trial. 
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  General	  Methods	  and	  Materials	  	  
Aim and Scope of Chapter: 
• To summarise experimental approaches used within this thesis. 
• To consider the role and design of clinical trials in producing evidence for the 
efficacy of interventions in healthcare. 
• To consider the role of the placebo/control in clinical trials of food products. 
• To consider the six types of marker that were defined in Chapter One for 
assessing the effect of chocolate in type 2 diabetes mellitus (T2DM). 
• To consider the safety assessments and participant reported outcome measures. 
To address these aims this chapter will be split into three sections: 
2.1 - Introduction to study design. 
2.2 - A review of clinical trial methodologies relating to food. 
2.3 - General procedures and methodologies.  
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2.1	  –	  Introduction	  to	  Study	  Design	  	  
An exploratory review (Section 1.4), with limited meta-analysis (Chapter 3), on the 
effect of chocolate on measures of diabetes control and cardiovascular risk was 
undertaken first to determine gaps in the knowledge base. This meta-analysis focussed 
on biological markers of health in one of six areas noted in Chapter One; Section 1.3.3: 
1. Blood pressure 
2. Lipid profile 
3. Diabetes control and insulin resistance 
4. Endothelial function 
5. Oxidative Stress 
6. Inflammation 
In addition to these measures, weight change was determined as a marker for the 
additional energy load consumed that may adversely affect diabetes control. 
Following this meta-analysis de novo clinical trial data was obtained from three 
randomised clinical trials in participants with T2DM summarised in Table 2.1.1, 
namely: 
1. A pilot proof of concept study (Chapter Four – Study One). 
2. An acute response study using transient hyperglycaemia to induce metabolic 
stress (Chapter Five – Study Two). 
3. A three-arm double-blinded randomised controlled trial, which included a 
flavanol, enriched milk chocolate (Chapter Six – Study Three).  
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Table 2.1.1: Summary of study protocols, which constitute the experimental data presented within 
this thesis. 
 Exploratory 
Review and Meta-
analysis 
Pilot Proof of 
concept study 
Acute response 
study 
Three-arm study 
Chapter Chapter Three Chapter Four Chapter Five Chapter Six 
Design Exploratory Review 
and Meta-analysis 
Randomised 
Controlled Trial 
Double blind 
Intervention 
Cross-over 
Randomised 
Controlled Trial 
Double blind 
Intervention 
Cross-over 
Randomised 
Controlled Trial 
Double blind 
Intervention 
Parallel 
Regulatory 
framework 
PRISMA Guidelines 
 
(Adapted for a single 
author due to the 
nature of this piece of 
work, search limited 
and estimation of 
variance of mean 
difference limited) 
ICH 
NHS ethics/ NHS 
Research & 
Development  
Trials registration 
ISRCTN 25655161 
ICH 
NHS ethics/ NHS 
Research & 
Development  
Trials registration 
ISRCTN 35988358 
ICH 
NHS ethics/ NHS 
Research & 
Development  
Trials registration 
NCT01617603 
Funding None Diabetes Research 
funds / chocolate 
provided as a gift 
Barry Callebaut Nestlé 
07.52.NRC 
Publication One Abstract only to 
date (Accepted) 
Not suitable in current 
state for publication 
due to limitations in 
methodology 
Mellor et al., (2010) 
+ 3 abstracts 
Mellor et al.,  
(In press) + 2 
abstracts 
Three abstracts only 
to date 
Participants RCTs with well-
defined interventions 
T2DM (lifestyle or 
oral medications 
only) 
T2DM (lifestyle or 
metformin only) 
T2DM (lifestyle or 
metformin only) 
Duration All 8 weeks (2 months) 
+ 
4 weeks (1 month) 
washout 
3 hours + 1 week 
washout 
12 weeks following a 
4 week run in period 
Chocolate Chocolate or Cocoa 
in any dose 
 
Control matched in 
terms of appearance/ 
taste and energy/ 
macronutrients 
45g per day 
 
 
Formulated high 
polyphenol 
chocolate 
 
Dyed white 
chocolate 
13.5g dose 
 
 
Acticoa (3% 
polyphenol) 
 
 
Acticoa (0.9% 
polyphenol) 
20g per day (40g 
acute feeding dose) 
Milk chocolate 
(20mg epicatechin) 
 
Nestlé Noir (20mg 
epicatechin) 
 
Chocolate (1mg 
epicatechin) 
Primary 
Outcomes 
Effects of chocolate 
or cocoa on health 
Improvement in lipid 
profile 
Improved 
endothelial function 
Reduced insulin 
resistance 
 
Secondary 
Outcomes 
Chocolate showing 
superior effect 
compared to cocoa 
Weight change 
Glycaemic profile 
Blood pressure 
Insulin resistance 
Oxidative stress, 
insulin and 
glycaemic response 
Lipid profile, blood 
pressure, 
inflammation and 
oxidative stress 
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2.2-­‐	  Clinical	  Trial	  Design	  
2.2.1-­‐	  Hierarchy	  of	  Clinical	  Evidence	  
Traditionally when evaluating and generating data regarding evidence for health 
outcomes, a hierarchy of evidence has been developed (Ho, Peterson & Masoudi, 2008). 
This is often represented as a pyramid (figure 2.2.1.1), which is capped with a further 
tier of systematic reviews and meta-analyses of well-designed randomised controlled 
trials. The evidence for how this shapes the current evidence can be seen in Chapters 
One (introduction and literature review) and Three (exploratory review and meta-
analysis). For the purposes of this chapter, it is being used to highlight the strength of 
the methods selected for the generation of the new data, which are presented in Chapters 
Three, Four, Five and Six. 
 
Figure 2.2.1.1: Pyramid or hierarchy of clinical evidence (adapted from Ho, Peterson and Masoudi 
2008). 
 
The selection of an exploratory review with meta-analysis for Chapter Three is to 
consider the weight of the data in the peer-reviewed literature, and how the 
experimental data presented in the preceding three chapters potentially influences it. 
This is partially to confirm previous meta-analyses findings of a benefit of cocoa and 
chocolate, although a number of these have included mixed interventions, including 
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other biologically active ingredients or exercise. The secondary outcome is perhaps 
more important; a sub-group analysis investigating whether chocolate offers greater 
efficacy compared to cocoa. 
2.2.1.1	  -­‐	  Randomised	  Controlled	  Trials	  
Although observational studies, supported by the mechanistic studies provided by basic 
scientific work, there is no clinical trial data to date, available which supports a 
beneficial causative effect of chocolate in individuals with T2DM.  
2.2.2-­‐	  Clinical	  Trial	  Conduct	  
Conduct and reporting of clinical trials is well described in the case of those using 
pharmaceutical agents or investigational medicinal products. In Europe and the United 
States of America, these are tightly regulated by legislation. This is closely linked to the 
guidelines developed by the International Committee for Harmonisation (ICH), which 
set about the development of good practice, and ethics in medical research (ICH, 2005).  
However, when considering the work reported in this thesis, which investigated the 
health effects of foods or other nutritional products; no such regulations, guidelines or 
legislation exist. 
The absence of regulation is in part circumvented by the recommendations of the 
International Committee of Medical Journal Editors (ICMJE) in 2005 who stipulated 
that all clinical trials prior to submission should have their protocol registered. This has 
become part of research culture in the United Kingdom, where National Health Service 
Research Ethics Committees (NRES) strongly consider it an ethical obligation, but not a 
statutory stipulation, that clinical trials should be registered (NRES, 2009). This also has 
its basis in pharmaceutical trials. In the USA, following the passing of the Food and 
Drug Administration (FDA) Amendment Act 2007 (FDA, 2007), all trial results needed 
to be registered.  
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The requirement is not simply aimed at pharmaceutical research targeting publication in 
highest quality medical journals as these recommendations have since been adopted by 
approximately a thousand titles. Additional what is considered to be a clinical trial has 
been expanded, since June 2007 the ICMJE adopted the WHO definition of clinical trial 
as:  
“Any research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health outcomes.” 
Where the meaning of a health-related intervention includes any intervention used to 
modify a biomedical or health-related outcome. This does not just include 
pharmaceutical agents, but extends to surgical procedures, devices, behavioural 
treatments, dietary interventions, and process-of-care changes. The health outcome 
being assessed includes any biomedical or health-related measures obtained in patients 
or participants, including pharmacokinetic measures and adverse events (ICMJE, 2009).  
As trial registration is generally seen as best practice, this was completed for all the 
clinical trials reported in this thesis, as shown in table 2.1.1. This is especially important 
for trials investigating interventions linked to potential intellectual property (not only 
pharmaceutical agents, but also medicinal devices and foods amongst others) where 
there is potential for commercial exploitation and therefore a tendency not to report 
negative findings. So, even if a trial is not fully reported in the form of a peer-reviewed 
paper, the registry entry will remain in the public domain. 
Although not a legal requirement, studies were conducted in accordance with ICH  
Good Clinical Practice Guidelines (1996) as would be expected in accordance with 
European law (European Union, 2001; 2005) and then their subsequent adoption into 
UK law (Statutory Instrument, 2004; 2006a; 2006b) for trials involving investigational 
medicinal products. The rationale for this was that the centre in which the work was 
undertaken was primarily engaged in pharmaceutical trials, and the nature of these 
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guidelines meant the conduct and data quality would be of the highest possible standard. 
As two of the studies were commercially funded but investigator led, it meant that the 
study protocol (although independently designed by myself with the supervisory team) 
together with the data, subject was to a high degree of scientific scrutiny throughout the 
data collect and analysis. This included full trial monitoring and blinded data scrutiny in 
the case of both of these trials funded by Barry Callebaut BV and Nestlé. 
2.2.3	   -­‐	  Parallel	  Compared	  with	  Crossover	  Design	  
All studies followed a controlled experimental design, which assessed changes in 
anthropometric and biomedical markers along with the use of quantitative 
questionnaires. This method was chosen so to define the study population, also it is 
excepted that observational and cohort methodologies would not be sensitive enough to 
show the subtle changes that would be expected within the time frame of the thesis (six 
years). It is also considered that only randomised controlled trials have the ability to 
demonstrate a potential causative effect, with observational studies limited to suggesting 
associations (Ho, Peterson & Masoudi, 2008). 
Cooper et al. (2008) suggested that future studies investigating the health effects of 
cocoa and chocolate should employ a crossover design as part of a randomised 
controlled study. Ideally this should also include a placebo or control, which, is blinded 
to both the participant and the investigator. The latter aspect will be considered later in 
this chapter (2.2.2.10). 
The first two clinical trials (Chapters Four and Five) attempted to follow the 
recommendations of Cooper et al. (2008). These were chosen as the recommendations 
to follow, for a number of logistical reasons in addition to enhancing their scientific 
validity. The primary one being that it was a way of undertaking the study within the 
constraints of the initially limited available population. This changed through the course 
of the thesis following the initiation of a potential trial participant database developed in 
Chapter	  Two	  –	  General	  Methods	  
	  90	  
conjunction with the local diabetes network.  Also considering the effect size seen in the 
studies reviewed in Chapter One, and whether the effect may be of a lesser extent in 
individuals with T2DM, it was felt that using individuals as their own control would be 
likely to reduce the risk of inter-participant variation at baseline. This was felt to be 
most likely to have occurred in the study reported in Chapter Five, as this involved an 
oral glucose challenge, as glycaemia can vary between individuals. Therefore, it was 
felt that a crossover methodology was vital as it would be almost impossible to match 
individuals in terms of their glycaemic response prior to randomisation and that could 
lead to a large number of individuals being excluded, resulting in potentially lengthy 
and expensive screening procedures, due to inter-individual variation. 
Despite the favouring of crossover-designed studies, they are not without their 
limitations and sources of confounding.  Lathyris, Trikalinos and Ioannidis (2007) in a 
meta-analysis of crossover arm studies concluded both study designs tended to produce 
the same outcome, although the crossover design tended to show a more conservative 
estimate of effect. The parallel arm design tended to be limited when sample sizes were 
small. The crossover design is limited, in that although it may require fewer 
participants, they take longer to complete, generally a washout period is required 
between interventions and it assumes the participants are clinically and biologically 
stable throughout the study.  
The issue with respect to the length of the washout period, is estimated from the half-
life of the interventional product, which in the case of cocoa flavanols is short, with 
biological activity no longer evident after 22 hours (Spadafranca et al., 2010). However, 
biological markers being assessed may not revert to baseline for several weeks, e.g. 
glycosylated haemoglobin (HbA1c), which has a half-life of 28.7 days (Allgrove & 
Cockrill, 1988). Therefore for acute effect studies a minimum washout of 24-48 hours is 
required, and for chronic studies four weeks would be logical if including assessments 
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of glycaemic control. This would mean that the minimum length for a crossover study 
would be five months (20 weeks), which would allow two half-lives to see an effect 
upon HbA1c, and one half-life period for the washout. So when considering the 
inclusion criteria; if participants need to have been on stable medication for at least 
three months prior to enrolment, this would require participants to be clinically stable 
for a total of least eight months. With the nature of diabetes being a progressive disease, 
it may mean that some of the change seen might be the effect of the disease rather than 
lack of effect of the intervention or its potentially negative effect. An example of the 
progressive nature of diabetes, could be the increase in estimated cardiovascular risk 
after 1 year seen with the control intervention, as the intervention prevented this 
progression (Curtis et al., 2012). 
The final consideration required in crossover-designed studies is to fully account for 
potential order effects. Theoretically, if the study is adequately randomised this should 
not be seen. Theoretically crossover studies can be confounded by carry over effects 
from one arm to the other. This can be controlled for statistically but with careful 
randomisation this should not be necessary.  
In the case of food trials including the type presented in this thesis, which employed 
chocolate as the intervention product it could be considered that unlike drugs, which are 
often in a pill form and who’s form result in little or no psychological or sociological 
attachment by the participant, food might evoke an emotive response. Therefore in 
clinical trials using foods a crossover methodology this could introduce a degree of 
confounding due to the emotional attachment of individuals to one of the interventional 
foods. It is possible that participants might have preconceived ideas from the media 
about the chocolate they expect to consume and that this might reflect how they respond 
to both the proposed ‘active’ and ‘placebo’ bars.  
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The potential participant response to having two different chocolates in a crossover 
study was one of the reasons why in the third study (Chapter Six) a parallel-randomised 
design was used. This avoids bias from preconditioning which is potentially seen in a 
crossover study design, although biases from previous life experiences could not be 
eliminated.  
Due to the nature of the funding of the studies presented within this thesis, the chocolate 
formulations used were different in each study (summary characteristics of the 
chocolates are shown in Table 2.2.7). All three studies were doubly blinded at the point 
of randomisation, although there were subtle differences between the suggested ‘active’ 
chocolate and the placebo or comparator chocolate which may lead to the participants 
becoming unblinded. The investigators encouraged participants not to discuss their 
thoughts about the study chocolate until the end of the study in order to reduce biasing 
influences towards the investigator. The potential bias of participants ‘unblinding’ 
themselves was partially addressed using taste trials in the studies reported in Chapters 
Four and Five. For the parallel designed study in Chapter Six, Nestlé as a sponsor did 
not see this as an issue, so no taste trials were conducted. The rationale being that a milk 
chocolate was one of the ‘active’ interventions so would not be as easily detected as a 
traditional high polyphenol dark chocolate, which has a bitter taste. The risk was also 
moderated by the studies parallel design.  
2.2.3.1	  -­‐	  Randomisation	  
All three studies were randomised prior to the enrolment of the first participants. The 
provider of the chocolate held the randomisation codes in all three studies. In the cases 
of Chapter Four (Study One) and Chapter Six (Study Three) this was Nestlé, Nestec 
York, UK and Nestlé Research Centre, Lausanne, Switzerland respectively and for 
Chapter Five (Study Two) Barry Callebaut BV, Lebbeke-Weize, Belgium. The 
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concealment of the randomisation was maintained until the initial analysis of the data 
was complete, at which point the code was broken. 
2.2.4	  -­‐	  Regulatory	  Approval	  
All studies underwent full ethical review by the Hull and East Riding NHS Local 
Research Ethics Committee, and obtained approval prior to their commencement. 
Research governance approval was obtained through the Research and Development 
Department of Hull and East Yorkshire Hospitals NHS Trust.  
All studies were conducted in accordance with the Declaration of Helsinki of the World 
Medical Association (WMA, 2000) and Good Clinical Practice (EMEA, 2002). The 
work in Chapter Four was supported by an unrestricted gift of the chocolate for the 
study by Nestec PTC, York, UK and was funded through the Diabetes Charitable fund. 
Funding and sponsorship from Barry Callebaut BV, Lebbeke-Weize, Belgium, 
supported the work in Chapter Five, although the author (along with the supervisory 
team) of the thesis was responsible for the trial design. The work in Chapter Six was 
supported, funded, sponsored and monitored by Nestlé Research Centre, Lausanne, 
Switzerland. The protocol and study design for the work presented in Chapter Six was 
developed by the author of the thesis in conjunction with their supervising team with 
support from the Nestlé Research Centre, Lausanne, Switzerland. 
All three trials were registered on public data bases of randomised clinical trials; the 
work in Chapter Four being ISRCTN 25655161, Chapter Five; ISRCTN 35988358 
(both available from http://www.controlled-trials.com/isrctn/) and Chapter Six; 
NCT01617603 (http://clinicaltrials.gov/ct2/home). 
2.2.5	  -­‐	  Population	  
Participants in all three studies had T2DM and were taking (if applicable) stable 
medication for at least three months prior to enrolment with different patients invited to 
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participate in each studies. Further details and of the inclusion and exclusion criteria are 
described in Chapters Four, Five and Six. All participants were recruited from within 
the Hull and East Riding Diabetes Network in which they were patients.  
Participants had all given consent to be contacted regarding research when they were 
referred to the networks diabetes programme. It is a recommendation that all individuals 
with diabetes receive structured education about how to self-manage their condition 
(NICE, 2003, 2008; Diabetes UK & Dept. of Health, 2005). This was selected as a key 
criterion, as all participants would have received the same basic information regarding 
their diabetes and the recommended dietary treatment of their diabetes, thus reducing 
lifestyle variability issues.  
2.2.6	  -­‐	  Demographics	  
The population age range for all three studies was between 40 and 80 years. To reduce 
the potential for confounding from insulin deficiency, apart from the initial study 
(Chapter Four), which had a body mass index (BMI) range of 19-45 kgm-2, the 
subsequent studies focused on overweight and obese individuals with a BMI range of 
25-40kgm-2. The limits on weight were largely set to avoid extremes of metabolism, 
including the sympathetic over activity and inflammation associated with morbid 
obesity (Pontiroli, Pizzocri, Paroni & Folli, 2006).  
All studies included both male and postmenopausal female participants. The rationale 
for only including postmenopausal women was to reduce potential causes of variation in 
insulin resistance associated with cyclical changes in female sex hormones and 
currently relatively few premenopausal women have T2DM (Geer & Shen, 2009). 
For the work in Chapters Four and Five there was no allocation of the proportion of 
males to females in the study. This was not considered to be a potentially significant 
source of confounding problem as both these studies involved a crossover design. With 
the larger three arm Study Three (Chapter Six), which had a parallel design, to reduce 
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any bias, equal age range and gender biases were assigned to each arm of the study, 
although the size of the randomisation blocks was not disclosed. 
2.2.7	  -­‐	  Investigational	  Products	  -­‐	  Chocolates	  
All chocolates, except the Nestlé Noir used in Chapter Six, were not commercially 
available. The chocolate in using in Chapter Four was formulated as an unrestricted gift 
for this study by Nestec, York; for the work presented in Chapter Five the chocolate 
comprised of research samples provided by Barry Callebaut BV, based on the 
Acticoa™ cocoa and has been used in other studies (Almoosawi et al., 2010; 2012) and 
for Chapter Six, the control iso-energy chocolate and high flavanol milk chocolate were 
specially formulated by Nestlé in Lausanne, Switzerland.  
2.2.9	  -­‐	  Sampling	  Methods	  
Participants were invited to take part in the studies following their expression of interest 
in the research. This was undertaken by the posting of information to individuals, who 
were then contacted by telephone calls. Interested individuals had the nature of each 
study explained to them and were sent written information, and if they still were 
interested they were invited to attend to give full written consent to take part in the 
study and then underwent screening for suitability. 
The sample possibly were not randomly obtained as initially the participants might have 
been clustered due to referrer bias as they were initially obtained from healthcare 
professionals referring their patients for diabetes education. This may have been 
compounded by self-selection bias, as some individuals may due to their nature be more 
likely to volunteer to participate in trials than others. 
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2.2.10	  -­‐	  Placebo	  and	  Blinding	  
The concept of the placebo in this type of study is a challenging one. Unlike 
pharmaceutical trials where the known ‘active’ under investigation is given as a single 
compound in a matrix of inert compounds, the placebo will be an identical formulation 
that is designed to look and taste exactly the same. With foods this is not as easy to 
achieve. 
The other major challenge is in varying the ‘active’ product and the control only in 
terms of a single bioactive compound. In chocolate it is hypothesised that these are the 
polyphenols, with epicatechins being seen as the predominant ‘active’ components. This 
is based on the assumption that these can be measured circulating following their 
consumption, often in association with a beneficial effect and thus implying a 
mechanism of action (Rein et al., 2000a; Engler et al., 2004; Schroeter et al., 2006; 
Spadafranca et al., 2010). However it has been suggested that other components might 
have an effect on health, these range from theobromine (Kelly, 2005; van den Bogaard 
et al., 2010), fatty acid composition (Mursu et al., 2004), through to the effect on the 
endocannabinoid system (Di Marzo et al., 1998). Some of these effects might even be 
psychological effects, linked to the organoleptic qualities of chocolate starting with the 
taste and mouth feel. This is before considering any effects of restriction have been 
imposed on chocolate consumption in individuals with T2DM.  To attempt to negate 
these effects, taste tests and study designs were adapted and described in the individual 
chapters relating to each of the studies. 
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2.3	  -­‐	   General	  Procedures	  and	  Methodologies	  
This section will focus on the common procedures across the three studies. In the first 
part it will describe the physical measurements associated with anthropometry and the 
second part will focus upon the biomarkers of cardiovascular risk and glycaemic 
control. 
2.3.1	   -­‐	  Physical	  Measurements	  
A trained member of the research team undertook all physical measurements, weight, 
height, circumferences and blood pressure; 92% of participant visits were conducted the 
author of the thesis. All measurements carried out following WHO protocols (WHO, 
2008a)  
2.3.1.1	  -­‐	  Height	  	  
Height was measured using a SECA 206 (SECA, Birmingham, UK) roll tape according 
to accepted practice to the nearest millimetre.  
2.3.1.2	  -­‐	  Weight	  	  
Weight was taken using SECA 877 (SECA, Birmingham, UK) which weighed in 100g 
increments up to 150kg and up to a maximum of 200kg. The scales were audited during 
the course of the work for this thesis achieving the necessary <1% error needed to be 
designated as fit for purpose. Weight was taken at all office visits for each of the studies 
presented in this thesis. Weight was recorded to the nearest 100g. 
2.3.1.3	  -­‐	  Calculating	  Body	  Mass	  Index	  
In combination with the height, using the formula: 	  	   	   Weight  (kg)       
Height (m) * Height (m) 
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This was used to calculate Body Mass Index (BMI) or Quelelet’s Index, BMI was then 
used to classify the participants, initially to assess their suitability for the studies and 
secondly to define participants level of obesity, on a scale from underweight through to 
obese (WHO, 2012).  
2.3.1.4	  -­‐	  Waist	  circumference	  
Waist measurements were taken to provide additional information regarding levels of 
obesity of the participants taking part in the studies. The methodology followed was that 
recommended by the World Health Organisation (WHO, 2008b), defining waist as the 
midpoint between the uppermost border of the iliac crest (top of the hip bone) and the 
lower border of the costal margin (rib cage). A constant tension, non-elastic tape was 
placed around the abdomen at the level of this midway point and a reading taken when 
the tape is snug but does not compress the skin. This measurement was taken directly 
over the skin, with the participant asked to expire normally (measurement taken at the 
end of normal expiration) with the arms relaxed by their sides. Measurements were 
taken to the nearest millimetre and repeated until two measurements were within 5mm 
of each other prior to recording in the case report form. 
2.3.1.5	  -­‐	  Hip	  circumference	  
The investigator stood to the side of the participant, and the tape was wrapped carefully 
around maximum circumference of the buttocks. The participant was asked to stand 
with their feet together and their weight evenly distributed over both feet and their arms 
relaxed by their sides. The tape was checked to insure that it was horizontal around the 
body and snug without constricting. The measurement was taken over a thin layer of 
clothing and participants were asked to wear similar or the same clothes at each visit. 
Measurements were taken to the nearest millimetre and repeated until two 
measurements were within 5mm of each other prior to recording in the case report form. 
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2.3.2	  -­‐	  Markers	  of	  Cardiovascular	  Risk	  –	  Established	  Clinical	  Markers	  	  
2.3.2.1	  -­‐	  Blood	  pressure	  
Blood pressure can be measured as a spot reading at clinical office visits or using an 
ambulatory blood pressure monitor. In Chapters Five and Six the protocol planned to 
use 24 hour ambulatory blood pressure monitoring. Initially this was planned for a 
subgroup of the participants represented in Chapter Five, but was subsequently 
abandoned due to bruising of participants. For Chapter Six it was not possible to 
undertake this type of monitoring as the visit schedule for the study and issues with 
participant attrition were identified after undertaking measurements on the first three 
participants.  
As with the anthropometric measurements WHO protocol was followed for all three 
studies (WHO, 2008a). For all three studies, blood pressure was measured using a 
calibrated NPB-3900, Nellcor, (Puritan Bennett, Pleasanton, CA, USA). Participants 
were asked to rest in a seated position for a minimum of 15 minutes. An appropriately 
sized cuff for the individuals was selected and placed on the non-dominant arm. Three 
blood pressure measurements were taken, with the mean of the second and third 
calculated and recorded in the case report form. If the two measurements varied by 
more than 10mm Hg, the participant was asked to rest and the process repeated after a 
further 15 minutes. 
2.3.2.2	  -­‐	  Lipid	  profile	  
Full lipid profile (total cholesterol, high density lipoprotein (HDL) cholesterol and 
triglycerides with low density lipoprotein (LDL) cholesterol calculated using 
Friedewald equation (Friedewald, Levy & Fredrickson, 1972) were measured in fasting 
participants at screening in all studies, and before and at the end of the chronic 
chocolate supplementation in Chapters Four and Six. In addition triglycerides were 
repeatedly measured during the meal tests of Chapters Five and Six. 
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Lipids were measured in plasma which was drawn via a cannula or butterfly and needle 
from the median-cubital or cephalic veins. Blood was drawn into a serum separator 
vacutainer blood collection tube. In the case of fasting samples this was labelled and 
sent to the Chemical Pathology Laboratories at Hull and East Yorkshire Hospitals NHS 
Trust for analysis. In the case of the samples drawn during the meal test these were 
centrifuged in a refrigerated centrifuge for 15 minutes at 3500RPM. Serum was then 
drawn off and placed in two labelled aliquots, which were frozen at -80oC before being 
batch analysed. Batch analysis was also undertaken at the Chemical Pathology 
Laboratories at Hull and East Yorkshire Hospitals NHS Trust. Where there were cases 
of missing data from samples taken on the day of the visit, but stored frozen aliquots of 
serum were available, these were sent at the end of the studies as part of the batch 
analyses full lipid profiles were measured on fasting samples. 
Assays were run using a Unicel DxC 800 analyzer (Beckman-Coulter, High Wycombe, 
UK) in a Clinical Pathology Accredited laboratory. This uses a spectrophotometric 
methodology to determine total cholesterol, HDL cholesterol and triglycerides with up 
to 92 further analytes.  
Computer software in the pathology reporting system then calculated LDL cholesterol, 
with the caveat that a raised triglyceride level may prevent this being valid or reported. 
The rationale for not relying on the data for the LDL cholesterol	  when triglycerides are 
raised is due to the nature of the Friedewald equation (Friedewald, Levy & Fredrickson, 
1972): 
LDL Cholesterol=Total Cholesterol–HDL Cholesterol - (Triglycerides/2.2)* 
*All data in mmol/l 
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2.3.2.3	  -­‐	  Glycaemia	  and	  insulin	  resistance	  
Glycosylated haemoglobin (HbA1C) (Selvin et al., 2010) and glucose (Kannel & 
McGee, 1979) were measured to assess glycaemic control, with both additionally 
having the potential as markers of cardiovascular risk (Chapter One). 
2.3.2.3.1	  -­‐	  Glucose	   	   	  
Glucose was sampled both fasting in all three studies, and in Chapters Five and Six 
sequentially as part of the meal test protocols. Where possible the blood was drawn into 
a vacutainer containing sodium fluoride. If this was not possible then a capillary sample 
was taken and analysed next to the participant using a Hemoecue (Hemcue AB, 
Stockholm, Sweden). Samples were drawn into a vacutainer containing sodium fluoride, 
were then inverted to mix, and then chilled on ice. The fasting samples were sent to the 
Chemical Pathology Laboratories at Hull and East Yorkshire Hospitals NHS Trust, 
where they were analysed using a Unicel DxC 800 analyzer (Beckman-Coulter, High 
Wycombe, UK). For the meal test samples, the vacutainers were centrifuged in a 
refrigerated centrifuge for 15 minutes at 3500RPM. Serum was then drawn off and 
placed in two labelled aliquots, which were frozen at -80oC before being batch analysed. 
Batch analyses were also undertaken at the Chemical Pathology Laboratories at Hull 
and East Yorkshire Hospitals NHS Trust.  
2.3.2.3.2	  -­‐	  HbA1c	  
HbA1c was analysed at screening and the end of chronic feeding. This was drawn in a 
venous sample using an EDTA vacutainer tube or a capillary EDTA tube (BD 
microtainer) if venous access was a problem. These samples were then sent to the 
Chemical Pathology Laboratories at Hull and East Yorkshire Hospitals NHS Trust for 
analysis. HbA1c was measured on a HA-8140 analyser (Menarini Diagnostics, 
Florence, Italy) using HPLC methodology, which assesses potential confounding from 
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variant haemoglobins. Most of the HbA1c data was collected prior to the change from 
DCCT aligned results to IFCC units, which began in June 2009. Conversion from 
DCCT units to IFCC used the equation; IFCC-HbA1c =(DCCT-HbA1c-2.15)*10.929) 
(Diabetes UK, 2011). 
2.3.2.3.3	  -­‐	  Insulin	  	  
Venous blood samples were drawn into vacutainer serum separator tubes at the same 
time samples were taken for analysis for glucose. Samples were centrifuged in a 
refrigerated centrifuge for 15 minutes at 3500RPM. Serum was then drawn off and 
placed in two labelled aliquots, which were frozen at -80oC before being batch analysed. 
Batch analyses were undertaken at the Chemical Pathology Laboratories at Hull and 
East Yorkshire Hospitals NHS Trust. Serum insulin was assayed using a competitive 
chemiluminescent immunoassay performed using the Siemens Immulite 2000 analyzer 
(Euro/DPC, Llanberis, UK).   
2.3.2.3.4	  -­‐	  Insulin	  resistance	  
Assessments of insulin function can either be dynamic assessing change over time in 
response to an oral or venous macronutrient load, or static, measured at baseline. The 
‘gold standard’ methodology is to use the hyperinsulinaemia-euglycaemic insulin clamp 
methodology (Defronzo, Tobin & Andres, 1979), though this was not possible from a 
logistic perspective. 
Instead, calculated measurements comparing fasting insulin were used, as dynamic 
methods were unsuitable owing to the addition of the study chocolate prior to the 75g 
glucose load in Chapter Five. The measurements selected were the Homeostatic Model 
Assessment (HOMA) (Rudenski, Matthews, Levy & Turner, 1991; Matthews et al., 
1985) and Quantitative Insulin Sensitivity Check Index (QUICKI) (Katz et al., 2000).  
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2.3.2.4	  -­‐	  Endothelial	  function	  
Endothelial function can be measured either functionally or using biomarkers in an 
attempt to associate the two in Chapter Five both were measured, whereas in Chapter 
Six only a functional measurements were undertaken. 
2.3.2.4.1	  –	  Reactive	  Hyperaemia	  Peripheral	  Artery	  Tonography	  (RH-­‐PAT)	  (EndoPAT)	  
Many studies investigating the effects of cocoa or chocolate upon cardiovascular risk 
have assessed endothelial function. Only five studies, starting with Fisher, Hughes, 
Gerhard-Herman, and Hollenberg (2003) used a peripheral tonometry (RH-PAT) 
methodology; whereas the majority of studies have used flow-mediated dilation (FMD). 
The ‘gold standard’ methodology of angiography with acetylcholine infusion as 
recognised by the Food and Drink Administration (FDA) for assessing endothelial 
function of coronary artery endothelial function is not practical in a routine research 
clinic environment. Flow mediated dilation is in part limited by potential operator error, 
in that it relies on the investigator measuring the effect. Both FMD and RH-PAT are 
based on measuring the dilation of blood vessels following an occlusion. (RH-PAT) is 
based on the site of the assessment being the fingers; meaning that sites for blood 
sampling were more accessible. Assessments were made on both the occluded and non-
occluded arms measurements and were automated meaning the data could be readily 
quality assured. For this reason, the EndoPAT 2000 (Itamar Medical, Caesarea, Israel) 
(RH-PAT) was selected. Nohria et al. (2006) demonstrated that changes in 
measurements made using this methodology are nitric oxide dependent. 
Manufacturers recommendations for protocol were adapted for Chapters Five and Six. 
Participants were invited into a climate-controlled room, which had its temperature set 
at 22oC. The room was free from environmental distractions, with low level lighting and 
was kept quiet. After asking participants to relax for 15 minutes blood pressure was 
measured according to the protocol outlined in section 2.3.2.1, following a further five 
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minutes rest the EndoPAT 2000 probes were placed on the index finger of each hand 
and on the left arm a suitably sized blood pressure cuff was place around the upper arm. 
The probes were attached to the EndoPAT 2000, and the computer to which the 
EndoPAT was attached was programmed to start the test. Following five minutes of 
recording to assess baseline readings, the blood pressure cuff was inflated to 50mmHg 
above the recorded systolic blood pressure or 200mmHg which ever was the greater. 
The occlusion was maintained for five minutes, with the degree of occlusion being 
checked by amplifying the size of the signal. When the occlusion was released, 
recording continued for a further five minutes, the difference between size of the flow 
before and after the occlusion was use to calculate RH-PAT. This was then moderated 
using a comparison corrected for by flow measured from the control arm. 
The EndoPAT 2000 assessment was taken prior to cannulation; it was considered that 
following 60 minutes, the trauma associated would have subsided. The cannula was 
inserted in the right arm so would have only effected the control arm. Throughout the 
study visits, which included EndoPAT 2000 assessment, the participants were asked to 
remain in the climate-controlled room, resting in an environment involving minimal 
stimulation. 
2.3.2.4.2	  -­‐	  Adhesion	  molecules	  
Adhesion molecules were only assessed in Chapter Five. These were measured in 
serum, which were drawn into serum separator vacutainer tubes, prior to the 
consumption of chocolate and at the end of the test. The samples were centrifuged in a 
refrigerated centrifuge for 15 minutes at 3500RPM. Serum was then drawn off and 
placed in two labelled aliquots, which were frozen at -80oC before being batch analysed. 
Batch analyses were undertaken in the Biomedical Research Laboratories, Postgraduate 
Medical Institute, University of Hull. All assays were carried out by Enzyme-linked 
immunosorbent assay (ELISA) using kits provided by Bender MedSystems (Vienna, 
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Austria). Calibration curves were estimated using Microsoft Excel using polynomial 
equations, where necessary having to achieve an R2 of at least 0.995. Microsoft Excel 
was then used to convert data into ng/ml. 
2.3.2.5	  -­‐	  Oxidative	  stress	  
2.3.2.5.1	  -­‐	  Malondialdehyde	  and	  TBARS	  
Despite the limitations of these markers (Mensink et al., 2003), they were assessed for 
Chapters Four and Six, in order to allow comparison of the data with published data. 
These were measured in fasting plasma, which were drawn into EDTA vacutainer tubes. 
The samples were processed as described in Section 2.3.2.4.2. The level of TBARS, 
which is deemed to be equivalent the amount of malondialdehyde (MDA) was assayed 
for using an ELISA kit provided by R&D Systems (Minneapolis, MN, USA). 
Calibration curves were estimated as described in Section 2.3.2.4.2, data was presented 
in ng/ml. 
2.3.2.5.2	  -­‐	  Isoprostanes	  (15-­‐F2t-­‐isoprostane)	  
For Chapters Five and Six, urinary 15-F2t-isoprostane α (formerly known as 8-iso-
PGF2α and 8-epi-prostaglandin F2) were measured. All participants in these two studies 
undertook 24-hour urine collections prior to each visit, starting at 08:00 the day before 
and finishing at 08:00 when arriving at the clinical trials facility. This was the point 
when they emptied their bladder prior to their commencing the study visit. From this 
point the second 24-hour urine collection began. Total volume for each collection was 
recorded and aliquots taken and frozen at -80oC until batch analysis could be undertaken 
on the completion of the study. For Chapter Five, the urine collection was undertaken 
the day before the study visit, then the day of the study. In the case of Chapter Six, the 
urine collection was undertaken for the 24 hours prior to visits 1 and 4. 
Urinary 15-F2t-isoprostane-α was measured by ELISA kit (Oxford Biochemical 
Research, Oxford. USA). Data was presented as both absolute and corrected for 
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creatinine. Calibration curves were estimated using Sigmaplot V11 (Systat Software, 
Chicago, IL, USA).  Data was then converted using Microsoft Excel to mg per 24 hour 
(absolute value) and mg/mol (creatinine ratio) 
2.3.2.6	  -­‐	  Inflammatory	  markers	  
For all studies C-Reactive Protein (CRP) was measured, for Chapter Six additionally 
interleukins (IL1RA and IL6) and Tumour Necrosis Factor (TNF-α) were also 
measured. 
2.3.2.6.1	  -­‐	  C-­‐reactive	  protein	  
C-reactive protein was measured using a high sensitivity assay so more accurately it 
should be described as high sensitivity-C-Reactive Protein (hs-CRP). This was 
measured from serum that had been collected in serum separator vacutainer tubes, these 
were analysed using a Unicel DxC 800 analyzer (Beckman-Coulter, High Wycombe, 
UK) at the Chemical Pathology Laboratories at Hull and East Yorkshire Hospitals NHS 
Trust. This assay was carried out for fasting samples as part of routine pathology 
samples, and for meal tests, samples were centrifuged, pipetted into aliquots and stored 
prior to batch analyses as previously described in Section 2.2.3.3.2. 
2.3.2.6.2	  -­‐	  Interleukins	  (IL1RA	  and	  IL6)	  and	  TNF-­‐α	  
These were measured using heparinised plasma collected in vacutainer tubes and 
processed as described in Section 2.3.2.4.2. All assays were undertaken using ELISA 
kits, for IL1RA (R&D Systems), IL6 and TNF-α (both BenderMedSystems). Calibration 
curves were estimated using Microsoft Excel using polynomial equations where 
necessary with the curve having to achieve an R2 of at least 0.995. Microsoft Excel was 
then used to convert data into pg/ml. 
2.3.2.7	  -­‐	  Participant	  reported	  outcomes	  
Chapters Four and Six included questionnaires which were incorporated to obtain 
additional information about changes in mood, function, sleep pattern and appetite. As 
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the instruments were not the same for both studies, these will be described in detail in 
the relevant chapters. 
2.3.2.8	  -­‐	  Assessment	  of	  background	  diet	  	  
In all three studies background diet were monitored and participants were instructed to 
consume chocolate evenly through the day if part of chronic feeding. During the study 
participants were asked to refrain from altering their intake of polyphenol rich foods (details 
presented in Appendix II). Just before and during the acute phase investigations, participants were 
asked to abstain from these foods all together. 
Dietary intake for Chapter Four was assessed by recall undertaken by myself, the author 
of this thesis and a registered dietitian, but was not formally analysed. For Chapters 
Five and Six, these were formally recorded and analysed using Microdiet (Downlee 
System Ltd, Chapel-en-le-Frith, Derbyshire, UK) to assess change over course of the 
study. The methodologies of recording dietary intake were all over a maximum of 48 
hours. For Chapter Five participants also recorded all their physical activity levels, food 
and drink consumption for 24 hours before and after each study visit. In Chapter Six 24-
hour dietary recalls undertaken by the study dietitian (myself). A conscious decision 
was made not to follow a more formal diet diary methodology over four or more days as 
this it was considered, might lead to a change in food intake. 
2.3.2.9	  -­‐	  General	  data	  handling	  and	  statistical	  methodology	  
2.3.2.9.1	  -­‐	  Data	  handling	  
All three studies considered in this thesis were supported by the use of a case report form. 
For Chapters Four and Five, these were internally designed and the data monitoring was the 
responsibility of the Research and Development Department of Hull and East Yorkshire 
Hospitals NHS Trust. For Chapter Six, data were collected in a case report form provided 
by the sponsor, with case notes and data monitored by the sponsor to insure compliance 
with Good Clinical Practice (ICH, 1996). All data (anthropometry, biochemistry and 
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questionnaire data) were transcribed into Microsoft Excel for transfer to sponsors for 
analysis. 
All data were managed in accordance with the Data Protection Act 1998 and institutional 
requirements. The study visits were also recorded within the participant’s medical notes, 
which also included a copy of the informed consent. Finally the participant’s (with their 
permission) General Practitioners were informed regarding their participation in the studies. 
2.3.2.9.2	  -­‐	  General	  statistical	  methodology	  
The data analyses reported within Chapters Three (exploratory review with meta-analysis), 
Four and Five (Studies One and Two) were undertaken by myself with advice from Mr 
Alan Rigby, (Statistician, University of Hull). Due to contractual restrictions associated 
with Chapter Six (Study Three) statistical analyses were in part, undertaken by the 
sponsors’ statistician. 
All three interventional studies were powered based on previously published studies using 
cocoa (Balzer et al., 2008) and were at least post hoc tested using power calculation 
software (N-Query, Statistical Solutions, Sargus, MA, USA or G*Power (Faul, Erdfelder, 
Lang and Buchner, 2007). Data were processed primarily using Microsoft	  Excel, and in the 
case of Chapters Four and Five analysed using PASW Statistics 18.0 (IBM, New York, NY, 
USA), Microsoft Excel and GraphPad Quick Calcs (GraphPad, La Jolla, CA, USA). For 
Chapter Six, data was transferred from the case report forms and Microsoft Excel onto 
ClinTrial 4.2 (Domain Pharma, Lexington, MA, USA). The data were then analysed within 
the sponsor organisation before producing a report in LaTeX (LaTeX Project). The nature 
of the tests for normality and methods of statistical analysis used in each study will be 
described as part of the relevant chapters. 
2.3.3	  -­‐	  Summary	  
This Chapter details the methodologies used for the study design underpinning the structure 
of this thesis, the assays used and overall description of data handling and analysis methods. 
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Chapter	  Three:	  An	  Exploratory	  Review	  with	  Meta-­‐Analysis	  -­‐	  the	  
Effects	  of	  Cocoa	  Flavanols	  on	  Markers	  of	  Cardiovascular	  Risk	  
and	  Glycaemic	  Control:	  Which	  is	  Better	  Chocolate	  or	  Cocoa?	  
 
This chapter considers the data from the published randomized controlled trials 
published to then end of June 2012 and prior to the subsequent chapters (Four, Five and 
Six) that describe the experimental work from the series of themed clinical trials.  
This review focuses on the potential benefits of cocoa and chocolate in the management 
of diabetes and the potential reduction in associated complications. It aims to investigate 
if there are any differences as a result of the matrix of formulation of the product in 
which the cocoa flavanols are consumed. It will assess whether it is preferable to 
consume these flavanols in the form of a cocoa drink or in chocolate.  
Aim and Scope of Chapter: 
• To undertake a meta-analysis of the published randomized controlled trials 
reporting effect of flavanols on markers of cardiovascular disease risk and 
glycaemia.  
• To attempt to assess the effect of the formulation of the product (either cocoa or 
chocolate) on efficacy using subgroup analysis. 
Table 3.0 sets out the PICOS (Participants, Interventions, Comparisons, Outcomes and 
Study Design) approach to this chapter and how the data will be used to meet the above 
aims 
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Table 3.0: Study questions and PICOS (Participants, Interventions, Comparisons, Outcomes and 
Study design) for meta-analysis and review. 
Study 
Question(s) 
Do chocolate and cocoa formulations rich in polyphenols reduce markers of 
cardiovascular risk and glycaemic control? 
Is chocolate rich in polyphenols more effective in reducing cardiovascular risk 
and glycaemic control markers than cocoa formulations rich in polyphenols? 
Participants Healthy and individuals with risk factors of cardiovascular disease including 
type 2 diabetes 
Excluded studies which recruited pregnant women and children.  
Interventions Cocoa or chocolate formulations rich in polyphenols, flavanols or epicatechins 
where the polyphenol, flavanols or epicatechin content has been defined 
Comparisons A comparator cocoa or chocolate formulation which is low in polyphenols, 
flavanols or epicatechins where the polyphenol, flavanols or epicatechin content 
has been defined 
Outcomes Change in risk markers of cardiovascular risk or diabetes control, only 
numerically presented data will be used due to the risk of published figures may 
not have accurately presented scales: 
1. Blood pressure (systolic and diastolic blood pressure) 
2. Lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides) 
3. Glycaemia (fasting glucose and HbA1c) 
4. Endothelial function  
5. Oxidative Stress (isoprostanes) 
6. Inflammation (subject to comparable data being available) 
7. Weight 
 
Study design Randomised controlled trials published in the peer reviewed literature 
investigating the effects of chocolate and/or cocoa on cardiovascular risk up 
until 30th June 2012 
 
To address these aims, the meta-analysis will be presented in four parts: 
3.1 - Introduction. 
3.2. - Methodology. 
3.3 - Results.  
3.4 - Discussion. 
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3.1	  –	  Introduction	  	  
There is strong epidemiological evidence for the potential benefits of foods rich in 
flavanols and related compounds as has been previously reviewed in Chapter One. 
However, it needs to be acknowledged that the absorption and metabolism of these 
compounds is somewhat complex (Crozier, 2009). In foods these compounds exist as 
monomeric catechins (mainly epicatechins) and oligomeric flavanols, typically varying 
from dimers to decamers. The ratio of these depends on a range of factors; from the 
country of origin of the cocoa, through to the method of processing the cocoa beans 
(mainly fermentation and roasting) (Hurst et al., 2011). Typically, 34-37% of the 
flavanols in cocoa are monomeric and as such have greater potential in terms of 
bioavailability (Langer et al., 2011; Hii et al., 2010; Wollgast & Anklam, 2000). 
The stability of these compounds in post-harvest food is also an important 
consideration. In chocolate and cocoa the flavanols (especially flavano-3-ol) content has 
been reported as being stable for at least two years (Hurst, Payne, Miller & Stuart, 
2009). Such that chocolate has been described as an ideal matrix for the preservation 
and potentially the delivery of flavanols (McShea et al., 2008).  
There are a number of variables that need to be considered when comparing the 
potential for solubilised cocoa or chocolate as a delivery to act as vehicles for flavanols. 
Beyond the food chemistry, there are nutritional considerations linked to the energy, fat 
(especially saturated fatty acids) and sugar content which may be metabolically 
significant. However these points are potentially of no consequence if the end product is 
unacceptable to the consumer. The critical first point is to consider the bioavailability 
and biological activity of the cocoa flavanols and how this may relate to the food 
product formulation. 
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3.1.1	  -­‐	  Influences	  upon	  Absorption	  
Animal and human studies indicate there are a range of conditions through which the 
absorption of monomeric flavanols can occur (Hackman et al., 2007; Schramm et al., 
2003). Following a systematic search, there appears to be only one small study that has 
attempted to compare chocolate and cocoa matched for carbohydrate, epicatechins and 
other potentially biologically active compounds (e.g. caffeine and theobromine) (Baba 
et al., 2000). This was a crossover study of five healthy males, which, unfortunately was 
not designed with the necessary power to determine a difference in absorption between 
the cocoa and chocolate. It claimed that the only difference between the cocoa and the 
chocolate was the contribution of cocoa butter to the fat and energy content of the 
chocolate.  
Baba et al. (2000) suggested that there was no significant difference in uptake from the 
gut between cocoa and chocolate, although the clearance of epicatechin metabolites in 
the chocolate group was 29.8±5.3% of the ingested epicatechins, compared with 
25.3±8.1% (p=0.329) for the cocoa. However, the levels of non-conjugated epicatechins 
appeared to be higher with cocoa at the one and two hour points following ingestion 
(0.10±0.03 compared to 0.22±0.06 µmol/l and 0.15±0.04 compared to 0.22±0.02 µmol/l 
respectively). This single study presents a mixed picture of the effects of cocoa and 
chocolate on the bioavailability of epicatechin. If urinary recovery is used as a measure 
of bioavailability, a study with a sample size of 21 would have an 80% power to detect 
a significant difference between chocolate and cocoa at the 0.05 level (G*Power 3 (Faul 
et al., 2007)). This suggests there is potential for a difference in the absorption of 
epicatechins from chocolate and cocoa that warrants further study.  
There are a number of mechanisms to explain why flavanols administered in the form of 
chocolate may have enhanced absorption compared with flavanols administered in a 
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cocoa drink. These include a combination of physical and chemical properties of the 
cocoa or chocolate, along with the nutrient and non-nutrient effects on gastrointestinal 
physiology.  
A common feature of dietary polyphenols including flavanols, is their need to be 
hydrolysed, as in the plant, they mostly exist in a glycoside form. This can occur as 
either an acid or enzymic hydrolysis. The length of time and amount of hydrochloric 
acid secreted in the stomach will influence the acid hydrolysis, and the second will be 
influenced by the levels of enzymes such as lactase phloridzin hydrolase and cytosolic 
β-glucosidase in the intestine (Crozier, 2009). Initially, based on data from in vitro 
studies, it was considered that increased time in the stomach might hydrolyse a greater 
proportion of procyanidins and thus increase the pool of epicatechin and other 
monomeric flavanols available for absorption (Spencer et al., 2000). These data were 
somewhat refuted by (Rios et al., 2002) who suggested that in humans fed via a 
nasogastric tube there were no differences seen with respect to degradation of 
procyanadins after a gastric transit of ~50-60minutes.  
The potential for acid hydrolysis in the stomach of both the glycosides and the 
procyanadins to increase bioavailability of the polyphenols from chocolate or cocoa, 
could be of considerable importance. It has been widely described that stomach 
emptying is quicker for liquids than solids, which could infer that the increased 
viscosity of chocolate compared to cocoa drinks might slow gut transit time. The 
difference in the fat content might also lead to an increase in the time the food is in the 
stomach. Gut peptides, including cholecystokinin produced by the duodenal mucosa 
under the influence of fat are known to supress gastric emptying (Liddle, Morita, 
Conrad & Williams, 1986). This highlights two potential mechanisms on how chocolate 
might act to slow gastric emptying when compared to cocoa. However to date, no 
published work has tested this hypothesis. To this end, more work is required to explore 
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this idea, and the nature of the metabolites identified by Baba et al. (2000) after the 
three-hour point for chocolate, which were not seen, with cocoa. 
The product formulation or matrix also has a number of physical effects that could 
affect bioavailability. From the studies reported, the quality of the cocoa powder used 
was not always clear. This included its ability to be dispersed in the medium (typically 
water) (Fogliano et al., 2011). Cocoa is not very soluble even in hot water and this 
might be a barrier to bioavailability, with the hydrophobic cocoa particles being less 
readily digested, preventing the procyanadins and monomeric flavanols from being 
hydrolysed to more bioavailable forms (Fogliano et al., 2011). In chocolate, these 
physical characteristics are very different; the cocoa tends to be evenly distributed 
within the product, the effect of which is to increase surface area available for 
hydrolysis and digestion, resulting in increased bioavailability. It is logical that the high 
fat content will provide a hydrophobic matrix, but the particle size is likely to be much 
smaller. It is not clear which of these two factors is more important in influencing 
bioavailability.  
The effect of food ingredients other than cocoa has concentrated on the effects of adding 
milk or altering the sugar (usually sucrose) component of the end product. The sucrose 
or other carbohydrate content may be of interest in terms of its biological activity, in 
addition to its potential effects on bioavailability. In human studies, where cocoa was 
administered with or without sugar (sucrose), it appears that sugar might enhance 
flavanols absorption (Schramm et al., 2003). The same group continued this work to 
investigate the effects of other carbohydrate-rich foods with cocoa, which produced a 
similar enhancing effect on flavanols absorption.  
Where the sugar used in chocolate was changed from sucrose to maltitol (Rodriguez-
Mateos et al., 2012) with the aim of reducing the glycaemic burden and energy density, 
it appears to reduce the absorption of the flavanols. This was especially evident at the 
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one and two hour time points, which are of importance when considering potential 
postprandial effects which are investigated in Chapters Five and Six. In terms of the 
nutritional management of diabetes, this is of further interest, as historically maltitol 
along with other sugar alcohols have been used in the manufacture of confectionary for 
people with diabetes. This is despite the sugar alcohols having an equal energy content 
and in quantities greater than 25 grams per day, increase the risk of osmotic diarrhoea 
and not being recommended in the evidence based nutritional guidelines of Diabetes 
UK (Dyson et al., 2011). 
From a bioavailability perspective there is a case to suggest chocolate might be 
preferable to cocoa alone. The rational for this could be explained by differences in 
composition between the two products. A property that could account for this effect is 
that the flavanols are co-administrated along with carbohydrate (including sucrose). The 
rationale for using sugar alcohols (polyols) in the study by Rodriguez-Mateos et al. 
(2011), was that high intakes of sugar and its accompanying energy (which is associated 
with chocolate) are undesirable from a public health perspective, let alone when trying 
to manage T2DM. What is unclear is whether flavanols are biologically active when 
provided with any type of carbohydrate preferentially (either as starch, sucrose or other 
sugars e.g. lactose). 
3.1.2	  -­‐	  Influences	  upon	  the	  Biological	  Action	  of	  Carbohydrate	  on	  
Flavanols	  Absorption	  
There is evidence to suggest that although carbohydrate may facilitate flavanol 
absorption, this might not necessarily translate into an enhancement of biological 
efficacy. To date only one study (Njike et al., 2011) has tempted to address this issue 
however, it used a complex crossover design, resulting in the need for post hoc analysis, 
and might have been prone to error. This was reported by Faridi et al. (2008) (acute 
effects) and Njike et al. (2011)  (six weeks feeding data). Both papers were based on the 
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published study protocol NCT00538083. In the first phase single doses of chocolate 
(placebo or dark (flavanols rich) chocolate) were administered; in the second phase, 
there were three arms where a single dose of placebo, sugared cocoa or sugar-free 
cocoa, were given. All 44 participants who completed the trial received both chocolates 
and all three cocoa formulations.  The authors reported significant improvements in 
endothelial function and blood pressure with the dark chocolate compared to the cocoa-
free chocolate bar, however, the focus of their conclusions was that the sugar-free cocoa 
improved endothelial function to a greater extent than the sugared cocoa. From this it 
was suggested that sugar content might negatively impact on the beneficial effects seen 
with cocoa flavanols (Faridi et al., 2008).  However they did not explore or consider 
differences between the chocolate and cocoa phases.  
A post hoc t-test based on the data of Faridi et al. (2008) (GraphPad, La Jolla, CA, 
USA) suggested that for endothelial dysfunction there was significantly greater 
improvement in flow mediated dilation for the dark chocolate compared to the sugared 
cocoa (p=0.0076, standard error of difference (SED) = 0.82) with no significant 
difference between the dark chocolate and the sugar-free cocoa (p=0.1325, SED 
=0.913). The principle difference between the sugared cocoa and the chocolate was that 
the dark chocolate contained approximately two-thirds less carbohydrate (in the form of 
sucrose) than the cocoa (39g compared to 104g). Although these participants were 
overweight they were otherwise ‘healthy’, and the authors did not report any assessment 
of metabolic syndrome or insulin resistance. The difference in carbohydrate content, 
only resulted in a 30% reduction in the energy content (327kcal compared with 460 
kcal); a reflection of the significantly greater fat content of the chocolate (27g compared 
with 2g) for the cocoa. 
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3.1.3	  -­‐	  Potential	  Mechanisms	  
Type 2 diabetes and other insulin resistant states are associated with hyperinsulinaemia 
and hyperglycaemia (which characterises the former). Both pathological states have 
been associated with a reduction in nitric oxide bioavailability. As described in Chapter 
One, an increase in the bioavailable pool of nitric oxide is considered to be the primary 
mechanism of cocoa flavanols, with the systemic effects seen via reduced endothelial 
dysfunction and blood pressure. The unifying theory of Brownlee (2005) supports this 
mechanism, since the uncoupling of the mitochondria resulting in superoxide generation 
along with activation of NADPH oxidases results in an overall increase in oxidative 
stress (Dworakowski et al., 2008; Munzel et al., 2008). The net effect of which is a 
reduction in the amount of bioavailable nitric oxide, leading to endothelial dysfunction 
and hypertension. Ironically, ingesting carbohydrate with cocoa flavanols might 
increase their bioavailability but reduce their biological effects. 
3.1.4	  -­‐	  Linking	  Plasma	  Flavanols	  to	  Biological	  Effects	  
In vitro and animal work have demonstrated mechanistic pathways to link the dosage of 
cocoa flavanols to their effects. The same methodology has not always been as 
thoroughly applied in humans. A number of studies have assessed levels of flavanols 
and epicatechin metabolites as part of clinical trials; generally this has been to measure 
compliance or check the presence of these metabolites following ingestion to link to the 
physiological effect. Engler et al. (2004) using a randomized double blind crossover 
study design with low and high flavonoid dose content chocolate, reported a 
synchronous rise in epicatechins and improvement in endothelial function following 
consumption of flavonoid rich chocolate. Few dose-finding studies have been 
undertaken to obtain an optimal concentration of cocoa flavanols, especially with 
respect to the form of presentation and accompanying nutrients or food components. 
Chapter	  Three	  –	  Meta-­‐analysis	  
	   119	  
Despite this, as previously discussed in Chapter One, ESFA subject to EU commission 
has granted authorisation for chocolate manufacturer - Barry Callebaut BV, to use a 
proprietary claim for chocolate and cocoa containing 200mg of polyphenols (EFSA, 
2012a). 
The observations of Faridi et al. (2008) together with the bioavailability data present an 
interesting picture. To increase palatability, many of the studies using cocoa use a 
significant amount of sucrose to enhance compliance. This may have the effect of 
increasing bioavailability (Schramm et al., 2003), but might reduce biological activity 
(Faridi et al., 2008). This suggests that chocolate may be a better option since less 
carbohydrate may be needed to make it palatable when compared to cocoa formulations: 
The result being that chocolate has a formulation with enough carbohydrate to enhance 
absorption, but not enough to influence nitric oxide availability negatively and as such 
impede its beneficial effects. It is highly plausible that chocolate may have physical, 
biological and organoleptic properties to enhance cocoa flavanol intake, bioavailability 
and biological activity, although Ried et al. (2009) suggested 50g of chocolate was not 
acceptable to their study population, sales data of chocolate might refute this argument. 
The co-ingestion with other macronutrients might enhance bioavailability, whilst the 
relatively modest (compared to cocoa preparations) sugar content might enhance 
biological action. 
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3.2	  -­‐	  Methodology	  
The exploratory review in Chapter One, along with the material presented in this 
chapter have been conducted and presented in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane 
methodology guidelines (Moher, Liberati, Tetzlaff & Altman, 2009; Higgins & Green, 
2011). The notable deviation is that this work is being produced primarily for this 
thesis, so instead of being done by a group of experienced reviewers, I have taken 
responsibility for the conduct of the review. As such it was therefore not possible to 
publish a protocol for the review, as has been done by others (Ried et al., 2010b). 
3.2.1	  –	  Study	  Selection	  
All clinical trials included had human participants and only included adults who were 
either healthy or had a chronic non-communicable disease (e.g. obesity, diabetes, 
cardiovascular disease). The key selection criterion was that they were randomised 
controlled trials of either parallel or crossover design. Initial searches were less 
restrictive and included trials that did not have a control arm or non-matched placebo. 
These were screened and accepted or rejected based on the afore mentioned selection 
criterion.  
Interventions were chocolate or cocoa as the primary intervention, including studies 
using cocoa extracts and refined flavanols or epicatechin supplements. Studies were 
only selected if the investigators had attempted to match the high polyphenol/flavanol 
arm with a similar comparator or placebo. Each study had to meet at least two of the 
following four criteria; appearance or taste, weight or volume, energy content and 
carbohydrate load. The studies also define the amount of epicatechin, flavanols, 
procyanadins or polyphenols in both arms and no other potential biologically active 
compounds could be added to the cocoa or chocolate, other than those which occur 
naturally. Studies or study arms, which included physical activity (as this may lead to 
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change in the level of oxidative stress) isoflavones or sterol esters as part of the 
chocolate formulation, were therefore excluded. These were developed as key criteria to 
define the validity control of the material presented in this chapter. 
3.2.2	  –	  Biomarkers	  and	  Clinical	  Measurements	  
The study focused upon the primary outcomes of the selected trials then six categories 
as defined in Chapter One, were used to categorize the data from these outcomes, being: 
1. Glycaemia or insulin resistance (e.g. HOMA, HbA1c, glucose or insulin) 
2. Blood pressure (either ambulatory or measured in the clinic room) 
3. Lipid profile (Total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides) 
4. Endothelial function (Flow mediated dilation, reactive hyperaemia and soluble 
markers e.g. adhesion molecules) 
5. Oxidative stress (e.g. urinary or plasma isoprostanes) 
6. Inflammatory markers (e.g. C-Reactive Protein) 
Additionally, weight changes were included from studies that reported baseline and end 
of study weights. 
Markers were generally chosen on the basis of their clinical relevance to diabetes and its 
management or prevention, or linked to the recommendations of the PASSCLAIM 
group with respect to accepted surrogate markers which might be appropriate for a 
health claim associated with a food (Riccardi et al., 2004; Mensink et al., 2003; Mann et 
al., 2004). It was not possible to identify hard endpoints for macrovascular or 
microvascular complications of diabetes, or in fact the onset of diabetes in high-risk 
groups. This was a reflection of the short nature and small size of interventional studies 
using chocolate and cocoa. 
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3.2.3	  –	  Search	  Strategy	  
A structured search strategy was carried out to the end of June 2012. This included 
Medline (http://www.ncbi.nlm.nih.gov/pubmed) and EMBASE (http://www.embase.com/), 
the Cochrane Library (CENTRAL) (http://www.thecochranelibrary.com/view/0/index.html), 
and the WHO clinical trial database (International Clinical Trials Registry Platform) 
(http://apps.who.int/trialsearch/). Bibliographies of included studies and previously 
published reviews, systematic reviews and meta-analyses were checked. Searches were 
limited to English. For a full description of the search strategies and search terms and 
search strategy along with the PRISMA checklist, see Appendix I. 
Titles and abstracts and potential full-text articles were assessed for inclusion. Due to 
time constraints, it was not possible to contact the authors of studies for further data or 
clarification. The author of this thesis extracted the data used in the analysis from the 
numerical data presented in the papers. The quality of the graphical presentations was 
deemed insufficient to allow adequate estimation of the size of any effect and the 
measure of spread around the mean, it was considered the reliability of the reproduction 
in print of the scales could additional introduce error. 
3.2.4	  –	  Inclusion	  Criteria	  
Initially the aim was to stratify studies by disease of the participants, however with the 
exception of the work presented in Chapters Four, Five and Six, only one other study on 
individuals with T2DM as defining characteristics that met the inclusion criteria was 
available. With only a single study feeding cocoa to individuals with T2DM (Balzer et al., 
2008), it was not possible to rely on this approach, so it was necessary to include all clinical 
trials.  There was no exclusion criterion set for study duration; studies that were both acute 
(a few hours) and continuous or prolonged feeding (2-26 weeks) were included. The only 
exception was for studies of a minimum of 14 days where blood pressure and weight, were 
excluded. 
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Changes in continuous variables were initially aligned to match the units, and converted 
using standard equations if needed (e.g. for lipids from mg/dl to mmol/l), with the measure 
of spread standardised to the standard deviation. Changes from baseline to the end of study 
were recorded, as were the standard deviations using the assumption that variances were 
equal. Where more than one outcome point was reported, the data was extracted for 
baseline and the final endpoint of the study (or change). For parallel studies with more than 
one group, the control groups were used for all interventions. Where studies reported 
several doses, only the highest was selected for comparison with the control. In groups 
where the study population were stratified, e.g. lean and overweight, these data were split. 
This approach was applied for any study reporting acute and prolonged feeding data. 
Crossover studies were treated as parallel studies, with the total number of participants 
completing being recorded in both the intervention and control arms. 
3.2.5	  –	  Trial	  Quality	  and	  Assessment	  of	  Risk	  Bias	  
Trial quality was partially addressed by the strict inclusion criteria which formed the 
validity control. Review Manager 5.2 (Nordic Cochrane Centre, Copenhagen, Denmark) 
was used to assess the risk of bias with respect to selection (random sequence generation 
and allocation concealment), performance, detection, attrition and reporting bias. 
Additionally an assessment of other bias was made with respect for the similarity with 
respect to appearance and taste of the intervention and control. In addition, the influence of 
commercial interest was assessed, to see if the studies described their source of funding 
and/or interventional products, and whether this was linked to a cocoa or chocolate 
manufacturer, or a company with commercial or intellectual property associated with them.  
3.2.6	  –	  Statistical	  Methods	  
Variability between studies was estimated by I2, which is the proportion of total observed 
variability due to genuine variation, as apposed to random error within studies. This was 
considered significant when I2> 50% (Higgins et al., 2003). Where this was observed, a 
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random effects model was selected to assess the mean differences between groups, and the 
data were interpreted with caution. 
The extracted data was converted where necessary to SI units to prior to undertaking the 
analysis. Where data was presented with a 95% confidence interval or standard error of 
mean, these were converted to standard deviation using standard equations. A calculation of 
the mean change was then estimated, along with its variation of change (standard deviation, 
using variance sum law 1) from studies where the baseline and post intervention data was 
presented using standard formula. This included Almoosawi et al. (2012) who reported 
change to a post intervention baseline (which was not used) and for the purposes of this 
analysis an estimate based upon the pre-intervention baseline was used in order to be 
comparable with the other studies. The data selected for analysis constituted of the baseline 
compared to the end of chocolate supplementation. Where more than one dose of 
polyphenol rich chocolate was used, the lowest (control) was compared with the highest 
polyphenol content chocolate. Where possibly comparisons were made between products 
most similar with respect to nutrient profile. 
The differences between intervention and control were estimated with Review Manger 5.2 
software (Nordic Cochrane Centre, Copenhagen, Denmark), using mean differences in 
random-effects meta-analysis. For all outcomes where there were greater than eight 
published cohorts the data were explored by a sub-group analysis to discover if there were 
differences in effect between chocolate and cocoa. Where studies gave both cocoa and 
chocolate as the intervention, this was considered as chocolate. Funnel plots were run for all 
analyses to access for publication or small study biases. Results were reported as the mean 
difference between intervention and control with 95% confidence interval, p value and 
assessment of heterogeneity.  
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3.3	  -­‐	  Results	  
A total of 1351 studies were found following a Medline, Embase and Cochrane Library 
(CENTRAL) search for clinical trials linked to chocolate or cocoa up until the end of 
June 2012 (see PRISMA flowchart, figure 3.3.1). Following the removal of duplicates, 
there were 243 relevant titles and abstracts, which were screened. All abstracts were 
screened for relevance to the outcomes and criteria described in the methodology and a 
total of 69 full papers of clinical trials were selected for inclusion. These excluded the 
work of the author (only where I was the lead author), as this work is presented in the 
subsequent chapters of this thesis. A total of 31 studies met all of the inclusion criteria, 
and reported relevant outcomes with adequate description of the intervention and 
control.  
The 69 studies (not all reported relevant outcome data) reviewed represented a total of 
2772 participant exposures to cocoa or chocolate and this represented 17750 participant 
years of cocoa or chocolate consumption. Of the 31 included studies, which reported 
relevant outcomes, represented 1285 participant exposures and a total of 2752 
participant years (table 3.3.1; for summary data). This might imply that the trials 
meeting the inclusion criteria represented approximately half of the total participant 
exposures, but some tended to have a shorter duration. Ten of the studies declared no 
link to industry, with thirteen studies being linked to Mars/Masterfoods, five to Nestlé 
and three to Hershey. The remaining studies were linked to non-multinationals or trade 
bodies. Twelve of the studies utilised a parallel design and the remainder used a 
crossover design. It was also noted that there were a number of authors contributing to a 
number of papers, with seven authors contributing more than one paper as either first or 
second author. 
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Figure 3.3.1: The PRISMA flowchart for the selection of the studies for the meta-analysis included 
in this chapter. (Moher et al., 2009) 
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Sixteen of the studies described their participants as being healthy, although in the case of 
one study, the population was elderly and three others had overweight or obese participants. 
Two studies focused on cardiovascular disease, a further two studies investigated the effects 
of cocoa or chocolate upon heart failure and a single study investigated heart transplant 
patients. In terms of risk factors, one study considered the effect of cocoa upon individuals 
with T2DM; a further study investigated the effects of chocolate in participants with 
impaired glucose tolerance and hypertension, eight studies focused upon participants with 
hypertension alone and two studies recruited participants with dyslipidaemias. Of the 
remaining studies, one recruited smokers and the other participants with chronic fatigue 
syndrome.  
The interventions included two studies that used tablets containing cocoa polyphenols, one 
that utilised both chocolate and cocoa and one that included bread with supplementary 
cocoa. Of the twelve studies using cocoa as the intervention, eight clearly defined this as 
being mixed with water, one with cream, and one described a dairy-based cocoa drink. 
Eighteen studies described their intervention as chocolate; of these, one utilised milk 
chocolate, with the remaining studies described their chocolate as dark or high in 
polyphenol (and therefore flavanols).  
The polyphenol content of the control intervention was described as zero in 19 studies; 
however, in all cases the source of the analysis was not defined. Two of the studies reported 
a control intervention with greater than 100mg of polyphenols/flavanols. These studies 
therefore had a greater dose of polyphenols in the control arm than in the intervention arm 
(one study in the case of Sathyapalan et al. (2010) and four studies in the case of Monahan 
et al. (2011)). Studies which included sham eating, or a placebo which was not well 
matched to the flavanols rich cocoa or chocolate, e.g. milk or sugar solution were excluded 
from any analysis. 
The primary outcome of the studies varied, as not all the studies were registered: Only 
eleven were found to have pre-publication study registration, and not all matched their 
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proposed primary outcomes to those reported in the final peer reviewed publication. 
Fourteen studies had endothelial function as the primary outcome, five had a reduction in 
blood pressure and two had an improvement in lipid profile. Five studies had a focus upon 
composite measures; in one study this was cardiovascular risk, another focused upon insulin 
resistance and three considered metabolic syndrome. Of the remaining nine studies, five 
focused upon oxidative stress, two on the effects of cocoa polyphenols upon platelet 
aggregation, one on probiotic effects of cocoa and one on reduction in symptoms of fatigue 
and function.  
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In terms of duration, ten studies reported data in an acute or post-prandial state and 
20 investigated supplementation for fourteen days or more with the longest duration 
of feeding 126 days (mean 22 days; median 15 days). For the purposes of the meta-
analysis all data were included, except in the case of blood pressure and weight 
where a minimum of 14 days was used as the criterion for selection. 
3.3.1	  -­‐	  Study	  Validity	  
The	  risk	  of	  selection,	  performance,	  detection,	  attrition,	  reporting	  bias	  and	  the	  bias	  introduced	  from	  the	  adequacy	  of	  the	  matching	  of	  the	  control	  to	  the	  intervention	  were	  categorised	  into	  low,	  unclear	  and	  high	  risk	  of	  bias.	  The	  matching	  of	  the	  intervention	  to	  the	  control	  product	  appeared	  to	  insufficiently	  describe	  or	  a	  high	  risk	  of	  bias	  in	  about	  70%	  of	  the	  studies.	  High	  risk	  of	  bias	  was	  more	  common	  in	  studies	  using	  chocolate,	  however	  there	  were	  a	  number	  of	  examples	  of	  taste	  trials	  and	  careful	  matching	  of	  the	  products	  used	  in	  both	  arms	  of	  studies	  using	  chocolate.	  Figure	  3.3.1.1	  shows	  the	  summary	  data,	  which	  suggested	  that	  there	  is	  a	  high	  risk	  of	  bias	  particularly	  with	  respect	  to	  blinding	  and	  matching	  of	  the	  intervention	  to	  the	  control,	  however	  about	  90%	  appeared	  to	  have	  low	  levels	  of	  reporting	  bias,	  largely	  a	  reflection	  of	  reporting	  baseline	  and	  post	  intervention	  data.	  Figure	  3.3.1.2,	  presents	  the	  judgments	  about	  bias	  for	  the	  studies	  individually.	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Figure 3.3.1.1. Risk of bias graph, judgements about each risk of bias item presented as 
percentages across all included studies. 
 
Figure 3.3.1.2: Risk of bias summary judgements about each risk of bias item for each included 
study. 
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The studies varied greatly with respect to their design, investigational product and 
conduct. Participant blinding was not clear in all studies; it was reported as being 
adequate by the researchers in 15, and by the participants in 12 of the studies. This 
difference was primarily due to the use of white chocolate as a control where there was a 
risk that the participant might be unblinded by the nature of their prior knowledge and 
experience. As previously described, all but ten of the 33 studies were associated with 
industry or trade bodies, and that 14 of the publications shared seven authors which also 
might represent the possibility of additional bias. Where data was extracted as baseline 
and end of study (and standard deviation/ standard error or 95% confidence interval) 
rather than mean change, the analysis resulted in a larger 95% confidence interval for the 
mean difference. This increased the degree of heterogeneity in a number of the forest 
plots. 
The nature of the formulations varied greatly in terms of amount of product, mean 
weight (g)± standard deviation across 33 studies was 65.9±40.1g for the control and 
67.7±38.7g active with a range from 5.6 to 180 g. This led to a difference in energy and 
carbohydrate content; from negligible carbohydrate and energy in the cocoa polyphenol 
capsules, to 2352Kj (560kcal) where there was in excess of 100g of carbohydrate. When 
cocoa supplementation was compared with the chocolate, there was a significant 
difference in the energy (p=0.027) but not the amount of carbohydrate (p=0.213) 
content. The mean (± standard deviation) energy and carbohydrate content of the cocoa 
interventions (placebos and interventions combined) were 872±653Kj (208±155kcal) 
energy and 34.2±35.8g carbohydrate compared to 1341±808kj (319±192kcal) energy 
and 24.3±19.5g carbohydrate for chocolate interventions. This related to a mean ± 
standard deviation percentage of energy provided by carbohydrates in the cocoa 
intervention studies of 68.2±13.8% and for the chocolate intervention studies a 
significantly lower proportion, at 38.8±13.1% (p<0.0001). 
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3.3.2	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Blood	  Pressure	  
3.3.2.1	  -­‐	  Systolic	  blood	  pressure	  
Data from sixteen trial data sets were included in the meta-analysis (figure 3.3.2.1). 
This represented 16 published trials and 576 participants. The meta-analysis 
suggested a significant reduction in systolic blood pressure with high polyphenol 
chocolate or cocoa (-3.46mmHg; 95% Confidence Intervals -4.80, -2.11, I2 =84%; 
p<0.0001) after a minimum of 14 days supplementation. 
3.3.2.1.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from nine data sets (extracted from eight published trials) representing 313 
participants suggested a significant improvement in systolic blood pressure with high 
polyphenol chocolate (-4.72mmHg; 95% Confidence Intervals -6.27, -3.17, I2 =87%; 
p<0.0001) after at least 14 days supplementation. This was in contrast to the data for 
cocoa, which did not appear to influence systolic blood pressure (-0.59mmHg; 95% 
Confidence Intervals -3.21, 2.03, I2 =68%; p=0.66) 
Analysis of the sub-groups within the meta-analysis suggested a significant 
difference between studies utilising chocolate and cocoa. The meta-analysis 
suggested that chocolate was more effective in improving systolic blood pressure 
than cocoa in well-controlled clinical trials lasting at least 14 days (p=0.008; Chi2 
=7.07, I2 =85.9). 
3.3.2.1.2-­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  systolic	  blood	  pressure	  	  
The funnel plot in figure 3.3.2.1 and the measure of heterogeneity, suggest that the 
data are very heterogeneous, and there are a number of studies suggestive of small 
study bias by the nature of their standard error of mean differences. Although 
Taubert et al. (2003) was included in the review, as there was not enough numerical 
data, it was not included in the analysis for blood pressure. 
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3.3.2.2	  -­‐	  Diastolic	  blood	  pressure	  
Data from sixteen trial data sets were included in the meta-analysis (figure 3.3.2.2). 
This represented 16 published trials and 576 participants. The meta-analysis 
suggested a significant improvement in diastolic blood pressure with high 
polyphenol chocolate or cocoa (-2.11mmHg; 95% Confidence Intervals -3.30, -0.91, 
I2 =87%; p<0.0001) after a minimum of 14 days supplementation. 
3.3.2.2.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from nine data sets (extracted from eight published trials) representing 313 
participants suggested a significant improvement in diastolic blood pressure with 
high polyphenol chocolate (-3.05 mmHg; 95% Confidence Intervals -4.46, -1.63, I2 
=90%; p<0.0001) after at least 14 days supplementation. This was in contrast with 
the data for cocoa, which did not appear to significantly influence diastolic blood 
pressure (-0.53 mmHg; 95% Confidence Intervals -2.17, 1.10, I2 =54%; p=0.52). 
Analysis of the sub-groups within the meta-analysis suggested that chocolate was 
more effective in improving diastolic blood pressure than cocoa in well-controlled 
clinical trials lasting at least 14 days (p=0.006; Chi2 =7.68, I2 =87.0%). 
3.3.2.2.2-­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  diastolic	  blood	  pressure	  	  
The funnel plot in figure 3.3.2.2 and the measure of heterogeneity, suggest that the 
data are very heterogeneous and there are a number of studies suggestive of small 
study bias by the nature of their standard error of mean differences. This is 
particularly notable for the studies using cocoa based interventions where three 
studies showed very little effect but a larger standard error. 
Chapter	  Three	  –	  Meta-­‐analysis	  
	   139	  
  
Chapter	  Three	  –	  Meta-­‐analysis	  
	   140	  
 
3.3.3-­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Fasting	  Lipid	  Parameters	  
3.3.3.1	  -­‐	  Total	  cholesterol	  	  
Data from fourteen trial data sets were included in the meta-analysis (figure 3.3.3.1). 
This represented 561 participants. The meta-analysis suggested a small but 
statistically significant reduction in total cholesterol with high polyphenol chocolate 
or cocoa (-0.14 mmol/l; 95% Confidence Intervals -0.23, -0.05, I2 =89%; p=0.003). 
3.3.3.1.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from eight published trials representing 261 participants included in the meta-
analysis suggested no significant improvement in total cholesterol with high 
polyphenol chocolate (-0.17mmol/l; 95% Confidence Intervals -0.34, 0.00, I2 =92%; 
p=0.06). The meta-analysis of studies utilising cocoa as the vector, also suggested no 
significant improvement in total cholesterol (-0.09 mmol/l; 95% Confidence 
Intervals -0.19, 0.01, I2 =72%; p=0.07). 
Analysis of the sub-groups within the meta-analysis suggested there were no 
significant difference between studies utilising chocolate and cocoa (p=0.43; Chi2 
=0.62, I2 =0.0%). 
3.3.3.1.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  total	  cholesterol	  	  
The funnel plot in figure 3.3.3.1 and the measure of heterogeneity, suggest that the 
data are very heterogeneous and there are a number of studies suggestive of small 
study bias by the nature of their standard error of mean differences. The funnel plot 
highlights two studies, which included chocolate with very small standard error or 
mean difference, otherwise the plot appears as would be expected.	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3.3.3.2-­‐	  HDL	  cholesterol	  	  
Data from fourteen trial data sets were included in the meta-analysis (figure 3.3.3.2). 
This represented 561 participants. The meta-analysis suggested the improvement in 
HDL cholesterol with high polyphenol chocolate or cocoa was not significant (0.04 
mmol/l; 95% Confidence Intervals -0.00, 0.08, I2 =92%; p=0.09). 
3.3.3.2.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from eight published trials representing 261 participants included in the meta-
analysis suggested no significant improvement in HDL cholesterol with high 
polyphenol chocolate (0.05mmol/l; 95% Confidence Intervals -0.02, 0.12, I2 =91%; 
p=0.17). The meta-analysis of studies utilising cocoa as the vector, also suggested no 
effect on HDL cholesterol (0.03 mmol/l; 95% Confidence Intervals -0.03, 0.09, I2 
=92%; p=0.29). Analysis of the sub-groups within the meta-analysis suggested there 
were no significant differences between studies utilising chocolate and cocoa 
(p=0.66; Chi2 =0.19, I2 =0.0%). 
3.3.3.2.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  HDL	  cholesterol	  	  
The funnel plot in figure 3.3.3.2 and the measure of heterogeneity, suggest that the 
data are very heterogeneous and there are a number of studies suggestive of small 
study bias by the nature of their standard error of mean differences.  
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3.3.3.3	  -­‐	  LDL	  cholesterol	  	  
Data from fourteen trial data sets were included in the meta-analysis (figure 3.3.3.3). 
This represented 561 participants. The meta-analysis suggested a small significant 
reduction in LDL cholesterol with high polyphenol chocolate or cocoa (-0.17 
mmol/l; 95% Confidence Intervals -0.31, -0.02, I2 =98%; p=0.03). 
3.3.3.3.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from eight published trials representing 261 participants included in the meta-
analysis suggested no significant improvements in LDL cholesterol with high 
polyphenol chocolate (0.01mmol/l; 95% Confidence Intervals -0.18, -0.20, I2 =95%; 
p=0.91). The meta-analysis of studies utilising cocoa as the vector, suggested a 
significant reduction in LDL cholesterol (-0.39 mmol/l; 99% Confidence Intervals –
0.67, -0.12, I2 =99%; p=0.006). The degree of heterogeneity could be a reflection of 
the different study populations and durations of study and that LDL cholesterol is 
calculated and would be influenced by variation in triglyceride levels. 
Analysis of the sub-groups within the meta-analysis suggested that cocoa rich in 
polyphenols were more effective at lowering LDL cholesterol than chocolate rich in 
polyphenols (p=0.02; Chi2 =5.50, I2 =91.8%). 
3.3.3.3.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  LDL	  cholesterol	  	  
The funnel plot in figure 3.3.3.3 and the measure of heterogeneity, suggest that the 
data are very heterogeneous and there are a number of studies suggestive of small 
study bias by the nature of their standard error of mean difference. 
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  3.3.3.4	  -­‐	  Triglycerides	  
Data from fourteen trial data sets were included in the meta-analysis (figure 3.3.3.4). 
This represented 561 participants. The meta-analysis suggested no significant 
improvement in triglycerides with high polyphenol chocolate or cocoa (-0.07 mmol/l; 
95% Confidence Intervals -0.14, -.000, I2 =89%; p=0.06). 
3.3.3.4.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from eight published trials representing 261 participants included in the meta-
analysis suggested no significant improvements in triglycerides with high polyphenol 
chocolate (-0.05mmol/l; 95% Confidence Intervals -0.15, 0.06, I2 =86%; p=0.39). The 
meta-analysis of studies utilising cocoa did suggest a significant reduction in serum 
triglycerides (-0.11 mmol/l; 95% Confidence Intervals -0.19, -0.02, I2 =80%; p=0.01) 
However, analysis of the sub-groups within the meta-analysis suggested there were no 
significant differences between studies utilising chocolate and cocoa (p=0.41; Chi2 
=0.69, I2 =0.0%). 
3.3.3.4.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  triglycerides	  
The funnel plot in figure 3.3.3.4 and the measure of heterogeneity, suggest that the data 
are very heterogeneous and there are a number of studies suggestive of small study bias 
by the nature of their standard error of mean difference. 
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3.3.4	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Insulin	  Resistance	  and	  Fasting	  
Glucose	  
3.3.4.1	  -­‐	  HOMA	  
A number of trials reported data linked to insulin metabolism, however in the case of two 
studies this was not presented numerically nor was not in a format that was readily 
accessible. This resulted in only three data sets (from two publications) being included. The 
meta-analysis (figure 3.3.4.1) represents 107 participants’ data. This was not split into 
subgroups for cocoa or chocolate. No significant improvement in HOMA was seen (-0.55 
mmol/l; 95% Confidence Intervals -1.15, 0.04, I2 =93%; p=0.7). The funnel plot, suggested 
that the data might not be representative, due to its asymmetry. 
3.3.4.2	  -­‐	  Fasting	  glucose	  
Data from ten trial data sets (extracted from nine publications) were included in the meta-
analysis (figure 3.3.4.2).  This represented 420 participants. The meta-analysis suggested no 
significant effect on fasting glucose with high polyphenol chocolate or cocoa (-0.06 mmol/l; 
95% Confidence Intervals -0.22, 0.09, I2 =92%; p=0.41). 
3.3.4.2.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from four published trials representing 188 participants included in the meta-analysis 
suggested no significant improvement in fasting glucose with high polyphenol chocolate (-
0.28mmol/l; 95% Confidence Intervals -0.50, -0.07, I2 =79%; p=0.01). The meta-analysis of 
studies utilising cocoa as the vector, also suggested, slightly negative effect on fasting 
glucose (0.11 mmol/l; 95% Confidence Intervals 0.03, 0.20, I2 =33%; p=0.008). Analysis of 
the sub-groups within the meta-analysis suggested there was a significant differences 
between studies utilising chocolate and cocoa, (p=0.0008; Chi2 =11.20, I2 =91.1%). The 
funnel plot suggests there was little in the way of small study bias. The data of Allgrove et 
al. (2011) although had glucose as an outcome was not included as not enough data was 
available. Variation in variance of mean difference appears to be linked to a couple of 
studies with very small inherent standard deviation (Taubert et al., 2007; Davison et al., 
2008). 
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3.3.5	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Endothelial	  Function	  
Data from twelve trial data sets (extracted from ten published studies) were included in 
the meta-analysis (figure 3.3.5.1). Both acute and post-supplementation changes were 
included. This represented 554 participants. The meta-analysis suggested a significant 
improvement in endothelial function measured by change in flow-mediated dilation with 
high polyphenol chocolate or cocoa (1.62%; 95% Confidence Intervals 0.88, 2.36, I2 
=92%; p<0.0001). 
3.3.5.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from four published trials (extracted from five data sets) representing 211 
participants included in the meta-analysis suggested a significant improvement in 
endothelial function with high polyphenol chocolate (1.74%; 95% Confidence Intervals 
0.51, 2.96, I2 =72%; p=0.005). The meta-analysis of studies utilising cocoa as the vector, 
also suggested a significant improvement on endothelial function (1.56%; 95% 
Confidence Intervals 0.62, 2.50, I2 =94%; p<0.0001). Analysis of the sub-groups within 
the meta-analysis suggested there were no significant differences between studies 
utilising chocolate and cocoa (p=0.99; Chi2 =0.00, I2 =0.0%). 
3.3.5.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  endothelial	  function	  	  
The funnel plot in fig 3.3.5.1 and the measure of heterogeneity, suggest that the data are 
very heterogeneous and there are a number of studies suggestive of small study bias by 
the nature of their standard error of mean differences. Although the paper of Westphal 
and Luley (2011) was identified for inclusion in the meta-analysis, the time frame and 
the inclusion of a meal lead to the decision to exclude its data from the final analysis. 
There is a degree of variability in the standard deviation of change of the studies 
presented here, this could reflect differing populations and methodologies, which could 
have led to greater variation. 
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  3.3.6	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Oxidative	  Stress	  
Data from eight published studies were included in the meta-analysis (figure 3.3.6.1). Both 
acute and post-supplementation changes were included. This represented 213 participants. 
The meta-analysis suggested no significant effects upon oxidative stress as assessed by 
changes in urinary or serum isoprostane markers with high polyphenol chocolate or cocoa 
supplementation (0.95pg/ml 95% Confidence Intervals -12.98, 14.88, I2 =88%; p=0.89). 
3.3.6.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from five published trials representing 137 participants included in the meta-
analysis suggested non-significant improvement in oxidative stress with high polyphenol 
chocolate (-26.08pg/ml; 95% Confidence Intervals -55.74, 3.58, I2 =94%; p=0.08). The 
meta-analysis of studies utilising cocoa as the vector, however suggested a non-
significant increase in oxidative stress (51.70pg/ml; 95% Confidence Intervals -23.05, 
126.45, I2 =95%; p=0.18). It is important to note that this was based on only three studies 
and data from 76 participants. Analysis of the sub-groups within the meta-analysis 
suggested the difference between studies utilising chocolate and cocoa did not reach 
significance (p=0.04; Chi2 =4.38, I2 =77.1%) possibly a reflection of the heterogeneity of 
the data resulting from differing methodologies used in the studies. 
3.3.6.2	  -­‐	  Potential	  small	  study	  and	  publication	  bias	  for	  oxidative	  stress	  	  
The funnel plot in figure 3.3.6.1 suggested there was an even distribution. There is a 
degree of variability in the standard deviation of change of the studies presented here, 
this could reflect differing populations and methodologies, which could have led to 
greater variation. Although oxidative stress was assessed in Allgrove et al. (2011), it was 
only presented as a figure with no numerical data, and was excluded 
3.3.7	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Inflammatory	  Markers	  
Only four studies that met the inclusion criteria, reported data on inflammatory markers, 
these in turn reported three different markers. Therefore it was not possible to include 
these in the meta-analysis. 
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3.3.7	  -­‐	  Effect	  of	  Cocoa	  and	  Chocolate	  on	  Weight	  Change	  
Data from eight data sets (extracted from seven published studies) were included in the 
meta-analysis (figure 3.3.7.1). To meet the inclusion for the meta-analysis the 
intervention needed to be at least 14 days long. This represented 328 participants. The 
meta-analysis suggested no significant effect upon weight following supplementation 
with high polyphenol chocolate or cocoa (-1.15kg 95% Confidence Intervals -2.38, 0.08, 
I2 =86%; p=0.07). There was the suggestion of a trend to weight loss, however some 
studies reported weight gain in the control arms. This was notable in the cocoa 
supplementation trials more than in the chocolate studies. 
3.3.7.1	  -­‐	  Sub-­‐analysis	  of	  chocolate	  supplementation	  
Data from three published trials representing 148 participants included in the meta-
analysis suggested no significant effect on weight with high polyphenol chocolate 
feeding as part of controlled trials (-0.09kg; 95% Confidence Intervals -0.62, 0.45, I2 
=0.0%; p=0.74). The meta-analysis of studies utilising cocoa as the vector, appeared to 
have no significant effect upon weight (-2.07kg; 95% Confidence Intervals -5.57, 1.43, I2 
=93%; p=0.74). Analysis of the sub-groups within the meta-analysis suggested there 
were no significant differences between studies utilising chocolate and cocoa (p=0.27; 
Chi2 =1.19, I2 =16.2%). 
3.3.7.2	  –	  Potential	  small	  study	  and	  publication	  bias	  for	  weight	  change	  	  
In the funnel plot in figure 3.3.7.1 suggested there was a larger than expected change in 
weight, but this was largely due to the study of Davison et al. (2008), which might have 
led to a small study bias effect. This also accounts for the wide 95% confidence interval 
for the cocoa subgroup. There is a degree of variability in the standard deviation of 
change of the studies presented here, this could reflect difference in the degree of dietary 
restrictions within studies and natural variance in body weight of the participants. 
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3.4	  Discussion	  
This exploratory review and meta-analysis identified 31 randomised controlled trials 
(representing the data from 1285 participants) where cocoa or chocolate supplementation has 
been used in an attempt to demonstrate a health benefit. All had a well-designed protocol and 
clear explanation of the intervention and control. Until the end of June 2012, eleven 
systematic reviews had been published which supported the potential beneficial effects of 
cocoa and chocolate polyphenols on a ranged of health outcomes. These range from the 
meta-analysis of blood pressure data from randomised controlled trials, through to 
cardiovascular disease reduction, from systematic reviews of epidemiological studies 
(reviewed in Chapter One). This review was limited by the lack of the use of indexing of the 
terms chocolate and flavanols, along with the lack of being limited to randomised controlled 
trials. In part the potential bias this may have induced would have been limited by the hand 
search and use of clinical trial registers to attempt to insure all relevant literature was 
collated. This together with the limitations of the method of analysis which relied on 
estimates of variance linked to assumptions about the distribution of the data and did not 
account for the data being paired and any correlations between the baseline and end of study 
data sets, leading to increased heterogeneity and larger confidence intervals for a number of 
studies. These factors need to be considered when interpreting this exploratory review, and 
more robust methodology incorporate, should this study be undertaken for consideration for 
publication. 
This is an initial exploratory review and meta-analysis to consider the potential difference in 
effect of chocolate as a vector for delivering the cocoa polyphenols (epicatechins and 
procyanadins) compared to cocoa. The rationale for a difference in effect is, based on the 
practicalities of feeding cocoa, its chemo-physical properties and a number of biological and 
psychological factors linked to its consumption. The data supports the case that chocolate has 
greater efficacy than cocoa for two of the parameters associated with cardiovascular risk. 
However, for LDL cholesterol, cocoa appeared to have significantly greater efficacy. Perhaps 
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this is a reflection of the saturated fat content of chocolate, perhaps acting via increasing 
triglyceride levels as this marker in the cases of these studies has been estimated using the 
Friedewald equation (Friedewald, Levy, & Fredrickson, 1972). For none of the six 
parameters (blood pressure, lipid profile (excluding LDL cholesterol), insulin resistance and 
glycaemia, endothelial function, oxidative stress and inflammation) did any data support the 
greater efficacy of cocoa, whereas for chocolate it demonstrated clear statistical superiority 
for its effects on lowering blood pressure  (both systolic and diastolic) and fasting glucose 
(with the data for cocoa showing a statistically significant increase).  
The results for the subgroup analysis for oxidative stress did not reach significance (p=0.06), 
this could be linked to the heterogeneity of the data presented in the literature, or a limitation 
of the analysis which led to variability in the variance of the mean difference.  This warrants 
further study both in thorough systematic review and more robust meta-analysis and clinical 
trials. As a potential mechanism for the effect of increased insulin and carbohydrate to 
increased oxidative stress has been well described in the hypothesis of (Brownlee, 2001; 
2005). Alternatively, Mursu et al. (2004) suggested that cocoa butter might have anti-
inflammatory or antioxidant capacity based on the reduction of LDL cholesterol oxidation 
from low polyphenol chocolate. Although it is clear that more work needs to be undertaken, 
which falls outside of the scope of this thesis. 
The studies were mostly of a crossover design (n=19), compared to 12 parallel design 
studies. However, the study design did not appear to have a significant effect on the 
outcomes suggesting that both study designs are valid in conducting of clinical trials of this 
nature. As discussed in Chapter Two, there are advantages and disadvantages in both 
approaches. It is likely the effect of treating data as independent in estimating the variance of 
the mean difference has added to the variability seen in the forest plots and the high level of 
heterogeneity. This should be considered if this work were to be repeated as part of a 
systematic review with meta-analysis. 
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Although only one study was found which investigated the effects of cocoa polyphenols 
alone, it was in a study population entirely made up from participants with T2DM. Curtis et 
al. (2012) investigated the effects of cocoa polyphenols in combination with soy isoflavones 
in postmenopausal women with T2DM. However, this study was discounted, as it was not 
possible to extract the effect of the cocoa polyphenols from the effects of the soy isoflavones. 
The work of Balzer et al. (2008), which, until my studies reported later in this thesis, was the 
only one to have considered the effects of cocoa flavanols only in diabetes. The additional 
benefit of this meta-analysis was to try to identify potential effects of both the intervention 
and control arms. It was clear from the mean change data, that there was no indication of 
harm from either arm in the studies. This was a potential limitation of this type of work, as 
the forest plot reports the mean and 95% confidence interval of the difference between the 
intervention and control arms and it is possible that if the control arm produces a negative 
effect, a modest negative effect of the intervention will show as a positive mean difference 
effect. 
This exploratory review and meta-analysis was limited by the nature of the studies included, 
a critical limitation being that interventions varied widely, with studies using from 5 to over 
100g of chocolate per day. The nature and presentation of the polyphenols also varied 
widely; some studies used commercially available products, whereas others used specially 
formulated products. This has often been a criticism made by EFSA (2012b) of the data used 
to support health claims, in that the dose of the active component is not defined and the 
studies presented have a wide degree of heterogeneity. This was an artefact of the way the 
research is being conducted with a number of small groups working with manufacturers 
testing different formulations in small cohorts. To investigate the potential benefits of cocoa 
polyphenols on health more fully, ultimately larger studies will need to be undertaken, using 
the minimum of a standard dose of epicatechin and polyphenols, if it is not possible to use a 
standard chocolate formulation. Such investigations are unlikely to be carried out due to 
funding restrictions and commercial interests. The challenge of limited funding is reflected in 
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this thesis where lack of funding meant that different chocolate formulations had to be used 
in each of the three clinical trials. 
It should be noted that the potential additional benefits of chocolate rich in polyphenols 
might be exaggerated due to the confounding introduced by the poor matching of control to 
intervention. With eight studies using white chocolate as the control to either dark or milk 
chocolate as the intervention. This introduces a high risk of bias, and the details are not 
available to assess the effect this might have on participant perception of benefit/ risk. It may 
depend on how the study was presented and the participant information provided on how this 
may influence the study outcome. For example a study presented as ‘does dark chocolate 
lower blood pressure’ may induce a response in favour of the dark chocolate above what 
might be expected. Therefore the potential additional benefits of chocolate rich in 
polyphenols compared to cocoa need to be further explored as part of well designed studies 
with carefully selected control chocolates. 
Further limitations of the exploratory review and meta-analysis could be due to the widely 
different baseline characteristics of the participants, which varied from healthy volunteers to 
those with diabetes, cardiovascular disease and even heart failure and postoperative heart 
transplants patients. This might have influenced the data on hypertension in particular.  
The final and perhaps key limitation of this exploratory review is that was is based entirely 
upon the numerically published data, due to time and resource limitations of this piece of 
work (one author and as a part component of a PhD thesis), it was not possible to contact 
study authors for clarification of data. Should this work to be repeated, a clearer search 
strategy would be employed using at least two researchers (one experienced in conducting 
systematic reviews), to insure that it was correctly index to reduce the risk of missing 
articles. The search strategy would also be adjusted so that it was more clearly limited to 
randomised controlled trials (which would need to be indexed to controlled trials and clinical 
trials) to insure a more precise search.  
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The use of more than one researcher would assist in identifying potential errors, e.g. where 
data is presented as mean± standard error of mean rather than standard deviation. This would 
potentially allow for the contacting of authors to reduce the reliance on calculating estimates 
of the variance of change and potentially use papers, which were excluded from this study 
due to the lack of numerical data being presented. Alternatively, instead of variance law 1 for 
the estimate of the variance of the change, variance law 2 could be used with the necessary 
sensitivity analyses where assumed correlation coefficients are deployed. This should reduce 
the variability in the estimate of variance for the mean differences, as it will account for the 
correlation and paired nature of the data, which this review did not. 
3.4.1	  -­‐	  Summary	  
This exploratory review and meta-analysis suggests (subject to further work and analysis) 
that: 
1. Chocolate consumption may provide greater efficacy when compared to cocoa with 
respect to markers of cardiovascular risk and diabetes control. This is clear for the 
greater beneficial effects seen with chocolate with respect to cocoa, for blood 
pressure, fasting glucose and oxidative stress, although cocoa may be improve LDL 
cholesterol. This may be in part be reflecting the effect of poor matching of control 
chocolates to the intervention product. 
2. Chocolate preparations tend to have a low percentage of energy as carbohydrate, 
despite a higher mean energy content. This might make chocolate more suitable for 
people with T2DM, as the excess carbohydrate may adversely influence the 
metabolic disturbances and glycaemia associated with this condition. 
3. There is no evidence from either the controls or interventions of negative effects on 
the parameters associated with cardiovascular risk or diabetes control. 
This exploratory review and meta-analysis justifies the selection of chocolate as a vector for 
cocoa polyphenol delivery to investigate their potential health effects in individuals with 
T2DM as it may have mechanistic advantages supported by some of the findings of the sub-
group analyses. However, it needs to be appreciated the high risk of bias which resulted from 
inadequate blinding in the studies and weaknesses in this review means that these findings 
need to be treated with caution. 
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Chapter	  Four:	  Proof	  of	  Concept	  Study:	  Investigating	  the	  Effects	  
of	  High	  Cocoa	  Polyphenol	  Rich	  Chocolate	  on	  Cardiovascular	  Risk	  
in	  Individuals	  with	  Type	  2	  Diabetes	  Mellitus	  
 
Aims and scope of chapter: 
• To undertake a proof of concept study to investigate the safety of prolonged 
feeding of chocolate to individuals with type 2 diabetes mellitus (T2DM). 
• To access the potential health benefits of consuming high polyphenol chocolate 
for individuals with T2DM. 
Table 4.0, defines the study question and PICOS approach to achieving the above aims 
of this chapter. 
Table 4.0: Study questions and PICOS for the proof for study one. 
Study 
Question(s) 
Can chocolate rich in polyphenols reduce cardiovascular risk in individuals with 
type 2 diabetes mellitus? 
Can chocolate rich in polyphenols improve lipid profile; primarily increase HDL 
cholesterol in individuals with type 2 diabetes mellitus? 
Participants Twelve individuals with type 2 diabetes mellitus controlled by lifestyle alone, or 
in combination with oral hypoglycaemic medication.  
Interventions Chocolate rich in polyphenols (783mg total polyphenols/ 55mg epicatechins) 
Comparisons Chocolate low in polyphenols (176mg total polyphenols/ <2mg epicatechins) 
Outcomes Primary outcomes: 
1. HDL cholesterol 
2. Cholesterol:HDL cholesterol ratio 
Secondary outcomes: 
1. Change in weight 
2. Glycaemia (glucose or HbA1c) 
3. Blood pressure, insulin resistance and inflammation. 
Study design A double blind randomised controlled trial, with two - eight week intervention 
periods separated by a four-week washout period. 
 
To address these aims the clinical study will be presented in three parts: 
  4.1 - Background and study-specific methodology. 
  4.2 - Results, safety, efficacy and participant-reported outcomes. 
  4.3 - Discussion and conclusion. 
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4.1	  –	  Background	  and	  Study	  Specific	  Methodology	  	  
Type 2 diabetes mellitus is associated with excess cardiovascular risk at least some of 
which can be moderated by lifestyle factors, including the diet. One of these risk 
factors, dyslipidaemia, is known to be a especially prevalent in individuals with T2DM 
(Haffner et al., 1998) and high intakes of refined carbohydrates such as sucrose are 
associated with worse glycaemic control, increased obesity and hypertriglyceridaemia 
(Laville & Nazare, 2009). Concern over the effect of sugar on glycaemia has been 
reduced by work on the glycaemic index (GI) (Brand-Miller, Hayne, Petocz, & 
Colagiuri, 2003). The concept of the GI has led to the realization that foods such as 
chocolate, although high in carbohydrate, and in particular, sugar/sucrose, may have a 
lesser effect on blood glucose than foods that are low in sugar, including potatoes and 
bread (Foster-Powell, Holt, & Brand-Miller, 2002). 
It has been hypothesized that flavonoid compounds found in foods, including 
epicatechins found in high-cocoa-solid chocolates, decrease in mortality rate from 
coronary heart disease, cancer and stroke (Buijsse, Feskens, Kok, & Kromhout, 2006).  
Short-term administration of dark chocolate is followed by a significant increase in 
insulin sensitivity and a decrease in blood pressure in healthy participants (Grassi, et al., 
2005a). Dark chocolate consumption has been reported to increase HDL cholesterol 
concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy 
participants (Mursu et al., 2004). 
The hypothesis was therefore that the daily consumption of chocolate (45 g daily) 
containing polyphenol-rich, high-cocoa solids improves cardiovascular risk factors 
when eaten chronically, whilst being safe for individuals with T2DM. Additionally, 
safety was assessed by monitoring weight changes and glycaemia along with incidence 
of adverse events. 
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4.1.1	  -­‐	  Research	  Design	  and	  Methods	  	  
The principle methodology was to assess the effect of consuming of 45g chocolate with 
a high cocoa solid content (and therefore rich in flavanols) daily versus a placebo 
chocolate for a total of five months. The protocol involved two months (eight weeks) of 
one chocolate, one-month (four weeks) washout prior to a further two months (eight 
weeks) consuming the alterative chocolate. This was judged to be a safe regime for 
individuals with T2DM and would hopefully be weight neutral and improve lipid 
profile and thus reduce the cardiovascular risk factors associated in this condition.  
Cardiovascular risk factor reduction was assessed by: 
Primary outcome; 
• Increased HDL cholesterol, along with assessments of overall lipid profile 
improvement (HDL: Total cholesterol ratio). HDL cholesterol is known to 
be supressed in T2DM, and is not significantly improved even with 
medication (Krauss, 2004). 
Secondary outcomes; 
• Reduced insulin resistance, this is not proposed as a primary outcome, owing 
to the poly-pharmacy of the participant group (the inclusion criteria included 
all oral hypoglycaemia agents, which is in contrast to the studies reported in 
Chapters Five and Six). 
• Reduced blood pressure, this was not deemed to be appropriate as a primary 
outcome, since many individuals with T2DM are often on antihypertensive 
therapies, with primary care incentivized to the use of ACE inhibitors 
(Information Centre, 2011). 
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Safety was assessed by: 
• Weight remained neutral, since a common side effect of many therapeutic 
strategies in the management of diabetes (e.g. sulphonylureas and insulin) is 
weight gain (UKPDS Group, 1998a; Holman et al., 2008)  
• Lack of an effect upon HbA1c, self monitored glycaemia and the continuous 
monitoring of interstitial glucose (using the Glucoday (A.Menarini, 
Wokingham, Berkshire, UK). 
Participant Reported Outcomes were assessed by: 
• Hospital Anxiety Depression Scale  (HADS) (Bjelland, Dahl, Haug, & 
Neckelmann, 2002; Zigmond & Snaith, 1983) 
• SF-36 (short form) (Ware, 2000) 
• Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989) 
The first two questionnaires were modified from a previous study investigating the 
effect of chocolate in chronic fatigue syndrome (Sathyapalan, Beckett, Rigby, Mellor, & 
Atkin, 2010). In designing the study, feedback was obtained feedback from a patient 
user group who questioned whether cocoa taken as a pre-bed time drink might improve 
sleep quality leading to the addition of the questionnaires. 
4.1.2	  –	  Participants	  
A total of 19 individuals with T2DM were screened for inclusion in the study. The 
conduct of the study can be seen in the CONSORT flowchart (figure 4.1.2.1). The 
diagnosis of T2DM was based on the WHO/IDF guidelines (2006). An exclusion 
criterion of Hba1c >9.0% (DCCT aligned) or >75mmol/mol was used. In addition, 
rescue criteria were employed, so that an increase in HbA1c of 1% or 11mmol/mol 
during the study or a weight gain of greater than 2kg between study visits would have 
led to the participant being withdrawn from the study for their own safety. 
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Figure 4.1.2.1: CONSORT flow diagram of the conduct of the trial, including the outcome for all 
participants. 
 
Of the total of 19 participants recruited to the study; three were excluded; two because 
of concurrent medications that had been altered in the last three months, and one subject 
was excluded because they were lost to follow up following the initial study visit. 
Twelve participants completed the study, with four participants not completing. One 
withdrew because of reported loss of energy within a week of starting the low 
polyphenol chocolate arm of the study. The other three who did not complete the study 
were withdrawn due to inter-current illness associated with their pre-existing conditions 
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(bowel disease and two respiratory illness), all of which occurred during the washout 
phase between chocolate interventions. 
4.1.3	  -­‐	  Study	  Design	  
A randomized, placebo-controlled crossover study methodology was employed. 
Following screening, five participants were assigned the ‘placebo’ chocolate and seven 
the ‘active’ flavanols rich chocolate for eight weeks, and advised to follow their same 
dietary patterns, with the exception of excluding all other chocolates and cocoa 
products. This was followed by a four-week washout period where no chocolate was 
dispensed and the participants were instructed not to consume any chocolate or cocoa 
products. Participants then returned for reassessment and were dispensed the alternate 
chocolate to the one their received in the first eight weeks. 
A copy of the randomization code was kept secure by the hospital pharmacy and was 
available to the investigator only in case of an emergency. All participants gave written 
informed consent and the Hull and East Riding NHS Research Ethics Committee and 
Hull and East Yorkshire Hospitals NHS Research and Development Department 
approved the protocol. The chocolate was provided as an unrestricted gift from Nestlé 
PTC, York and the study was paid for out of charitable funds. The trial was registered 
(ISRCTN 25655161) and conducted in accordance with the Declaration of Helsinki 
(WMA, 2000). 
The active product was flavanol (polyphenol) rich chocolate containing 85% cocoa 
solids (derived from a high cocoa liquor content) compared with a comparator control 
chocolate containing cocoa butter alone with no non-fat cocoa solids (cocoa liquor) 
(simulated iso-calorific chocolate). The control chocolate was low in polyphenols, but 
was dyed to the same colour as the high cocoa liquor/polyphenol rich chocolate (with a 
recipe specially prepared by Nestlé PTC York. UK). Details of the chocolate 
formulations can be found in Section 2.2.7 of Chapter Two, and tables 4.1.3.1 and 
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4.1.3.2.  Individual 15g foil wrapped bars were provided and participants were asked to 
consume one bar three times daily. Participants were advised not to consume extra 
chocolate during the study period; apart from this, they were asked not to change their 
diet. To assess the ability of potential participants to be able to identify which chocolate 
is the ‘active’ and which is the control, a taste trial was conducted was described by 
Sathyapalan et al. (2010).  
Nestlé PTC in York performed the analyses of the chocolates.  The control chocolate, a 
simulated iso-calorific chocolate that was dyed to match the colour of the flavanols rich 
chocolate, contained 2293Kj/100g  (547 Kcal/100 g)(1033Kj (246Kcal) for the 45g 
chocolate daily dose of three 15g bars) whereas the dark, flavanol rich chocolate with 
cocoa powder contained 2289Kj/100g (545 Kcal/100g) (1029Kj (245Kcal) for the daily 
dose). Calculations were done using the Genesis for Windows (Esha Research, Salem, 
OR, USA).  The glycaemic index of dark chocolate was estimated at 41 whereas for 
simulated iso-calorific chocolate it was 34 – 44 based upon the data of Foster-Powell et 
al. (2002).   
The composition of high cocoa liquor/polyphenol rich chocolate and the simulated iso-
calorific chocolate are given in table 4.1.3.1, and the polyphenol content of each, shown 
in table 4.1.3.2.  The percentage of non-fat cocoa solids (cocoa liquor) in polyphenol 
rich chocolate was 33.17%.  Microbiological analyses were carried out on a cross 
section of samples and showed that salmonella or enterobacter laceae were absent.  
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Table 4.1.3.1: Polyphenol analysis* high cocoa liquor/ polyphenol rich chocolate and simulated 
iso-calorific chocolate (cocoa liquor free / low polyphenol) 
Polyphenols 
High Cocoa 
Liquor / 
Polyphenol Rich 
chocolate 
Dose for 45g 
(3 bars) Daily 
Dose per 
participant 
Simulated iso-
calorific chocolate 
Cocoa Liquor Free 
/ Low Polyphenol) 
Dose for 45g 
(3 bars) Daily 
Dose per 
participant 
Folin 17.4 mg ECE/g 783mg ECE 3.9 mg ECE/g 176mg ECE 
Catechin 0.37 g/kg 16.6 mg <0.05 g/kg <2mg 
Dimer B2 0.80 g/kg 36.0mg <0.05 g/kg <2mg 
Epicatechin 1.23 g/kg 55.3mg <0.05 g/kg <2mg 
Trimer C 0.58 g/kg 26.1mg <0.05 g/kg <2mg 
Tetramer D 0.33 g/kg 14.9mg <0.05 g/kg <2mg 
Dimer B5 0.32 g/kg 14.8mg <0.05 g/kg <2mg 
* All analysis undertaken and provided by Nestlé PTC, York, UK 
 
All participants attended a structured, group patient education programme (XPERT) and 
were on stable medication for their diabetes, hypertension, lipids and gout, for three 
months prior to entry into the study. Participants were encouraged to incorporate the 
chocolate into their normal habitual diet as advised during the XPERT programme, 
which all participants undertook at least one month before being enrolled onto the study 
(Deakin, Cade, Williams, & Greenwood, 2006). At each visit, dietary compliance was 
monitored by 24-hour dietary recall undertaken by myself (data not presented), as a 
registered dietitian. Participants were instructed to consume the chocolate at each of the 
following points in the day, either mid-morning, mid afternoon and in the evening or as 
a supper snack. The returned empty packets, marked with the date, and time each bar 
was consumed, together with the any uneaten chocolate, were used to monitor 
compliance with the study and the intake of chocolate. 
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Table 4.1.3.2: Nutritional composition of chocolate bars, shown per 100g, per bar and per thrice-
daily dose. 
Energy and Nutritional Profile 
Nutrient 
Per 100g Per bar Par 3 bars (daily dose) 
High 
polyphenol 
Low 
polyphenol 
High 
polyphenol 
Low 
polyphenol 
High 
polyphenol 
Low 
polyphenol 
Energy (kcal/ Kj) 547/2297 540/2268 82 / 344 81/340 326/ 1032 323/1020 
Fat (g) 
Of which saturates 
(g) 
45.4 
25.3 
31.3 
16.0 
6.8 
3.8 
4.7 
2.4 
20.4 
11.4 
14.1 
7.2 
Carbohydrate (g) 
Of which sugars (g) 
28.9 
23.8 
60.0 
49.3 
4.3 
3.6 
9.0 
7.4 
12.9 
10.8 
38.7 
32.6 
Protein (g) 7.3 8.0 1.1 1.2 3.3 3.6 
Composition by 
Macronutrient % % 
Protein 5.43 5.72 
Carbohydrate 19.51 41.78 
Fat 75.05 52.44 
 
4.1.4	  Study	  Measurements	  
Following an overnight fast, weight and blood pressure were measured and blood 
samples drawn at baseline and at the end of the intervention phase (eight weeks later), 
following the four weeks washout and at the end of the second phase (following a 
further eight weeks). All blood samples were drawn and processed as described in 
Chapter Two. Routine biochemistry, liver function tests and a full blood count were 
performed using the hospital pathology labs to screen for any changes as part of safety 
monitoring.  
All participants were requested to test their own capillary glucose using a glucose meter 
supplied by the research team (Glucomen; Menarini Diagnostics, Wokingham, UK). 
Participants were asked to take a 7-point glucose profiles (pre-breakfast, 2-hours post 
breakfast, pre-midday meal, 2-hours post midday meal, pre-evening meal, 2-hours post 
evening meal and pre-bed) on two occasions, in two separate weeks during the period 
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they were consuming the chocolate. Each participant recorded a minimum of at least 28 
readings. In addition, three participants volunteered to have interstitial glucose 
measurements made during each chocolate intervention arm and at the mid-point of the 
wash out period. This was undertaken using the Glucoday Continuous Glucose 
Monitoring System (CGMS) (A Menarini Diagnostics, Wokingham, UK). 
4.1.5	  -­‐	  Statistical	  analysis	  and	  sample	  size	  calculation	  
For a two-sided 5% significance level, a sample of five participants per group was 
needed, assuming a 10% dropout rate for a pilot cross over trial. This gave the study 
80% power to detect a 20% difference in HDL between treatments (assuming a common 
standard deviation of 0.25). This is similar to published studies investigating the effects 
of chocolate in healthy individuals. The results were considered significant if the two-
tailed P value was <0.05. The sample size was derived using nQuery version 4 
(Statistical Solutions Ltd. Cork, Ireland). Statistical analysis was performed using SPSS 
16.0 (SPSS, Chicago, IL, USA) and Microsoft Excel 2007 (Microsoft, Redmond, 
Washington, USA). 
All data from were tested for normality, using Kolmogmorov-Smirnov, as advised by 
the University statistician (Mr Alan Rigby). Mean percentage changes obtained at the 
end of the ‘active’ chocolate phase were compared with the results at the end of the 
placebo phase, using the paired Student’s t-test for normally distributed data and 
Wilcoxon’s signed-rank test for data which violated normality. The period and the 
carryover effect that may have occurred from the crossover design were tested using the 
appropriate Student’s t test.  
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4.2	  –	  Results	  
4.2.1	  –	  Safety	  Data	  and	  Biomedical	  Results	  
Table 4.2.1: Baseline characteristics of participants 
Characteristic  
Age (Mean years ± standard deviation) 58.33±6.79 
Gender ratio (Male: Female) 7:5 
Duration of Diabetes (Mean years ± standard deviation) 4.17±1.95 
Weight (Kg ± standard deviation) 89.4±21.6kg 
BMI (Kgm-2± standard deviation) 31.77± 9.90 
Oral Diabetes Medication (Metformin Only: Other: None) 7:2:3 
Lipid Lowering Medication (Yes : None) 9:3 
Blood Pressure Medication (Yes : None) 7:5 
 
Initial safety was assessed by reviewing the baseline to end of study data. This 
represented a total of four months (16 weeks) of consuming 45g chocolate per day, split 
into two periods of eight weeks of chocolate consumption separated by a four-week 
washout period. This was used in addition to assessing the effect of the control, as it 
was felt that this would indicate if prolonged consumption of any chocolate might have 
negative effects. This methodology is commonly used in pharmaceutical trials to assess 
safety in terms of exposure to a compound or product. Weight was unchanged at 
89.4±21.8kg (mean± standard deviation) at the end of the study compared to 
89.4±21.6kg (p=1.00) at baseline. The dietary recall data suggested that the chocolate 
tended to replace other snack foods and there was some reduction in portion size at the 
subsequent meal. Compliance with chocolate consumption was a median of 92% based 
on returned and dated chocolate wrappers (91% for the high polyphenol chocolate 
(range 89-98%) and 94% for the low polyphenol chocolate (range 89-98%).  
There were no effects on glycaemia in terms of Hba1c 6.43±0.81% on study entry 
compared to 6.50±0.76% at the end of the study (p=0.84); Total cholesterol 
(4.84±1.49mmol/l versus 4.98±1.34mmol/l; p=0.84); HDL cholesterol 
(1.18±0.29mmol/l versus 1.26±0.27mmol/l; p=0.49); LDL cholesterol 
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(3.01±1.25mmol/l versus 3.20±1.21mmol/l; p=0.76) and triglycerides (1.18±0.85mmol/l 
versus 1.15±0.59; p=0.31). No effect was seen for systolic blood pressure (p=0.97) or 
diastolic blood pressure (p=0.46).  
The nutrient and flavonol composition of the chocolates, given in tables 4.1.3.1 and 
4.1.3.2, shows that the chocolates were matched for energy content; the main difference 
being in flavonol content. Since palatability of the chocolate was a key issue, the 
primary aim of formulation for the control chocolate was be similar to the flavanols rich 
bar. This necessitated a compromise and it was not possible to match the macronutrient 
content of the bars.  
Further safety data were collected with all 12 participants recording self-monitored 
blood glucose (SMBG) readings, undertaken while they were consuming the chocolate 
at six points (pre and post-prandial) on two occasions through the two-month period. 
The data in figure 4.2.2.1 show that the glycaemic excursion was greater following 
breakfast for the low polyphenol chocolate compared to the high polyphenol chocolate. 
To investigate this further, continuous glucose monitoring (CGMS) shown in figure 
4.2.2.2 was undertaken using the Glucoday on the three participants who gave their 
further consent. The results appear to match the observations from the SMBG. 
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Table 4.2.2.1: Mean values for biochemical of cardiovascular risk. P values were obtained by t-test. 
All biochemical tests were tested for normality using the Kolmogorov-Smirnov test which none of 
the data violated. 
 
Pre-low 
polyphenol 
Chocolate 
(placebo) 
Post-low 
polyphenol 
Chocolate 
P -
value 
Pre-high 
polyphenol 
Chocolate 
(active) 
Post-high 
polyphenol 
Chocolate 
P -value 
Systolic blood 
pressure (mmHg) 132±5 134±6 0.67 132±5 134±5 0.55 
Diastolic blood 
pressure (mmHg) 80±3 82±3 0.10 82±3 84±2 0.51 
HbA1c (%) 6.4±0.8 6.4±0.7 0.63 6.4±0.8 6.5±0.8 0.07 
Glucose (mmol/l) 6.8±1.5 7.2±1.3 0.17 7.0±1.4 6.9±1.5 0.71 
Insulin (uIU/l) 10.8±8.3 14.8±9.7 0.07 13.91±9.0 14.13±10.6 0.92 
HOMA 3.4±3.3 4.6±3.2 0.08 4.5±3.5 4.5±3.9 0.95 
Hs-CRP (mg/l) 2.6±2.5 2.4±2.2 0.72 3.0±2.1 2.0±1.5 0.22 
Serum Cholesterol 
(mmol/l) 4.9±1.4 5.0±1.3 0.55 5.0±1.5 5.0±1.3 0.94 
Serum Triglycerides 
(mmol/l) 141±0.89 1.30±0.61 0.52 1.33±0.5 1.20±0.65 0.32 
Serum LDL 
Cholesterol (mmol/l) 3.02±1.21 3.15±1.13 0.18 3.20±1.42 3.18±1.24 0.83 
Serum HDL 
Cholesterol (mmol/l) 1.18±0.26 1.20±0.30 0.78 1.17±0.27 1.24±0.26 0.04 
 
4.3±1.6 4.4±1.5 0.83 4.4±1.4 4.1±1.3 0.03 
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Figure 4.2.2.1: Self monitored capillary glucose monitoring (at least 12 recordings for each time 
point) 
 
 
Figure 4.2.2.2: CGMS for ‘active’ chocolate, washout (twice for each of the participants) and 
placebo. Two participants undertook CGMS  	  
The data in table 4.2.2.1 and figure 4.2.2.3 demonstrate a significant improvement in the 
lipid profile with high polyphenol chocolate in terms of an increase in HDL cholesterol 
and cholesterol: HDL ratio. This matched a non-significant reduction in triglycerides. 
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Figure 4.2.2.3: Difference in lipid profile parameters between high polyphenol chocolate compared 
to low polyphenol chocolate. All samples measured fasting at baseline and following 8-weeks of 
consuming 45g chocolate per day (3 times 15g bars) data presented as mean ± standard error of 
mean. 
Along with the observed absolute changes in lipid parameters (table 4.2.1.1) the positive 
effect of high flavanol chocolate can be seen on HDL cholesterol levels and as an 
improved HDL:total cholesterol ratio. There did not appear to be an adverse effect on 
total cholesterol despite the 16g of saturated fatty acids the chocolate added to the 
participants’ diets. These results are suggestive of a change greater would be seen from 
a variation HDL cholesterol of a coefficient of variation of 6.2-7.7% in a similar well 
controlled T2DM population (Sathyapalan, Atkin & Kilpatrick, 2008). The coefficient 
of variance for other lipid parameters, in this population have been reported to vary 
from 6.9% for total cholesterol for individuals treated with atorvastatin to nearly 20% 
for triglycerides in the same cohort of patients (Sathyapalan, Atkin & Kilpatrick, 2008). 
This is similar to the coefficients of variation seen in healthy subjects (Bookstein, 
Gidding, Donovan and Smith, 1990).  The Data on the hospital pathology records were 
reviewed 6-9 months following completion of the study and showed that lipid profiles, 
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especially HDL cholesterol, had reverted back to pre-study levels. Although HOMA 
appeared to significantly improve, with the high polyphenol chocolate relative to low 
polyphenol chocolate (p=0.013), this was an effect of the increase HOMA following 
low polyphenol chocolate (increase of 1.23±1.13 following low polyphenol chocolate, 
compared to 0.04±1.03). Systolic blood pressure, did not change significantly following 
eight weeks of either chocolate, high polyphenol chocolate slightly decreased -
0.88±13.5mmHg whereas following low polyphenol chocolate it slightly increased 
1.55±8.19mmHg (p=0.83). A similar lack of effect was seen with respect to diastolic 
blood pressure, following high polyphenol chocolate an increase of 2.63±4.53mmHg, 
with low polyphenol chocolate having a similar effect 1.55±7.57mmHg (p=0.57). 
Neither the changes in HOMA or blood pressure were clinically significant.	  
4.2.3	  -­‐	  Participant	  Reported	  Outcomes	  	  
Figure 4.2.3.1: Hospital Anxiety Depression Scores for Anxiety and Depression following 8 weeks 
of consuming either low polyphenol chocolate and high polyphenol chocolate.  The HADS(Anxiety 
Score) significantly decreased following 8 weeks of consuming HPC (p=0.002; baseline to 8 weeks) 
and was significantly different between the HPC and LPC (p=0.027). No differences were seen in 
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other aspects of HADS or PSQI . Analysis by 2-way ANOVA (p>0.05) with presented p values from 
post-hoc analysis using LSD. 
The participants reported outcomes did not show any difference between or within the 
groups following chocolate consumption (Figures 4.2.3.1 and 4.2.3.2., with the 
exception of a reduced anxiety score from the HADS questionnaire following the 
consumption of high flavanol chocolate (p=0.002) and between the two chocolate 
groups following 8 weeks of daily chocolate consumption (p=0.027). 
 
Figure 4.2.3.2: SF-36 (short form) score including the individual parameters following 8 weeks of 
consuming either low polyphenol chocolate and high polyphenol chocolate. No differences were 
seen  between the arms of the study or within the study arms (2-way ANOVA) 
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4.3	  -­‐	  Discussion	  
This is the first study to give individuals with T2DM the equivalent of a standard 
chocolate bar (45g, as three 15g bars) a day chronically for 5 months (16 weeks of 
chocolate consumption) with minimal adverse events (two of the three adverse events 
occurred during the washout period), weight gain or deterioration in glycaemic control. 
This study was also novel because of the chronic nature of providing the chocolate over 
the five-month period as previous studies have been over a much shorter timeframe.  
With the flavanols-rich chocolate, HDL cholesterol was seen to increase significantly; 
an effect in accord with a study in populations without diabetes (Mursu et al., 2004) and 
indicating that this effect can be sustained. In addition, the reciprocal reduction in HDL: 
total cholesterol ratio, suggests that the high polyphenol chocolate might be a useful 
adjunction to lipid lowering in individuals with T2DM. This suggests that high 
flavanols chocolate may be of benefit in individuals who are on lipid lowering therapy, 
but have suppressed HDL cholesterol, and is worthy of further investigation, 
particularly as when the high flavanol chocolate intervention was stopped, the beneficial 
effects were reversed. 
Previous studies have reported acute beneficial effects of chocolate supplementation on 
blood pressure (Grassi et al., 2005a; Taubert, Roesen, & Schomig, 2007) and insulin 
resistance as assessed by HOMA (Grassi et al., 2008); something which was not found 
in the present study. This may have been due to the more chronic nature of this study, 
that the participants had T2DM and raised blood pressure that can be more resistant to 
treatment, or were taking concurrent antihypertensive therapy that prevented further 
improvement. Along with a lack of effect on glycaemia there were no increases in 
weight despite an increase in   participants’ energy intake of 1Mj (320kcal) per day.  
In order to detect gross changes in dietary habits, I carried out a 24-hour food and 
physical activity. The only difference detected was with the low polyphenol chocolate, 
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where portion sizes tended to decrease at meal times. In other words, participants 
appeared to compensate for eating chocolate by eating less at meal times. The recall, 
was aimed at assessing compliance, and was unable to detect whether these changes 
were intentional. It was a deliberately decided not to use more in-depth dietary intake 
methods since these are acknowledged to affect habitual food intake and might have 
biased the data and even result in weight loss. 
Glycaemic control was not affected by chocolate intake, in agreement with the initial 
hypothesis, but due to the pilot nature of this study, this finding may have lacked power. 
In terms of glycaemia, the data showed that post-prandial peaks in glycaemia were 
reduced following breakfast. This finding was statistically significant for the Self 
Monitored Blood Glucose (SMBG) (p=0.041) and was mirrored by the CGMS data. 
High-cocoa flavanol-rich chocolate has been shown to reduce insulin resistance in 
participants without diabetes but this was not seen as a change in HOMA in the present 
study. However the reduction in post-prandial glycaemia may have been the result of 
improved insulin sensitivity or insulin secretion. This observation needs further work to 
elucidate the underlying mechanism.  
This study differed from previous studies investigating cocoa flavanols in T2DM, which 
have used much shorter intervention periods and used only cocoa (Balzer et al., 2008) 
which the meta-analysis presented in Chapter Two indicated was not the ideal 
formulation for administering flavanols, with chocolate appearing to be more 
efficacious.  Subsequently the work of Curtis et al. (2012), combined chocolate rich in 
flavanols with isoflavones in postmenopausal women with T2DM which concurred with 
my data suggesting a reduction in cardiovascular risk 
The mechanism by which high-polyphenol chocolate improves lipid profile remains 
unclear. It has been suggested that the polyphenols may have either an insulin 
sensitizing effect (Grassi et al., 2005b), which was not seen in this study, or that there is 
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a reduction in the inflammation-independent action of insulin (Mursu et al., 2004). 
Lipid peroxidation was reduced, although this could not have been inferred from the 
high-sensitivity C-reactive protein (CRP) levels, which did not differ between groups. It 
has further been hypothesized that additional beneficial effects of flavanols on the 
endothelium may be mediated through increasing nitric oxide levels (Fisher, Hughes, 
Gerhard-Herman, & Hollenberg, 2003; Heiss et al., 2006; Persson, Persson, Hägg, & 
Andersson, 2011; Schmitt & Dirsch, 2009). 
The small sample size of this study potentially placed the data at risk from type 1 errors 
(with a false positive finding), although the crossover design probably overcame this to 
some extent. Being a crossover study, there was concern that participants may have 
been able to tell the difference between the two preparations and a blinded taste study 
was therefore undertaken prior to the trial. Reassuringly, this showed that the 
participants could not tell any difference in appearance or taste between the high-
polyphenol chocolate and low-polyphenol chocolate preparations. A further criticism of 
this study could be the lack of measurements of plasma polyphenols in this study; this 
was due to lack of available funds. Chocolate rich in flavanols, increase HDL 
cholesterol significantly based upon the reported data. It may be useful in future studies 
to measure epicatechin metabolites as these would be useful if the protocol aims to 
include an aspect of dose–response effects. 
4.3.1	  -­‐	  Conclusion 
This is the first study to investigate the potential of chocolate to reduce cardiovascular 
risk in individuals with T2DM. It has demonstrated that consuming 45g per day of (high 
flavanol chocolate over eight weeks increases plasma HDL with no detrimental effect 
on glycaemic control or weight gain; effects which are likely to reduce cardiovascular 
risk. Further work is needed to investigate the effects of chocolate and polyphenols on 
lipid metabolism and their potential interactions with lipid lowering medication.
Chapter	  Five	  –	  Study	  Two	  
	   181	  
Chapter	  Five:	  High-­‐Polyphenol	  Chocolate	  Reduces	  Endothelial	  
Dysfunction	  and	  Oxidative	  Stress	  during	  Acute	  Transient	  
Hyperglycaemia	  in	  Type	  2	  Diabetes:	  A	  Pilot	  Randomized	  
Controlled	  Trial	  
 
This chapter investigates the effects of high polyphenol (flavanol rich) chocolate on 
markers of endothelial dysfunction and oxidative stress during acute transient 
hyperglycaemia in individuals with type 2 diabetes mellitus (T2DM).  
Aims and Scope of Chapter: 
• To undertake formally a taste test trial to investigate the ability of individuals to 
distinguish between the study chocolates.  
• To undertake a proof of concept study to investigate the ability of high flavanol 
chocolate to reduce oxidative stress in the presence of transient hyperglycaemia. 
Table 5.0, defines the study question and PICOS approach to achieving the above aims 
of this chapter. 
Table 5.0: Study question and PICOS for the proof for study two. 
Study 
Question(s) 
Can chocolate rich in polyphenols administered one hour before a 75g oral 
glucose challenge ameliorate the postprandial increase in endothelial 
dysfunction and oxidative stress type 2 diabetes mellitus? 
Participants Ten individuals with type 2 diabetes mellitus controlled by lifestyle alone, or in 
combination with metformin.  
Interventions 13.5g of chocolate rich in polyphenols (3.5% polyphenols) 
Comparisons 13.5g of chocolate low in polyphenols (0.9 polyphenols) 
Outcomes Primary outcomes: 
1. Change in endothelial function 
2. Change in oxidative stress 
Secondary outcomes: 
1. Sensory evaluation of chocolates 
2. Glycaemic effects of chocolates 
Study design A double blind randomised controlled trial, following a seven day run in period, a 
familiarisation visit was undertaken prior to participants being randomly 
allocated the chocolates over the subsequent visits each seven days apart. 
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The clinical study will be presented in five parts: 
  5.1 - Introduction. 
5.2 - Taste trial. 
5.3 - Study specific methodology. 
5.4 – Endothelial Function and Glycaemia effects of chocolate 
  prior to a 75g oral glucose load, including analysis of the   
 familiarisation/ water control arm. 
5.5 – Biochemical effects of high polyphenol chocolate compared  to 
 low polyphenol chocolate prior to a 75 g oral glucose load. 
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5.1	  	  -­‐	  Introduction	  
 
Type 2 diabetes mellitus is associated with increased cardiovascular morbidity and 
mortality via accelerated atherogenesis. However this excess cardiovascular risk cannot 
be fully accounted for by traditional risk factors (Barr et al., 2007), and it is proposed 
that this is at least partially associated with hyperglycaemia (Raz et al., 2009). 
Hyperglycaemia itself is likely to increase risk via a number of mechanisms that may 
encompass a combination of acute and chronic inflammation. An inflammation centred 
model suggests this risk may be driven by increased endothelial dysfunction and 
oxidative stress (de Jager et al., 2006).  
The increase in endothelial dysfunction and oxidative stress by hyperglycaemia has 
been revealed by changes in functional endothelial assessment, biomarkers and 
metabolites of nitric oxide, in healthy individuals and populations at increased risk of 
cardiovascular disease and/or diabetes (Ceriello et al., 2008).   
Beneficial effects of cocoa polyphenols, especially the monomeric flavon-3-ols 
(predominantly epicatechins), which constitute 34-37% of total flavanol content in 
chocolate (Langer et al., 2011; Wollgast, Pallaroni, Agazzi and Anklam, 2001) have 
been demonstrated in the fasting state (Grassi et al., 2005b; Faridi et al., 2008) and 2 
hours following ingestion of cocoa polyphenols (Balzer et al., 2008). These effects have 
been seen in healthy individuals and those with T2DM. The initial mechanism was 
thought to be due to an antioxidant effect of these compounds; however, this has 
recently been disputed (Lotito and Frei, 2006; Hollman et al., 2011).  Currently the 
favoured hypothesised mechanism is via enhancement of the bioavailable pool of nitric 
oxide through the up-regulation of nitric oxide synthase. This view is supported by a 
study of smokers with endothelial dysfunction, which reported an increase in the level 
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of nitric oxide metabolites and improved endothelial function following 
supplementation with cocoa (Heiss et al., 2005). 
 A recent meta-analysis suggested an acute improvement in endothelial function of 
3.9% (CI 2.04-4.33%) (Hooper et al., 2012). However, it is not known whether 
chocolate or cocoa can negate the inflammatory effects of an oral glucose load.  
It was therefore hypothesised that that ingestion of polyphenol rich chocolate, prior to 
an oral glucose load, would ameliorate any adverse effects of acute transient 
hyperglycaemia on endothelial function and oxidative stress. 
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5.2	  	  -­‐	  Taste	  Differential	  Panel	  for	  Chocolate	  
5.2.1	  -­‐	  Background	  
High polyphenol content chocolate has been shown to reduce cardiovascular risk (Grassi et 
al., 2005a; 2008; Hooper et al., 2012; Taubert et al., 2003; Taubert et al., 2007). But 
however, could pose a potential problem in that eating a large quantity of chocolate might 
lead to an increased energy intake and potential weight gain, although this is disputed 
(Golomb, Koperski & White, 2012; O’Neil, Fulgoni & Nicklas, 2011a; 2011b). Palatability 
may be an issue; chocolate is widely acknowledged as being a desirable food however the 
high flavanol chocolates can tend to be more astringent and bitter tasting. It has been 
reported that in one study participants preferred to take tablets rather than dark chocolate 
habitually (Ried, Frank & Stocks, 2009). Acticoa™ (Barry Callebaut BV, Lebbeke-Wieze, 
Belgium) is a specially formulated chocolate containing twice the polyphenol content of 
regular plain chocolate (Bernaert, 2007), thus the same polyphenol/flavanol content is 
achieved in a smaller volume with potentially the same health benefits. However for this 
option to be successful, the chocolate must be acceptable to the consumer.  
It is important to the conduct of a truly double blind crossover design that the control or 
placebo chocolate which contains none or relatively low levels of the bitter polyphenols, is 
palatable and more importantly taste the same as the very high polyphenol (flavanol) 
chocolate. It is also important to match the bars with respect to the energy, sugar and fat 
content of chocolate. A simple pragmatic approach to these issues is a Sensory Evaluation 
II (O’Mahony & Rousseau, 2003) type of panel which aims to assess Participants’ ability to 
distinguish between food samples. Such tests can be undertaken as triangular or same-
different tests. Since the participants in the subsequent study reported in section 5.4, were 
likely to be naïve consumers of the type of chocolate being offered in the study, it is logical 
to adopt the methodology of Rousseau & O’Mahony, (2001) and use a same-different 
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design. This approach was also selected for its cognitive simplicity for the participants and 
its tendency to give to improved differential (t-D) values and greater statistical power. 
5.2.1.1	  -­‐	  Aim	  of	  taste	  trial	  
Demonstrate a lack of taste difference between the Acticoa™ and the Acticoa™ 
placebo. The panel also assessed the palatability and difference (or lack of taste 
difference) between the ultra high polyphenol content chocolate and the Acticoa™. 
5.2.1.2	  -­‐	  Objectives	  
To discover whether it is possible to distinguish the Acticoa™ chocolate from the 
placebo Acticoa™ chocolate. 
To discover whether there is equal subject tolerability of participants to the Acticoa™, 
the placebo Acticoa™ and the ultra high polyphenol content chocolate. 
5.2.2	  	  -­‐	  Participants	  and	  Methods	  
A double blind taste-testing panel methodology was adopted. Each testing panel lasted 
for 20-30 minutes. Participants were offered each of the 3 samples, Acticoa™, 
Acticoa™ placebo or the ultra high polyphenol content chocolate, in one of 3 sequences 
(table 5.2.2.1), which were assigned randomly prior to initiating each session.  
Table 5.2.2.1: Sampling sequence for the taste trial  
Test 1    Test 2    Test 3 
1 A + B   1 C + C   1 C + A 
2 A + A   2 B + B   2 B + A 
3 C + C   3 C + A   3 A + A 
4 C + A   4 B + A   4 C + C 
5 C + B   5 A + A   5 B + B 
6 B + B   6 B + C   6 C + B 
Key - A = 2g ultra high polyphenol content chocolate 
B = 2g Acticoa™ placebo 
C = 2g  Acticoa ™ 
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Participants were asked to abstain from food and all drinks, except for water for one 
hour prior to the test, and were asked to swill their mouths with water 3 times prior to 
the start. In between test pairs, participants were asked to swill their mouths out twice. 
When sampling pairs, no swilling of mouths with water was allowed. 
5.2.2.1	  -­‐	  Sample	  size	  
Based on the data of Rousseau & O’Mahony, (2001), 25 volunteers were recruited from 
the staff of Hull and East Yorkshire Hospitals NHS Hospitals Trust. The study was not 
deemed to require ethical or other governance permissions, following discussion with 
chair of the local research ethics committee and the hospital trust research and 
development department. Data were analysed using Chi2 to assess the subject opinion of 
the chocolate presented. 
5.2.4	  –	  Taste	  Trial	  Results	  	  
Twenty-five volunteers were recruited; one subject did not manage to consume the ultra 
high polyphenol chocolate due to its palatability. Generally the Acticoa™ was the 
preferred chocolate. 
Table 5.2.4.1: Same: difference data and analysis for the tasted chocolate pairs 
Chocolate Pair  Number Significance 
Acticoa™ Placebo Vs. 
Acticoa™ Placebo 
Same 14 
p=0.541 
Different 11 
Acticoa™ Placebo Vs. 
Acticoa™ 
Same 7 
p=0.043 
Different 18 
Acticoa™ Placebo Vs. Ultra 
high polyphenol 
Same 9 
p=0.230 
Different 16 
Acticoa™ Vs. Acticoa™ 
Same 18 
p= 0.043 
Different 7 
Acticoa™ Vs. Ultra high 
polyphenol 
Same 12 
p=1.000 
Different 13 
Ultra high polyphenol Vs. Ultra 
high polyphenol 
Same 21 
P= 0.001 
Different 3 
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This population of untrained taste testers were better able to distinguish the Acticoa™ 
from the Acticoa™ placebo (p=0.043) than the Acticoa™ placebo from the ultra high 
polyphenol chocolate (p=0.230) (Table 5.2.4.1). 
Subjective comments regarding the chocolate were collated; they mainly related to the 
difference in colour between the chocolates. The ultra high polyphenol chocolate was 
noted as being slightly harder and darker in colour than the other chocolates, with 
comments regarding its bitter aftertaste also being reported. A small number of 
participants found that this chocolate was of limited palatability, with one subject not 
able to complete the study after first tasting this particular chocolate. All chocolates 
were recognised as dark chocolate, but, apart from the Acticoa™, were reported as 
having a more bitter taste compared to chocolate normally consumed by the study 
population. 
5.2.5	  –	  Taste	  Trial	  Discussion	  and	  Conclusion	  
The data suggested that the three chocolates tested by the panels were well matched. 
There were similar perceptions of difference and similarity when the chocolates were 
the same as when they were different. This might be a reflection of the taste panel being 
untrained, or alternatively could demonstrate the care put into ensuring the flavour, 
texture and appearance of the three chocolates. 
The participants appeared to be very capable of distinguishing the Acticoa™ from the 
Acticoa™ placebo. This ability was not always associated with differences in perceived 
taste, but more to the differences in texture. The placebo was not readily distinguished 
from the ultra high polyphenol chocolate, even though the taste difference in theory was 
greater for this combination. This might have reflected a sequencing effect of previously 
being exposed to the bitter chocolate, or that these two chocolates shared a common 
texture and mouth feel.  
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The presentation of the chocolate was also of note was that, it appeared to vary in  tablet 
size or square size, which were the same for the placebo and high polyphenol 
chocolates, but different to the Acticoa™. It was felt from the comments made by the 
participants that alongside the difference in presentation, the texture of the placebo was 
‘foamy’ and the Acticoa™ smoother than the participants were expecting in terms of 
mouth feel for a dark or plain chocolate. 
The data from this preliminary taste trial suggested that these chocolates would be 
suitable for use in a double blind study. The study would need to be carefully designed 
to avoid bias, since the bitter nature may be perceived either as a sign of benefit or 
masking another ingredient of the chocolate. However, if chocolates were consumed a 
week apart, this was not likely to be a concern, and therefore appropriate for the design 
of this crossover study. 
The Acticoa™ was well tolerated and found to be acceptable to the participants. The 
placebo (polyphenol free chocolate) was also generally acceptable to participants, 
however, a few were not happy with the foamy mouth feel of the chocolate. The ultra 
high polyphenol chocolate was acceptable to the majority of participants, especially 
those who were male. From the taste trial, the bitter nature of the ultra-high polyphenol 
chocolate could potentially have led to a 10-20% drop out rate.  
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5.3	  -­‐	  Interventional	  Study	  
5.3.1	  -­‐	  Study	  Specific	  Methods	  
Eleven individuals expressed interest in the study; one was excluded after being found 
to be anaemic, with ten meeting the recruitment criteria  (Figure 5.3.1.1). All the 
participants were Caucasian with stable T2DM, treated with metformin or lifestyle 
alone. The age range was 40-75.  Nine were male and one was a post-menopausal 
woman.  All participants gave written informed consent and the study had full ethical 
and regulatory approval from the Hull and East Riding NHS Research Ethics 
Committee and the Hull and East Yorkshire Hospitals NHS Trust Research and 
Development department.  
Following screening, participants underwent a two-week ‘wash-out’ period during 
which they abstained from rich sources of polyphenol, using the list of foods described 
in Appendix II, and refrained from consuming all types of chocolate and cocoa.  
Following screening, studies attended for the first visit, which was a familiarisation visit 
consisting of water only before the 75g Oral Glucose Tolerance Test (OGTT) solution. 
Following a 12-hour fast, participants arrived for their first visit. They were asked to 
rest for 20 minutes in a temperature controlled (22oC) low-lit room in a supine position. 
Reactive Hyperaemia Peripheral Artery Tonometry (RH-PAT) (EndoPAT 2000, Itamar 
Medical, Caesarea, Israel) was undertaken to assess endothelial function, prior to blood 
being withdrawn via a cannula inserted into the median-cubital vein, for glucose, insulin 
and endothelial serum adhesion molecules (iCAM, e-selectin, p-selectin and p-selectin 
glycoprotein ligand 1(PSGL-1)).  
After baseline tests, participants were given 200ml of water. Sixty minutes after the 
ingestion of the water, further endothelial function blood tests were made prior to a 75g 
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OGTT solution being given. Participants then rested for a further 120 minutes after 
which time the assessment methods were repeated.  
 
Figure 5.3.1.1: Consort flow diagram to show enrolment and randomisation. This double-blinded, 
randomised control trial was designed to investigate the effects of high polyphenol chocolate on 
endothelial function and oxidative stress in T2DM during transient hyperglycaemia. 	  
At the second and third visits an identical protocol was followed, except that in addition 
to the 200ml of water, participants were given 13.5g chocolate. This was randomly 
assigned either to 13.5g of high polyphenol chocolate (containing 3.5% polyphenols 
(Folin-Ciocalteau (GA)) (Acticoa™, Barry Callebaut BV,  Lebbeke-Wieze, Belgium) or 
to 13.5g of low polyphenol chocolate (control) (identical in formulation to the high 
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polyphenol chocolate except, 0.9% polyphenols, Barry Callebaut BV, Lebbeke-Wieze, 
Belgium). The dose of polyphenol selected approximated that used in previous work 
(Grassi et al., 2005b; Faridi et al., 2008). Barry Callebaut BV provided both chocolates 
in identical presentations, and also held the randomisation code.  The study chocolate 
and the blood analysis was funded by Barry Callebaut BV via an unrestricted grant, but 
the study design and analysis were undertaken independently by the research team. 
Oxidative stress was measured using 24-hour urine collections; a baseline 24-hour urine 
collection which was undertaken prior to the test period and a second 24 hour urine 
collection was timed to start with from the ingestion of the chocolate. All participants 
were provided with a standard lunch following the completion of their chocolate and 
glucose tolerance tests.  
Alongside the urine collection, participants were asked to keep a food, fluid and 
exercise diary. A small nested cohort undertook CGMS and was asked to make at least 
1 self-measured glucose reading per 24 hours. With the participants’ additional consent, 
an Ambulatory Blood Pressure Monitor (ABPM) was fitted. However this had 
unfortunately to be abandoned, since other participants were either bruised following 
the occlusion with the blood pressure cuff during the EndoPAT assessment or had mid-
upper arm circumferences too large for the cuff. Participants then returned the next 
working day to deliver the urine samples, food diaries and CGMS. 
To assess dietary adherence and reduce potential confounding resulting from a change 
in background diet, food intake was recorded using 24-hour dietary recall undertaken by 
the study dietitian. Nutritional intake was then assessed using Microdiet (Downlee 
Systems Ltd., High Peak, UK). 
Endothelial function was assessed using an EndoPAT 2000. Adhesion molecules 
(ICAM, E-selectin, P-selectin and PSGL-1) were measured using serum ELISA assays 
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(Bender MedSystems, Vienna, Austria). Oxidative stress was assessed by the 
measurement of 15-F2t-Isoprostane from the 24-hour urine collections, which were 
frozen in aliquots at -80oC prior to analysis by ELISA (Oxford Biochemical Research, 
Mitchigan, USA); this was adjusted to urine creatinine concentrations. 
A power calculation was undertaken based upon the data of Balzer et al. (2008) using 
G*Power (Faul et al., 2007), which indicated a minimum sample size of seven (based 
on a difference of 1.8, power=0.80 for α <0.05). However, a sample size of ten was 
selected to allow for attrition. Data were tested for normality (Shapiro-Wilks), and 
paired data were then tested between conditions by t-tests or Wilcoxon’s signed ranks. 
All analysis was undertaken using PASW Statistics 18.0 (IBM, New York, NY, USA).  
The initial data were analysed comparing the three arms of the trial using analysis of 
variance (ANOVA) and where significance was found, post-hoc testing with a 
Bonferroni correction, which is presented in 5.4.3 and 5.4.5. However following initial 
peer review of draft manuscripts by an academic journal, editorial opinion was that as 
the study was a pilot, the small sample might lead to potential type 1 error (reporting a 
falsely positive finding); for that reason the results presented in section 5.5 compare the 
two interventional chocolate groups alone (discarding the water only arm) using t-tests 
or Wilcoxon’s signed ranks depending on the nature of the distribution of the data. The 
trial was registered (ISRCTN35988358). 
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5.4	  -­‐	  Results	  
5.4.1	  -­‐	  Baseline	  Characteristics	  
Table 5.4.1.1: Baseline Characteristics of Participants 
Characteristic and units Mean Standard Deviation 
Age (years) 59.2 8.0 
Duration of Diabetes (years) 6.3 3.3 
Alcohol intake (units per week) 9.4 10 
Weight (kg) 100.0 17.7 
BMI (kgm-2) 32.5 6.0 
Diabetes Medication (Metformin Only: 
None) 7:3 
Lipid Lowering Medication (Yes : None) 6:4 
Blood Pressure Medication (Yes : None) 7:3 
HbA1c % 6.5 0.7 
Total Cholesterol (mmol/l) 3.9 1.4 
Triglycerides (mmol/l) 1.7 0.7 
LDL Cholesterol (mmol/l) 2.2 1.2 
HDL Cholesterol (mmol/l) 1.0 0.2 
Estimated Glomerular Filtration Rate  
(ml per min) 82 10.8 
Haemoglobin (mmol/l) 14.6 0.9 
Hs-CRP (mmol/l) 1.3 0.7 
 
The study population consisted of nine males and one postmenopausal female. They 
were either diet controlled (three of the ten participants) or on a stable dose of 
metformin (seven of the ten participants) for more than three months. Of the ten 
subjects six were taking antihypertensive medication, seven were taking HMG-co-ase 
inhibitors (‘statins’) for dyslipidaemias and two were on aspirin as prophylactic anti-
platelet therapy. All were none smokers and were moderate self-reported consumers of 
alcohol (less than current UK recommended upper limits for intake). Although 
participants varied in terms of their medication, the risk of this being a source of 
confounding was minimised by the study having a crossover design. 
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5.4.2	  -­‐	  Dietary	  Intake	  Data	  
Dietary recall data were normally distributed (assessed by Shapiro-Wilks test). Table 
5.4.2.1 shows that there were no significant differences in the amount of food or the 
nutrient intake across the three visits of the study. Adverse events were recorded 
throughout the study and only one minor event was reported; a participant with 
weakness and light-headiness following the water-only test day.  
Table 5.4.2.1: Descriptive statistics and ANOVA of 24-hour dietary intake for the run in period, 
7 days prior to the chocolate phases of the studies.  Data were tested for normality using 
Shapiro-Wilks; all data was normally distributed. 
Nutrient Study Arm N Mean Std. Deviation ANOVA 
Total Weight 
of food 
consumed 
Water (run in) 10 2074.7g 734.8 
 
0.583 
High Polyphenol chocolate 10 2165.7g 709.6 
Low Polyphenol Chocolate 10 1827.5g 792.1 
Water 
Water (run in) 10 1648.2ml 710.6 
 
0.636 
High Polyphenol chocolate 10 1730.5ml 673.7 
Low Polyphenol Chocolate 10 1439.2ml 714.5 
Energy 
(Calories) 
Water (run in) 10 1736.2kcal 331.5 
 
0.588 
High Polyphenol chocolate 10 1865.6kcal 407.9 
Low Polyphenol Chocolate 10 1675.8kcal 494.3 
Energy (Kj) 
Water (run in) 10 7309.9Kj 1379.2 
 
0.590 
High Polyphenol chocolate 10 7847.9kj 1713.8 
Low Polyphenol Chocolate 10 7054.6kj 2077.4 
Protein 
Water (run in) 10 70.8g 12.3 
 
0.480 
High Polyphenol chocolate 10 81.8g 18.4 
Low Polyphenol Chocolate 10 75.7g 26.9 
Total 
Carbohydrate 
Water (run in) 10 228.2g 39.7 
 
0.754 
High Polyphenol chocolate 10 227.4g 59.9 
Low Polyphenol Chocolate 10 210.7g 71.8 
Sugars 
Water (run in) 10 74.8g 21.5 
 
0.215 
High Polyphenol chocolate 10 57.0g 21.3 
Low Polyphenol Chocolate 10 56.2g 33.7 
Fat 
Water (run in) 10 61.6g 24.7 
 
0.394 
High Polyphenol chocolate 10 73.4g 21.0 
Low Polyphenol Chocolate 10 59.0g 28.0 
Saturated 
Fatty Acid 
Water (run in) 10 19.7g 11.3 
 
0.134 
High Polyphenol chocolate 10 25.5g 9.3 
Low Polyphenol Chocolate 10 16.8g 7.4 
Fibre 
Water (run in) 10 15.7g 4.4 
 
0.718 
High Polyphenol chocolate 10 14.3g 4.6 
Low Polyphenol Chocolate 10 13.7g 7.3 
Sodium 
Water (run in) 10 3114.7mg 1308.2 
 
0.232 High Polyphenol chocolate 10 3832.7mg 1230.3 
Low Polyphenol Chocolate 10 28386mg 1377.2 
Iron 
Water (run in) 10 10.8mg 5.6 
 
0.417 
High Polyphenol chocolate 10 12.1mg 6.1 
Low Polyphenol Chocolate 10 9.1mg 2.8 
Vitamin C 
Water (run in) 10 74.6mg 34.9 
 
0.200 
High Polyphenol chocolate 10 48. 5mg 29.1 
Low Polyphenol Chocolate 10 62.mg 30.5 
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  polyphenol	  chocolate	  
p= 0.045 vs water 
p =0.040 vs Low  
Polyphenol  
Chocolate 
p= 0.028 vs water 
p= 0.048 Vs Low  
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5.4.3	  -­‐	  Endothelial	  Function	  Data	  
Figure 5.4.3.1: Reactive hyperaemia (RH-PAT) change in participants with Type 2 Diabetes 
corrected to a zero baseline, to remove the non-significant variation at baseline mean change ± 
SEM 	  
Reactive hyperaemia (RH-PAT) improved significantly for high polyphenol chocolate 
compared to both water and low polyphenol chocolate at 60 minutes (p<0.05) and 
following the 75g glucose load (OGTT) (p<0.05) (Figure 3.4.3.1). Since the change in 
RH-PAT has arbitrary units, it is best practice to consider the percentage change rather 
than change in arbitrary units.  
The data demonstrated a 30% improvement from baseline for the high polyphenol 
chocolate which was sustained throughout the oral glucose tolerance test, whereas 
consuming the low polyphenol chocolate resulted in a 15% reduction in endothelial 
function as measured by RH-PAT.  
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5.4.4	  -­‐	  Results	  of	  OGTT	  and	  Area	  Under	  the	  Curve	  (AUC)	  Glucose	  	  
There were no significant individual differences for fasting glucoses or glucose levels 
between subjects or for the groups at the end of the oral glucose tolerance test. Sixty 
minutes after consuming the chocolate, glucose levels were significantly higher for the 
high polyphenol chocolate than for the water group (p=0.01), while the increase 
following low polyphenol chocolate was not significant (p=0.07). The high polyphenol 
chocolate increased glucose significantly more than was seen with the low polyphenol 
chocolate.  
 
Figure 5.4.4.1: Mean Area Under the Curve (AUC) for Oral Glucose Tolerance Test (OGTT), with and 
without previous feeding of Chocolate 60 minutes (mmol/l/min). Red bars: the results for the OGTT 
only (120 minutes); Blue bars:  for the duration of the test (180 minutes). Choc A – high polyphenol 
chocolate; Choc B – low polyphenol chocolate 
 
No significant differences were seen between the chocolate groups or between the water 
and chocolate groups. The increase in total AUC may be linked to the difference in rise 
in the plasma glucose levels between 0 and 60 minutes. 
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5.5	  –	  Biochemical	  Assessments	  
 
The following data are for the two arms, which included the chocolate with 200ml 
water, prior to the 75g glucose OGTT. The data from the familiarisation test were 
discarded as this required analysis of variance to assess difference between groups, 
which had a greater potential for error due to the small sample size.   
5.5.1	  Fasting	  Data	  and	  120	  minutes	  after	  the	  75g	  Oral	  Glucose	  Load	  	  
No significant differences were seen in baseline fasting measures of glucose, insulin, 
endothelial function or oxidative stress at each visit (Table 5.5.1.1).  There were also no 
differences in area under curve between the two groups for plasma glucose for the 
duration of the 75g oral glucose load (p=0.77). Following the glucose load, a significant 
difference was seen in the 15-F2t-Isoprostane between high polyphenol chocolate  
(110.4±3.0 mg/mol (mean±SEM)) and control (207.1±5.7mg/mol) (p=0.03). 
The oral glucose load significantly increased glucose and insulin concentrations (Table 
5.5.1.1) in both groups, but as indicated previously there were no significant differences 
between them. However, when preceded by high polyphenol chocolate, an improvement 
in endothelial function (RH-PAT) was seen (p=0.01), whilst baseline measurements 
differed by 0.3%, which was not significant (p=0.09). A preload of the control, resulted 
in a significant deterioration in oxidative stress (p=0.02) and iCAM (p=0.04). 
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Table 5.5.1.1: The baseline and 120 minutes following the 75g oral glucose load.  
 
 
 
High Polyphenol Chocolate 
(mean±SEM) 
Low Polyphenol Chocolate  
(mean±SEM) 
Fasting 
120 minutes 
after 75g oral 
glucose load 
(180 minutes 
after 
consuming 
chocolate) 
P value Fasting 
120 minutes 
after 75g oral 
glucose load 
(180 minutes 
after 
consuming 
chocolate) 
P value 
Glucose mmol/l 6.6 ± 0.1 11.8±0.3 <0.01 
 
11.6 ± 0.3 <0.01 6.5 ± 0.1 
 
Insulin  µIU/l 16.6 ± 1.2 103.2±8.5 0.02 15.1 ± 0.8 101.6 ± 8.2 0.02 
RH-PAT % 1.7 ± 0.1 2.3±0.1 0.01 2.0 ± 0.1 2.1 ±0.1 0.44 
iCAM ng/ml 325.6 ± 9.0 310.0±8.4 0.20 
321.1 ± 
7.6 373.6 ± 10.5 0.04 
e-Selectin 
ng/ml 
111.3 ± 
5.8 96.6±5.6 0.09 94.4 ± 4.0 105.8 ± 3.5 0.28 
p-Selectin 
ng/ml 
253.0 ± 
14.8 235.0 ± 7.7 0.62 265 ±15.2 268.5 ± 12.4 0.92 
PSGL-1 U/ml 281.9 ± 12.2 212.6 ±8 .7 0.13 
262.9 ± 
5.5 327.5 ± 7.3 0.09 
Urinary 15-F2t-
isoprostane: 
creatinine 
mg/mol 
117.7 ± 
4.0 116.8 ± 5.7 0.48 
110.4 ± 
3.0 207.1 ± 5.7 0.02 
All data were tested for normality using Shapiro-Wilks. Data found to be normally distributed were 
analysed using paired t-test and that which violated normality were analysed using Wilcoxon’s 
signed ranks. All P values are the difference from baseline to 120 minutes following the 75g 
glucose load (taken 60 minutes after the consumption of either 13.5g of high polyphenol or low 
polyphenol chocolate) 
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The percentage changes from fasting (Figure 5.5.1) showed a significant improvement 
in endothelial function (RH-PAT) following high polyphenol chocolate compared to the 
control. In addition, three of the four adhesion molecules (iCAM, e-Selectin and PSGL-
1) reduced significantly following high polyphenol chocolate compared to baseline and 
control. Urinary 15-F2t-Isoprostane: creatinine ratio did not change with high 
polyphenol chocolate, whereas following low polyphenol chocolate this resulted in a 
significant increase in this oxidative stress biomarker (figure 5.5.1.2). Dietary analysis 
and assessment of physical activity levels showed no significance intra-subject 
differences between the two groups. 
 
Figure 5.5.1.2: Percentage changes from baseline to 120 minutes following ingestion of 75g oral 
glucose load (180 minutes after ingestion of 13.5g of chocolate). Improvement in RH-PAT indicates 
improved endothelial function, reduction in iCAM, e-Selectin, p-Selectin and PSGL-1 indicates 
improved endothelial function. Urinary 15-F2t-isoprostane compared 24 hours before the 
consumption of the 13.5g chocolate and 75g oral glucose load and the 24 hours comencing with 
the ingestion of the chocolate. A decrease in urinary 15-F2t-isoprostane suggests a reduction in 
oxidative stress. Non-significant change for p-selectin (p=0.86). All data was tested for normality 
(Shapiro-Wilks) * indicates a violation of normality. Data presented as mean±SEM. 
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5.6	  –	  Discussion	  
 
This is the first study showing an acute protective effect of high polyphenol chocolate 
on endothelial function with a concurrent reduction in an oxidative stress marker in 
patients with type 2 diabetes exposed to transient hyperglycaemia resulting from an oral 
glucose load. Previously Ceriello et al. (2008) demonstrated that periodic 
hyperglycaemia increases oxidative stress and endothelial dysfunction. The present data 
suggest that cocoa polyphenols in chocolate might mitigate some of the endothelial 
dysfunction and oxidative stress resulting from this hyperglycaemia.  
These results could be explained via an antioxidant effect of the polyphenols 
(predominantly epicatechins), as there was a reduction effect of the glucose load upon 
oxidative stress. However, it is also plausible that modulation through multiple 
metabolic pathways, including nitric oxide synthase and ACE could be likely candidates 
(Hollman et al., 2011). The results showing improvement of functional endothelial 
responsiveness are in accord with those showing that cocoa ingestion resulted in an 
acute response of endothelial function via flow mediated vasodilatation (Balzer et al., 
2008). However, this is the first study to show that the improvement in endothelial 
function was more pronounced following the induction of a hyperglycaemic state.  
It has been demonstrated that cocoa polyphenols (predominantly epicatechins) increase 
nitric oxide (NO) levels, which in turn result in endothelial relaxation and a reduction in 
endothelial markers such as iCAM and p-selectin (Vázquez-Agell et al., 2011). This 
would explain why the NO dependent adhesion molecule biomarkers iCAM and p-
selectin were significantly reduced within 180 minutes in this cohort. This observation 
is also in accord with animal data reporting that iCAM and e-selectin respond acutely, 
whereas p-selectin may take longer to induce (Liu et al., 1998). Therefore, the data 
suggest that high polyphenol chocolate has an acute beneficial and protective effect on 
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the endothelium in individuals with T2DM seen both functionally and through the 
expression of adhesion molecules in a dynamic hyperglycaemic state. 
Oxidative stress is a feature of type 2 diabetes, possibly as a result of hyperglycaemia 
increasing levels of reactive oxygen species (ROS) (Brownlee, 2001). ROS scavenges 
NO to produce peroxynitrite (ONOO-), reducing the NO pool and resulting in 
endothelial dysfunction (Hollman et al., 2011).  High polyphenol chocolate may reduce 
ROS levels, thus improving endothelial function, whilst also enhancing NO synthesis. 
Our observations are supported by observations in both healthy participants and those at 
increased cardiovascular risk where cocoa polyphenols increase the bioavailability of 
NO, reflected in improved endothelial function and reduced oxidative stress, suggestive 
of potential cardiovascular health benefits (Pieper, 1999).  
Oral feeding of a glucose load to individuals with T2DM has been shown to lead to an 
increase in oxidative stress and endothelial dysfunction (Ceriello et al., 2008), which 
was reflected in the findings for the low polyphenol chocolate group, where oxidative 
stress increased and the biomarkers for endothelial cell dysfunction increased. 
Conversely, protection was afforded by high polyphenol chocolate where oxidative 
stress and endothelial function markers decreased significantly. Although there were 
statistically significant differences in AUC for glucose for the high polyphenol 
chocolate, these had no adverse effects as oxidative stress or endothelial function were 
reduced following its consumption in this study. 
Whilst the study is limited by the nature of it being a pilot and its small sample size, the 
crossover design and careful controlling of variables, mitigate this, in part. The study is 
potentially further limited by the variability in the EndoPAT 2000 measurements of 
endothelial function varying at baseline, although this did not differ significantly. 
However, the consistency of the functional assessment of endothelial function was in 
agreement with the soluble biomarkers, and the reciprocal reduction in oxidative stress 
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was highly supportive of the hypothesis that high polyphenol chocolate has acute 
beneficial effects in T2DM that are maintained in a hyperglycaemic state.  
5.6.1	  -­‐	  Conclusion	  
High polyphenol (flavanols) chocolate has a beneficial acute effect in reducing 
endothelial dysfunction and oxidative stress in individuals with T2DM during acute 
transient hyperglycaemia. Further work is needed to investigate the potential benefits of 
cocoa polyphenols as modulators of post-prandial endothelial dysfunction and oxidative 
stress in T2DM, and the potential effects on reducing cardiovascular risk. 
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Chapter	  Six:	  	  Effects	  of	  Polyphenol	  Enriched	  Milk	  Chocolate	  in	  
Type	  2	  Diabetes:	  A	  Randomised	  Controlled	  Trial	  
Aim and scope of chapter: 
• To investigate the effects of milk chocolate rich in polyphenols upon markers of 
glycaemic control and cardiovascular risk in individuals with type 2 diabetes 
mellitus (T2DM). 
• Consider the effects of acute chocolate consumption alone upon insulin and 
glucose responses. 
To address these aims, the clinical study will be presented in four parts: 
  6.1 – Introduction and methodology. 
6.2 – Baseline features and characteristics and post study follow up. 
 6.3 – Effect of chronic consumption of milk chocolate. 
  6.4 – Effect of acute consumption of milk chocolate. 
Please note, due to contractual clauses with the sponsor of the work presented in this 
chapter, it is not possible to fully report all the clinical trial data. This particularly is 
with respect to the recipes and composition of the chocolates used beyond the data 
presented. 
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Table 6.0: Study question and PICOS for the proof for study three. 
Study 
Question(s) 
Can milk chocolate enriched with polyphenols improve measures of insulin 
resistance, cardiovascular risk and glycaemic control in type 2 diabetes 
mellitus? 
Is milk chocolate enriched with polyphenols more effective than a dark chocolate 
with the same epicatechin level? 
Participants 60 individuals with type 2 diabetes mellitus controlled by lifestyle alone, or in 
combination with metformin. These will be randomised to receive either a low 
polyphenol chocolate, a milk chocolate enriched with polyphenols or a dark 
chocolate rich in polyphenols  
Interventions 20g Milk chocolate rich in polyphenols (fortified to 19.2mg epicatechin per bar) 
by the addition of CocoanOX 12%. 
Comparisons 20g Dark chocolate (19mg epicatechin) as hypothesised active control 
20g Low polyphenol chocolate (2.7mg epicatechin) as hypothesised inactive 
control 
Outcomes Primary outcomes: 
1. Change in insulin resistance (HOMA) 
Secondary outcomes: 
1. Endothelial function (acute and over 12 weeks) 
2. Glycaemia (HbA1c) following 12 weeks of chocolate and glucose, both 
fasting and following consumption of 40g of chocolate 
3. Lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol and 
triglycerides) 
4. Blood pressure 
5. Weight, waist and hip circumference 
6. Inflammatory markers – hs-CRP, TNF-alpha, IL1Ra and IL6 
7. Oxidative stress, serum malondialdehyde and urinary 15f-2t isoprostane 
8. Participant reported outcome measures including attachment style, 
mood, fatigue and sleep. 
Study design A double blind randomised controlled trial following a parallel design. Following 
a 28 day chocolate and cocoa free run in period, participants will be attend for 
initial testing of biochemical and endothelial function following acute 
consumption of one of three randomly assigned chocolates. The effect of 40g of 
chocolate (2 bars of chocolate) over a three-hour period will be assessed. 
Participants will then be provided with 20g chocolate per day for 12 weeks before 
returning for a second assessment of biochemical and endothelial function. 
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6.1	  -­‐	  Introduction	  and	  Methodology	  
Short term studies of chocolate in healthy volunteer studies (Grassi et al., 2005a; 2005b) 
and in participants with insulin resistance (Grassi et al., 2008) have shown chocolate is  
effective in lowering blood pressure, improving lipid profiles and reducing insulin 
resistance. However, there are only two trials that have reported the effect of regular 
chocolate consumption in diabetes (Mellor et al., 2010b, Mellor et al., 2012), as 
described in Chapters 3 and 4 of this thesis. Others have investigated the effects of 
cocoa (Balzer et al., 2008) and chocolate with and without added isoflavones (Curtis et 
al., 2012). Very few studies have considered the potential effects of milk chocolate on 
cardiovascular risk reduction. 
Although initially promising, there are a number of potential considerations before 
chocolate might be accepted as a suitable and advantageous food for regular 
consumption in individuals with T2DM. The high energy content of chocolate may 
result in weight gain and the high sugar content of may affect glycaemia. Finally, 
chocolate is a rich source of saturated fatty acids, and the general consensus is a high 
intake of this type of fat is undesirable, having been associated with increased risk of 
cardiovascular disease (EFSA, 2010b). This may not be a true concern, as the 
predominant fatty acid in chocolate is stearate, which is considered to be benign with 
respect to cholesterol. Additionally, the emerging consensus is that saturated fat may 
not be as significant contributor to cardiovascular risk as has been historically thought 
(Astrup et al., 2011).  
The epidemiological data does not suggest that weight gain is associated with chocolate 
consumption (Golomb, Koperski and White, 2012) in children and adolescents (O’Neil, 
Fulgoni and Nicklas, 2011b) or in adults (O’Neil, Fulgoni and Nicklas, 2011a). The last 
two named studies used data from the NHANES data set to show that although ‘candy’ 
or confectionary consumers (including chocolate), consumed more energy, they had a 
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significantly lower mean body mass index. The doubt about sugar also does not appear 
to be significant since chocolate has a low glycaemic index, and a low glycaemic load 
(Brand-Miller et al., 2009). 
Initial studies focused on dark chocolate compared to white chocolate (that is cocoa 
butter and flavanol-free as the control) in large daily doses of up to 100g per day (Grassi 
(Grassi et al., 2005a; 2005b; Taubert et al., 2003). This quantity would provide up to 
20% of the recommended daily energy requirements for many participants (SACN, 
2011). One hundred grams of chocolate size was selected in these studies, as it provided 
an estimated dose of 500mg of flavon-3-ols. This is the quantity which was seen to be 
effective in the initial studies, and is approximately half the intake seen in the Kuna 
Indian populations of Panama, a population where cardiovascular disease and 
hypertension are extremely rare (Hollenberg, 2006). Reducing the quantity of chocolate 
but maintaining the flavanol content may prove challenging due to the bitter nature of 
these compounds, which could therefore make a chocolate less palatable and therefore 
unacceptable to the consumer. Evidence for this perspective was reported by Ried, 
Frank and Stocks (2009), who found the chocolate was less acceptable than the 
comparator tomato extract supplement over an eight-week period. 
In the UK, market research found that 66% of adults have a preference for milk 
chocolate (Valued Opinions, 2011),  with only 22% preferring dark chocolate; the 
predominant chocolate formulation demonstrating evidence of health benefits in the 
published literature. There are very few studies reporting the effects of milk chocolate 
perhaps because of concerns about milk inhibiting the bioavailability and action of 
flavanols. Initial research by Serafini, Ghiselli and Ferro-Luzzi (1996), suggested 
consuming milk with tea totally inhibited the activity of these flavonoids in vivo. 
Serafini followed this work up later (Serafini et al., 2003) to suggest that milk ingested 
alongside or when included as part of the manufacture process inhibited the antioxidant 
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activity of the epicatechins. However this position has largely been refuted by other 
research groups (Hollman, Van Het Hof, Tijburg & Katan, 2001; van het Hof, Kivits, 
Weststrate and Tijburg, 1998; Schroeter et al., 2003; Roura et al., 2007).  
To date, there are only very limited data on the effects of high flavanol milk chocolate. 
They include a short-term (14 day) study of young healthy footballers, which 
demonstrated a significant reduction in both blood pressure and lipid parameters (Fraga 
et al., 2005). However, this study did not report parameters of glycaemia or insulin 
sensitivity. Two further studies used active cocoa flavon-3-ol compounds including 
milk. Innes et al. (2003) provided single doses of milk chocolate. No improvement in 
platelet function was seen with the milk chocolate, when compared to dark chocolate. 
The only other study, which combined cocoa with milk in a drink, was by Balzer et al. 
(2008). This study of participants with T2DM demonstrated improvements in 
endothelial function, both following acute consumption and with daily cocoa 
supplementation for 30 days. Although changes in lipids and glycaemic control appear 
to have occurred, this was not commented on. Moreover, the data were potentially 
confounded by the formulation that provided approximately 50% of the recommended 
daily sugar intake (approximately 5% of total energy from sugar) for individuals with 
diabetes (Dyson et al., 2011), which is the same as that recommended for the population 
as a whole. 
The challenge of delivering an adequate dose of flavanols to be effective, without an 
excess of energy, sugar or fat, whilst still offering a palatable product, is clear. Despite 
initial work implying a lack of efficacy from the polyphenols in milk chocolate, there 
remains the potential for benefit, with the additional benefit of enhanced palatability and 
acceptability of this type of chocolate. This study aimed to investigate whether a dose of 
20g milk chocolate rich in polyphenols was able to demonstrate a beneficial effect upon 
cardiovascular risk factors and measures of glycaemic control.  
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6.1.1	  -­‐	  Research	  Design	  and	  Methods	  
6.1.1.1	  -­‐	  Participants	  
The study consisted of sixty-one participants, 31 men and 30 postmenopausal women 
who were on stable medication for at least 3 months for cardiovascular risk (including 
for lipids and hypertension) (Figure 6.1.1.1). With respect to their T2DM, the 
participants were treated with either lifestyle (diet and exercise) or lifestyle in 
conjunction with metformin. The participants were aged 45-80 years and receiving 
standard UK care for their T2DM, which included structured patient education (either 
X-PERT, DESMOND or Living with Diabetes (a local structured diabetes programme) 
at least one month prior to enrolment onto the study. All participants were recruited 
through the local diabetes network that generated a database, from which participants 
were invited to participant in this study. 
The study was conducted in accordance with the Declaration of Helsinki, and was 
approved by the Hull and East Yorkshire NHS Research Ethics Committee. All 
participants were required to provide written informed consent prior to enrolling in the 
study. 
6.1.1.2	  	  -­‐	  Study	  protocol	  
All participants underwent a 28-day run in period when they avoided polyphenol/ 
flavonoid rich foods, following discussion with a Dietitian (details in Appendix II). 
Participants were randomised to either 20g per day (40g for the acute testing) of high 
polyphenol milk chocolate (19.11mg epicatechin per bar) (referred to within this 
chapter as Milk Chocolate), low polyphenol chocolate (Control) as a control for sugar 
and fat content (2.71mg epicatechin per bar) or Nestlé Noir, a high polyphenol dark 
chocolate (Dark Chocolate) (19.0mg epicatechin per bar). The epicatechin content of 
the milk chocolate was matched to that of the dark chocolate. Previous studies indicated 
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that 20 g Nestlé Noir, the bar size used in this intervention contained 312mg of total 
flavonoids (Folin-Ciocaltaeu method), (Davison et al., 2012). Such data were not 
available for the other chocolates used in this study, as they had been specially 
formulated for use in this clinical trial.  
Table 6.1.1.2 Overview of study protocol outlining the tests at each visit 
Study plan: Screening Visit 1 ‘Meal test’ 
Visit 2 
‘Check up’ 
Visit 3 
‘Check up’ 
Visit 4 
‘Meal test’ 
Days 0 28 58 86 114 
Medical and Social History / 
Subjects’ demographic data x     
Clinical examination, including 
blood pressure measurements x x x x x 
Questionnaires  x   x 
Dispensing of study 
chocolate  x x x  
Fasting blood samples for 
screening: 
 HbA1c 
 Lipids 
 Liver and renal function 
x     
Fasting blood samples for: 
  Insulin 
 Glucose 
 HbA1c 
 Lipid profile 
 Oxidative Stress 
 Inflammatory Markers 
 x   x 
24 urine collection  x   x 
Acute feeding of 40g chocolate  x   x 
Bloods at 60, 120, 180 minutes 
for: 
 Glucose,  
 Triglycerides  
 Insulin  
 x   x 
Endopat measurement of 
endothelial function  x   x 
Treatment of 20g chocolate per 
day ... 
Chocolate 
Started→  →  →  
Chocolate 
Ends 
  
Treatment was allocated in a double blind fashion, with participants being 
informed that they were testing the effects of one of three types of chocolate on 
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heart disease risk in T2DM. The sponsor prior to the enrolment of the first 
participant via a predefined code provided the allocation of the randomisation; 
this was stratified by gender in six blocks, the size the block was not disclosed to 
investigator prior to analysis of the data. Table 6.1.1.2 outlines the conduct of the 
study and procedures undertaken. 
Participants were recruited from the Hull and East Riding Diabetes Network 
database. All individuals who consented to receive information regarding research 
were sent an invitation (approximate 850 from a population with diabetes of 
24,000). Interested individuals then contacted the author of this thesis to discuss 
the study and their potential suitability. Those suitable were sent the full 
participant information sheet, and if still interested invited to attend a screening 
visit. Following attending a screening visit and their results being assessed 
(typically one week from this visit) participants were allocated a study code based 
on their initials, this was then communicated to the sponsor who allocated a study 
number and the code for the chocolate dispensed at the subsequent visit. 
The author of this thesis enrolled the participants, with the assigning to treatment 
undertaken by the sponsor. The author of this thesis (except for 5% of visits 
undertaken by a clinical trials assistant), administered the questionnaires, 
undertook the follow up meetings and blood sampling. Plasma, serum and urine 
samples were analysed by chemical pathology laboratories of Hull and East 
Yorkshire Hospital for routine clinical markers, and for inflammatory markers 
and oxidative stress these were undertaken within the biomedical laboratories at 
the University of Hull (by Drs Madden and Courts). 
The study was conducted between May 2009 and June 2010, participants were 
typically enrolled in the study for a total of 112 days (84 days of chocolate 
consumption) this only varied if personal reasons (business or holidays) or illness 
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prevented attendance on the planned days. Data was then scrutinised by the 
sponsor until October 2011, with the primary data analysis report released in 
March 2012 when the study was unblinded. 
The sponsor provided the chocolates, with all three being formulated and manufactured 
in line with EU regulations for chocolate (European Union, 2004). Products were issued 
in a single batch to the research site and were tested for safety prior to delivery, and at 
the mid-point of the study. The dose was based on previous data on the effect of Nestlé 
Noir, (Flammer et al., 2007), which used a protocol based on 40g of chocolate. This was 
the same dose selected for use in the ‘meal test’ studies at the start and end of the 
intervention phase. For the continuous chronic feeding, a lower dose of 20g per day was 
provided since the aim was to keep the carbohydrate and fat in the bar below 10g, in 
order to provide an energy content around 420Kj (100Kcal).	   	   The	   chocolate	   was	  wrapped	   in	   identical	  white	  wrappers	  with	   labelled	  with	   the	   study	   identification	  code,	  the	  different	  chocolates	  were	  labelled	  either	  as	  A,	  B	  or	  C.	  
A three-arm study was chosen, to assess the primary comparison of a milk chocolate 
high in polyphenols with a low polyphenol chocolate along with a secondary 
comparison of milk chocolate high in polyphenols with a dark chocolate with equivalent 
epicatechin content. This design was chosen, in part for pragmatic reasons, to allow for 
two comparisons without the cost and administration of two separate clinical trials. This 
design also allowed for the efficacy of milk chocolate as a source of polyphenols to be 
assessed, with an assessment of potential additional effect compared to dark chocolate 
which might be an effect of either the different nutritional composition of milk 
chocolate including calcium and milk fats (including conjugated linoleic acid) or the 
effect on polyphenol metabolism of milk chocolate (Roura et al., 2007; Mullen et al., 
2009, Keogh, McInerney & Clifton, 2007). 
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Adherence was determined through the counting of returned wrappers, on which the 
participants marked the time and date of consumption. The participants were advised to 
consume the chocolate in two 10g portions, one mid-morning and one mid-afternoon or 
during the evening. The chocolate was dispensed every four weeks over the 12-weeks 
of the intervention period.  
	  
Figure 6.1.1.2: Consort flow diagram indicating the conduct of the study. A CONSORT checklist is 
presented in Appendix III 	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Nutritional and dietary compliance with the study was monitored along with any 
variation in energy and macronutrients by a dietitian interviewing participants and 
taking a 24-hour recall of intake on a four weekly basis at clinic and dispensing visits.  
Following informed consent, all participants attended for fasting blood tests along with 
clinical and anthropometric testing. Height and weight were measured and used to 
calculate BMI; waist circumference was measured to assess central obesity and blood 
pressure measured in accordance with the protocol described in Section 2.3.  
Twenty-four hour urine collections were made to measure 15-F2t-isoprostane: 
creatinine ratio following the protocol described in Section 2.3.2.5.2 ratio to assess 
oxidative stress. Bloods were also drawn to measure Hba1c, fasting glucose, fasting 
lipids profile, insulin and inflammatory markers as described in section 2.3 Insulin 
sensitivity was calculated by HOMA as described in section 2.3.2.3.4. 
Four weeks later, participants returned after fasting, for a meal test. Following 15 
minutes acclimatisation, participants had fasting endothelial function measured using 
EndoPAT 2000 (Itamar, Caesarea, Israel), in accordance with the method described in 
section 2.3.2.4.1. Following the assessment, participants blood was drawn the median-
cubital vein for the identical assays employed at screening. This was followed by a 
clinical and anthropometry assessment. Participants were then given two bars of 
chocolate (2x20g bars, 40g in total), of the same chocolate to which the participant had 
been randomized for the 12-week period (taking 20g daily). Blood samples were drawn 
at 60, 120 and 180 minutes for insulin, glucose and triglycerides. Participants also 
undertook two 24-hour urine collections; one before their first dose of chocolate and 
one on their last day of chocolate consumption. 
At the end of the assessment visit, participants were issued with enough chocolate for 
the following 28 days. All participants were instructed to consume their chocolate as 
part of their normal dietary routines, as described in section 2.3.2.8. Participants 
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returned for dispensing visits after 28 and 56 days to check compliance and have the 
anthropometric measurements repeated along with the reporting of any adverse events 
or changes in medication. At the end of the 86 days all participants returned for a final 
meal test visit which followed the identical protocol to the first meal test. Participant 
compliance was confirmed from the return of used packaging. Weight was also 
measured in 32 participants who attended a four-week post study follow-up.  
6.1.2	  -­‐	  Study	  Questionnaires	  
At baseline all participants were screened using the Relationship Questionnaire 
(Bartholomew & Horowitz, 1991), this was used in order to assess if the population is 
typical with respect to attachment style to the general adult population and populations 
with diabetes. This has been hypothesised to affect engagement with service and 
response to a placebo. In addition, at screening and each visit (both clinical and 
dispensing visits), participants completed the Stanford Sleep Scale, (Hoddes, Dement & 
Zarcone, 1972) subjective assessment of mood  (Bond & Lader, 1974) and Samn-Perlli 
subjective fatigue score (Samn and Perelli, 1982). These were used to assess participant 
reported outcomes linked with fatigue and mood; the rationale for their inclusion was 
following the findings of Sathyapalan et al. (2010) which suggested a beneficial effect 
of high polyphenol chocolate on symptoms of chronic fatigue syndrome. 
6.1.3	  -­‐	  Study	  Set-­‐up	  
• Group 1 (active): 20g/d of milk chocolate product, which provided 20mg epicatechin/day 
(high polyphenol).  The milk chocolate contained approximately 1 mg/g epicatechin from 
the cocoa liquor, which was supplemented by the addition of the high-polyphenol cocoa 
ingredient, CocoanOX 12%® (Natraceutical S.A., Valencia, Spain) added to the chocolate 
base. 
• Group 2 (control): 20g/d of product 1 mg epicatechin/day (low polyphenol). The 
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control was a milk-type product, which was matched to the group 1 (active) milk 
chocolate in terms of milk, energy, sugar and fat content. 
• Group 3 (active): 20g/d of dark chocolate product giving 20mg epicatechin/day. 
This was a 70% cocoa commercially available dark chocolate containing cocoa 
liquor, sugar, cocoa butter, milk fat, lecithin and vanillin. It naturally contained ap-
proximately 1 mg/g epicatechin from the cocoa liquor. This was identical to Nestlé 
Noir 70%, which is freely available for sale in continental Europe. 
A summary of the chocolate compositions is given in table 6.1.3 A-C. 
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Tables 6.1.3: A, B and C Composition of chocolate provided to participants throughout the course 
of the study. Further information regarding the composition and recipe for the chocolate have 
been restricted by the sponsor of the study. 
A. Chocolate 1 Milk chocolate 
Milk Chocolate 
with added 
flavanols 
g Kcal/g Kcal/100g 
EC mg/ 
20g 
EC 
mg/100g 
 
Cocoa liquor 
(55% fat) 5.5 5.6 30.8 2.71 14.91 
Cocoa butter 24.7 9.0 222.3   
Sugar 45.0 4.0 180.0   
Skimmed milk 
powder 14.9 3.6 53.6   
Milk fat 5.2 9.0 46.8   
Lecithin 0.41 3.6 1.5   
Vanilla 0.05 4.5 0.23   
CocoanOX 
(12%fat) 4.2 2.6 10.8 16.4 82.00 
 Per bar 20g 
Total epicatechin 
(mg) 95.55   19.11  19.11 
Total Kcal 546.0     109.19 
Cocoa solids 34.4     6.88 
Cocoa solids non 
fat 6.2     1.23 
Milk solids 20.1     4.03 
Milk solids non-fat 14.9     2.99 
Total sugar 45.0     9.00 
Total fat 33.8     6.77 
B. Control Chocolate – iso-fat/ iso-sugar 
Control iso fat/ 
iso sugar g 
Kcal
/g Kcal/100g 
EC mg/20 
g 
EC 
mg/100g 
 
Cocoa liquor 
(55% fat) 2.1 5.6 11.7 2.71 5.69 
Cocoa butter 30.0 9.0 270.0   
Sugar 45.8 3.6 183.0   
Skimmed milk 
powder 15.3 9.0 54.9   
Milk fat 6.3 9.0 56.7   
Lecithin 0.50 3.6 1.8   
Vanilla 0.05 4.5 0.22   
CocoanOX (12% 
fat) None     
 Per bar 20g 
Total epicatechin 
(mg) 5.69   2.71  2.71 
Total Kcal 578.4     115.68 
Cocoa solids 32.1     6.42 
Cocoa solids non 
fat 0.9     0.19 
Milk solids 21.6     4.32 
Milk solids non-fat 15.3     3.06 
Total sugar 45.8     9.15 
Total fat 38.0     7.59 
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Table 6.1.3.1C:  Nestlé Noir Chocolate – Dark Chocolate 
Dark Chocolate g Kcal/g Kcal/100g 
EC mg/ 
20g 
EC 
mg/100g 
 
Cocoa liquor 
(55% fat) 63.1 5.6  19 95.00 
Cocoa butter 7.4 9.0    
Sugar 26.2 3.6    
Skimmed milk 
powder  9.0    
Milk fat 2.9 9.0    
Lecithin 0.4 3.6    
Vanilla 0.05 4.5    
CocoanOX (12% 
fat) None     
 Per bar 20g 
Total epicatechin 
(mg) 95.0     19.0 
Total Kcal 551.5     110.3 
Cocoa solids       
Cocoa solids non 
fat       
Milk solids       
Milk solids non-fat       
Total sugar       
Total fat 44.7     8.94 	  
6.1.3.1	  -­‐	  Inclusion	  criteria	  
All participants were required to comply with all the following inclusion criteria: 
• T2DM managed by diet alone or diet and metformin. If metformin was used the dose should 
have been stable for a minimum of three months prior to the start of the study, 
• HbA1c below 9.9% DCCT aligned (85mmol/mol), 
• Aged between 45 and 75 years at the start of the study 
• All female participants post-menopausal, based on self-reported last date of 
menstruation being more than 12 months prior to the start of the study 
• BMI between 25 and 39 kg/m2, 
• Had attended a structured group patient education program and on stable medication for 
hypertension, lipids and gout for 3 months prior to entry into the study. 
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6.1.3.2	  -­‐	  Exclusion	  criteria	  
Participants representing one or more of the following criteria were excluded from participation in 
the study. 
• Participants with concurrent illness or any changes in medication in the previous three 
months, 
• Participants whose T2DM was managed with thiazolidinediones, DPP-IV inhibitors, 
GLP-1 analogues, insulin or sulphonylureas or prandial regulators, 
• Participants not wishing to allow disclosure to their GPs, 
• Hba1c at recruiting stage of >10.0% DCCT aligned (86mmol/mol), 
• Participants who could not be expected to comply with treatment, 
• Participants who were enrolled or had participated in another clinical trial during three 
months prior to the beginning of this study, 
•  Participants who consumed more than 20g/d of chocolate or had a very high polyphenol 
content in their diet, and were not willing to change their diet, 
• Participants taking high dose antioxidant supplements including single and multivitamin 
preparations including/containing A, C and/ or E, 
• Female participants taking HRT treatment. 
6.1.4	  -­‐	  Statistical	  Methodologies	  
An external statistician, as specified in the research agreement, undertook the analyses 
on differences between the three groups. I undertook additional analyses including the 
analysis of the baseline data, and the nutritional intake and the post study follow up 
data.  
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6.1.4.1	  -­‐	  Analysis	  of	  baseline,	  nutrition	  and	  post	  study	  data	  
Data were tested for normality using Shapiro-Wilks, both for the whole sample and 
between groups. Data were presented as mean and standard deviations, before and after 
the intervention. Where data violated normality, equivalent non-parametric tests were 
selected. For the whole cohort and each of the three arms, paired t-tests were used to 
assess the effect of the intervention on the various parameters. To determine the 
difference between chocolates prior to and after feeding a repeated measures design 
ANOVA was used. Where significant differences were found, the absolute change in 
parameter was tested with a one-way ANOVA with post-hoc testing using a Bonferonni 
correction. 
6.1.4.2	  -­‐	  Sample-­‐size	  calculation	  
The calculation suggested that 48 volunteers (16 per group) were required for this study. However, 
a dropout rate of approximately 20% was anticipated. Thus it was decided to enrol a total of 
60 volunteers (20 per treatment group) onto the study. The above calculation was implemented 
using N-Query software 4.0 (Statistical Solutions, Saugus, MA, USA). The calculation was 
primarily based on the effect of chocolate supplementation in hypertensive participants on insulin 
resistance as assessed by HOMA (Grassi et al., 2008; Grassi et al., 2005b) This was based on an 
analysis of covariance (ANCOVA) at a significance level of 5% with a statistical power of 80% 
assuming an estimated standard deviation of 0.9. Such power would enable a difference of Δ= 1.0 
in mean HOMA which was considered clinically meaningful to be detected 
6.1.4.3	  -­‐	  Planned	  statistical	  analysis	  (intervention	  data)	  
6.1.4.3.1	  -­‐	  Primary	  analyses	  
The treatment effects were estimated using ANCOVA where milk chocolate (rich in polyphenols) 
and the low polyphenol control chocolate were to be compared adjusting for the effect of relevant 
covariates in the model such as HOMA value at baseline. Appropriate non-parametric methods 
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were to be applied if the data did not meet the statistical model’s normality assumptions despite 
relevant transformation methods. The primary analysis was to be performed as both intention-to-
treat (ITT) and per-protocol (PP) populations. 
6.1.4.3.2	  -­‐	  Secondary	  analyses	  
The cardiovascular parameters; primarily endothelial function and cholesterol profile were assessed 
during the study as secondary outcomes. The treatment effects were estimated for the milk 
chocolate and the control chocolate using ANCOVA as for the primary analysis. In addition, the 
treatment effects on HOMA and cardiovascular parameters were estimated between milk chocolate 
and dark chocolate using ANCOVA as above. All secondary analyses were performed on the ITT 
population only. 
6.1.4.3.3	  -­‐	  Changes	  from	  planned	  analysis	  and	  updated	  statistical	  analysis	  plan	  
The primary analysis was performed on the log-transformed HOMA using a robust ANCOVA 
model based on MM-estimators to take into account the outlying values in the data adjusting for 
age and prior to starting chocolate supplementation for HOMA. 
Secondary endpoints: All the analyses of the secondary outcomes were based on the ITT 
population. 
– HbA1c percentage: A similar ANCOVA model as the primary endpoint was used 
after log-transforming the data. 
– Other secondary outcomes: A similar ANCOVA model as the primary endpoint was 
used after a suitable Box-Cox transformation. In case a suitable transformation was not 
found, Wilcoxon two-sample rank-sum test was used to test for differences between the 
appropriate contrasts while these differences were quantified using the Hodges-
Lehmann estimate with its 95% confidence interval. For measurements done over 
time such as glucose, insulin, triglycerides and body weight, a linear mixed 
modelling approach was used. 
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All the statistical analyses were done in R 2.14.0; a piece of proprietary software 
belonging to the sponsor. The sponsor undertook the statistical analysis in line with the 
research agreement. 
6.1.4.4	  -­‐	  Randomization	  
Participants were randomly assigned to one of the three groups using age and gender as the 
stratification factors. The randomization was performed using the software TRIALSYS which was 
developed by the sponsors. 
6.1.5	  -­‐	  Protocol	  Deviations	  and	  Analysis	  Populations	  
A total of 62 participants were recruited into the trial. The intention-to-treat (ITT) set 
comprised of a pseudo-population (full analysis set) with all the participants who completed all 
visits of the trial. One participant joined another trial after recruitment while two other 
participants dropped out during the course of the trial. These three participants were not 
included in the full analysis population. The per-protocol (PP) population was based on the blind 
data review. All the participants who were excluded from the PP dataset and the reasons for their 
exclusion are given in Table 6.1.5.1. The PP dataset therefore comprised 48 participants.	  
Table 6.1.5.1: The participants excluded from the per protocol analysis, exclusion criteria 
independently assigned by the sponsor. 	  
Subject ID Reason Value 
042 BMI at inclusion 44.5 kg/m2 
014 Restricted medication Simvastatin 
026 Restricted medication Simvastatin 
047 Restricted medication Simvastatin 
002 Visit 4 out of window (>101 days) 102 days 
008 Visit 4 out of window (>101 days) 130 days 
012 Visit 4 out of window (>101 days) 104 days 
020 Visit 4 out of window (>101 days) 105 days 
050 Visit 4 out of window (<81 days) 77 days 
056 Visit 4 out of window (>101 days) 140 days 
059 Visit 4 out of window (>101 days) 107 days 	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6.1.6	  -­‐	  Demographic	  and	  Baseline	  Characteristics	  
Several demographic and baseline characteristics were recorded during the screening visit (V0). 
These are summarized in Tables 6.2.1. and 6.2.1.1 Overall, 31 men and 31 women were 
enrolled into the trial. 8% of these were smokers of which 60% were male. 
6.1.7	  -­‐	  Compliance	  
Compliance with respect to chocolate intake was monitored throughout the trial. All 
participants were asked to keep wrappers from the consumed products, writing on them the 
dates when they were consumed during the entire trial and bring them back to the investigator for 
the intermediate and final visits.  
6.1.8	  –	  Adverse	  Event	  Reporting	  	  
Adverse events, both harms and unintended effects were assessed by asking all 
participants at each visit if they had any concomitant illnesses, symptoms or effects 
since their last visit. This included episodes of hypoglycaemia or symptoms from their 
diabetes. Additionally any changes to their medication were also recorded at each visit, 
including routine vaccinations (influenza vaccine), these were then cross referenced by 
discussion with the participant and medical notes to cross-reference any missed adverse 
events. Any severe adverse events, including hospitalisation, unplanned surgery and 
death would have been reported to the sponsor and ethics committee within 24 hours, in 
accordance with Good Clinical Practice (EMEA, 2002).  
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6.2	  -­‐	  Baseline	  features	  and	  characteristics	  
6.2.1	  -­‐	  Study	  Population	  	  
A total of 59 participants completed at least 11 weeks of daily chocolate consumption 
with complicance being very high (median complicance 96% of bars eaten, 97%, 95%, 
94% of bars respectively for high polyphenol milk chocolate, low polyphenol and dark 
chocolates). Mean age of the cohort was 63.9±8.0 years with a range of 44-79 years. 
There were two participants who failed to complete the study. The mean duration of 
diabetes was 3.7±2.3 years, with no difference between groups for age or duration of 
diabetes. Thirty males and 29 females completed the study. Table 6.2.1, summarises the 
baseline demographics. Waist and hip circumferences were omitted for 3 participants 
who declined to have the measurements taken. 
Table 6.2.1: Summary statistics for demographic and baseline characteristics following the four 
week run in period  
 Gender N Mean SD Min Max 
Weight (kg) 
Female 30.0 86.39 13.2 66.1 113.8 
Male 31.0 93.47 13.1 71.4 117.6 
Height (cm) 
Female 30.0 162.16 7.6 141.0 178.0 
Male 31.0 176.32 7.7 157.0 195.0 
BMI (kg/m2) 
Female 30.0 32.86 4.6 25.1 44.5 
Male 31.0 30.05 3.8 25.0 39.3 
Hip (cm) 
Female 29.0 115.32 10.8 94.0 134.9 
Male 29.0 109.62 7.0 99.0 130.0 
Waist (cm) 
Female 29.0 103.95 10.1 86.8 122.0 
Male 29.0 105.06 10.8 85.0 127.3 
 
  
Chapter	  Six–	  Study	  Three	  
	   225	  
Table 6.2.1.1: Summary statistics for demographic by chocolate at screening visit 
Characteristic Dark 
Chocolate 
High Polyphenol Milk 
Chocolate 
Low Polyphenol 
Chocolate 
Age (Mean years ± standard deviation) 62.8±8.8 61.6±7.5 64.8±8.0 
Gender ratio (Male: Female) 10:10 11:10 11:10 
Duration of Diabetes (Mean years ± 
standard deviation) 
3.9±2.7 3.5±2.1 3.6±2.4 
Weight (Kg ± standard deviation) 92.4±13.9 90.2±15.2 87.8±12.1 
BMI (Kgm-2± standard deviation) 35.3±14.3 31.3±4.3 30.9±3.9 
Oral Diabetes Medication (Metformin: 
None) 
6:14 9:12 11:9 
Lipid Lowering Medication (Yes : None) 12:8 12:9 12:8 
Blood Pressure Medication (Yes : None) 16:4 11:10 13:7 
There were only five participants who reported that they currently smoked at their 
screening visit, three were male (two were allocated to the dark chocolate and the other 
to the low polyphenol chocolate) and two females who were allocated to the high 
polyphenol milk chocolate and low polyphenol chocolate arms respectively 
6.2.2	  -­‐	  Anthropometrics	  
Weight for the whole population at screening was 89.1±13.0 kg, BMI 31.2±4.8kgm-2. 
This was found to reduce significantly in the whole study population during the four-
week run-in phase to 88.5±13.4kg, BMI 30.7±4.4kgm-2 (p=0.01). Table 6.2.1, shows the 
overall population at the start of the intervention. The population was characterised by 
central obesity, with mean BMI, waist and waist circumference all being indicative of 
this feature (Klein et al., 2007; Alberti, Zimmet and Shaw, 2006). No significant effect 
on weight was seen during the twelve weeks of chocolate consumption (88.2±13.3kg, 
BMI 30.9±4.5kgm-2, visit 1 – visit 4, p=0.825). Of the participants who were followed 
up four weeks after discontinuing daily chocolate consumption (n=32), a notable weight 
increase was seen across the whole study cohort, with 4 weeks after discontinuing the 
study, mean weight was 86.8±12.8kg and BMI 30.9±4.6kgm-2 (change from visit 4 to 
post study monitoring, p=0.02).  
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6.2.3	  -­‐	  Dietary	  Intake	  
With the exception of the statistically significant difference at visit four between those 
consuming the milk chocolate and control with respect to sodium intake (p=0.028), it 
appeared that the milk chocolate group consumed less sodium than the control  (Tables 
6.2.3.1 and 6.2.3.2). No significant differences were seen between visit one and visit 
four. 
Energy and macronutrient intakes were not found to be significantly different between 
the three groups. The same result was seen for fibre and vitamin C, intake suggesting 
that there were no changes in consumption of plant based foods or flavanols over the 
course of the study.  
Data regarding food intake were collected at the screening visit (V0) and intermediate 
visits (V1 & V4): no change in energy, macronutrient or micronutrients observed at 
these points (data not presented). 
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Table 6.2.3.1: Dietary Intake of the three study groups at Visit One and Four (beginning and end of 
12 weeks of chocolate consumption). P-values represent the ANOVA between groups and the 
overall population over time. Time group effects were not explored. All data were tested for 
normality using Shapiro-Wilks and found not to violate this assumption. 
	  
	   	  
 
Dietary Intake Visit One Dietary Intake Visit Four 
P value 
Between Chocolate 
Groups 
Between Visits 
Mean Std. Deviation Mean Std. Deviation Visit One Visit Four 
Weight of Food 
Milk 1895.2g 859.1 2012.9g 792.1 0.501 0.758 
Control 1619.6g 507.4 1869.7g 530.0 
0.252 Dark 1751.3g 520.5 1856.9g 587.1 
Water 
Milk 1538.7 ml 859.2 1644.5ml 734.7 0.399 0.664 
Control 1233.6ml 450.6 1489.6ml 461.9 
0.235 Dark 1368.7ml 471.3 1469.8ml 525.6 
Energy (calories) 
Milk 1428.7kcal 445.8 1495.0kcal 319.9 0.426 0.608 
Control 1649.7kcal 471.6 1662.3kcal 529.3 
0.604 Dark 1554.1kcal 511.0 1623.8kcal 570.5 
Energy (Kj) 
Milk 5652.0kj 2341.8 60144kj 1992.0 0.241 0.434 
Control 6921.7kj 1970.3 6982.9kj 2226.9 
0.592 Dark 6536.1kj 2135.7 6812.3kj 2372.9 
Protein 
Milk 61.1g 17.7 69.6g 14.2 0.410 0.136 
Control 71.8g 21.5 80.7g 20.1 
0.158 Dark 66.6g 27.2 67.9g 17.9 
Fat 
Milk 57.8g 25.8 60.1g 25.0 0.707 0.788 
Control 65.6g 23.1 67.3g 22.9 
0.730 Dark 62.1g 29.5 63.7g 35.3 
Saturated fatty 
acid intake 
Milk 18.9g 9.2 20.8g 8.3 0.822 0.949 
Control 21.0g 11.2 22.1g 10.3 
0.607 Dark 21.0g 12.3 21.4g 13.5 
Carbohydrate 
Milk 168.3g 64.83 170.3g 42.5 0.299 0.565 
Control 203.2g 70.3 192.8g 84. 0 
0.852 Dark 188.2g 53.0 188.3g 53.7 
Sugar 
Milk 52.5g 33.3 64.1g 34.4 0.353 0.939 
Control 66.0g 29.8 67.0g 37.4 
0.715 Dark 67.7g 35.1 62.3g 38.2 
Fibre 
Milk 13.2g 6.6 13.1g 8.3 0.916 0.690 
Control 13.0g 5.5 10.9g 4.8 
0.640 Dark 12.4g 5.0 12.6g 7.9 
Sodium 
Milk 2201.3mg 851.6 2099.1mg 771.5 0.152 0.028 
Control 2585.2mg 858.3 3022.4mg 1214.6 
0.849 Dark 2873.4mg 1138.6 2707.3mg 774.3 
Iron 
Milk 9.4mg 3.7 9.5mg 3.1 0.858 0.669 
Control 9.6mg 3.0 10.2mg 4.2 
0.582 Dark 10.1mg 3.6 10.7mg 4.2 
Vitamin C 
Milk 78.3mg 71.5 62.5mg 82.1 0.359 0.666 
Control 61.2mg 32.7 48.9mg 39.2 
0.760 Dark 51.9mg 43.9 68.1mg 44.1 
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Table 6.2.3.2: Differences in dietary Intake of the three study groups at Visit One and Four 
(beginning and end of 12 weeks of chocolate consumption). P-values represent the ANOVA 
between groups and the post-hoc analysis (least significant difference) for the primary and 
secondary comparisons. All data were tested for normality using Shapiro-Wilks and found not to 
violate this assumption. 
	  
	  
	  
 
Change in intake 
between Visit One 
and Visit Four 
ANOVA  
P value 
 
Post Hoc Analysis (LSD) 
Between Chocolate Groups 
Mean Std. Deviation 
High Polyphenol Milk 
Chocolate Vs Low 
Polyphenol Chocolate 
High Polyphenol 
Milk Chocolate Vs 
Dark  Chocolate 
Weight of Food 
Milk 126.1g 845.2 
0.895 0.719 0.930 Control 213.3g 598.8 
Dark 105.6g 462.3 
Water 
Milk 119.7 ml 796.2 
0.844 0.645 0.933 Control 224.7ml 556.2 
Dark 101.09ml 440.1 
Energy (calories) 
Milk 46.9kcal 418.1 
0.864 0.709 0.873 Control -8.5kcal 458.7 
Dark 69.6kcal 326.1 
Energy (Kj) 
Milk 322.0kj 1750.3 
0.831 0.577 0.939 Control -25.8kj 1892.6 
Dark 276.2kj 1346.9 
Protein 
Milk 8.3g 22.3 
0.675 0.800 0.389 Control 6.2g 20.3 
Dark 1.3g 25.0 
Fat 
Milk 0.9g 18.7 
0.996 0.970 0.929 Control 1.2g 27.7 
Dark 1.7g 25.5 
Saturated fatty 
acid  
Milk 1.3g 6.6 
0.968 0.855 0.807 Control 0.7g 13.2 
Dark 0.5g 8.5 
Carbohydrate 
Milk 1.0g 64.2 
0.775 0.521 0.965 Control -12.1g 63.2 
Dark 0.1g 34.5 
Sugar 
Milk 7.9g 34.2 
0.390 0.288 0.204 Control -3.2g 33.9 
Dark -5.4g 17.5 
Fibre 
Milk -0.2g 7.5 
0.449 0.329 0.834 Control -2.3g 3.8 
Dark 0.2g 4.7 
Sodium 
Milk -15.6mg 969.3 
0.284 0.252 0.701 Control 451.7mg 1041.0 
Dark -166.1mg 1211.0 
Iron 
Milk 0.9mg 3.5 
0.932 0.709 0.853 Control 0.4mg 3.0 
Dark 0.6mg 4.0 
Vitamin C 
Milk -2.6mg 101.2 
0.600 0.754 0.456 Control -10.8mg 37.7 
Dark 16.3 53.1 
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6.2.4	  -­‐	  Baseline	  Characteristics	  –	  Attachment	  Type	  
There were no significant differences in attachment style (how individuals relate to 
individuals or potentially services) between groups; also, attachment style did not 
predict a positive outcome. Eighty five percent of the participants who consented to take 
part in the study had a secure attachment style. A Chi2 test of independence, 
demonstrated that this was significantly different to that published for the general 
population (55-65%) and in populations of people with T2DM (30-40.2%) 
(Ciechanowski et al., 2004; Ciechanowski, Hirsch, & Katon, 2002) (p<0.001). 
6.2.5	  -­‐	  Interrelationships	  between	  Clinical	  Measures	  at	  Baseline	  
The published literature regarding the effects of cocoa flavanols and the six markers of 
diabetes control or cardiovascular risk were explored in the whole cohort of 60 
participants at baseline. A multiple regression analysis using a step 1 model and step 2 
model, suggested that the change in endothelial function appeared to account for 19.1% 
of the variance in HDL cholesterol (F=0.001); the addition of systolic blood pressure to 
endothelial function appeared to account for 26.4% of the variation in HDL cholesterol. 
The correlation between endothelial function (assessed by RH-PAT) and HDL 
cholesterol can be seen in figure 6.2.5.1 for the whole cohort and in figure 6.2.5.2 for 
the 28 participants who were not taking lipid-lowering therapy. In this group, 
endothelial function appeared to account for 32.6% of the variation in HDL cholesterol. 
This suggested that in the absence of statin therapy, the influence of endothelial 
function upon HDL cholesterol was greater than seen in those treated with statins. 
However, this might have been limited by the sample size. 
These analyses of variance were highly significant, supporting the hypothesis that there 
is an inter-relationship between these features of cardiovascular risk as discussed in 
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Chapter One, and shown to be moderated by chocolate consumption in Chapters Four 
and Five. 
	  
Figure 6.2.5.1: Correlation between endothelial function and HDL cholesterol at baseline across 
the whole study population (n=60) 	  
 
Figure 6.2.5.2: Correlation between endothelial function and HDL cholesterol at baseline in the 
study population not treated with HMG-Co-ase reductase inhibitors (statins)  (n=28, 26 on no 
treatment and 2 on ezetimide) 
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6.2.6	  -­‐	  Adverse	  Events	  and	  Concurrent	  Medication	  	  
The study was partly undertaken during the winter 2009 during the Swine Flu epidemic 
(Donaldson et al., 2009). It was noted that a number of the participants may have 
demonstrated an acute phase response indicated by a CRP >8mg/l, a potential indicator 
of acute infection. Thirty-one participants were taking metformin, 34 were on lipid 
medication (2 ezetimibe, managed with at least a statin) and 25 on blood pressure 
medication. Two participants had their medication adjusted by their general practitioner 
and were therefore removed from the analyses undertaken by the author, the only 
changes in the robust ANCOVA model used by the sponsor are reported in table 
6.1.5.1. A full summary of the adverse events (table 6.2.6), show that upper respiratory 
tract infections were the most common event, occurring more frequently in the dark 
chocolate and low polyphenol groups. This was unlikely to be an effect of the 
chocolates, but could have acted as confounding and lead to changes in inflammatory 
markers in these groups and possibly insulin resistance. 
Table 6.2.6: Summary frequencies of adverse events separated by the type of chocolate 
Adverse Event Dark 
Chocolate 
High 
Polyphenol 
Milk Chocolate 
Low 
Polyphenol 
Chocolate 
Association with chocolate 
Upper Respiratory 
Tract Infections 
(including Influenza) 
5 1 6 Unlikely 
Diarrhoea and 
vomiting 
2 1  Unlikely 
Nausea and 
Vomitting 
  1 Unlikely 
Depression and 
anxiety 
  1 Unlikely 
Dizziness and 
postural hypotension 
1   Possible, participant required a 
reduction in blood pressure 
medication 
Road Traffic Accident   1 Unlikely, no link of accident to 
diabetes/ hypoglycaemia 
Increase/ Change 
medication 
1 1  Unlikely as both participants 
demonstrated a reduction in 
Hba1c during the study 
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6.2.7	  -­‐	  Post	  Study	  Effects	  on	  Weight	  
No effect on weight was seen during the course of the study (Sections 6.3 and 6.4). 
However, figure 6.2.7.1 shows that during the run-in period participants (n=60) 
appeared to lose weight (p=0.001). The cohort of 32 participants who returned four 
weeks after completing the study had significantly gained weight since their last study 
visit (p=0.002, PP analysis). 
	  
Figure 6.2.7.1: Change in weight over the total course of the study from screening (-28 days), 
chocolate feeding (0-84 days) and post study monitoring (112 days). Weight screening to starting 
chocolate feeding (v1) p=0.001 with a mean weight loss of 0.75±0.17kg, weight was stable through 
the 20g (approx. 100kcal per day stage) 0.15±0.20kg weight gain (p=0.483) and with weight gain 
following the end of the study 0.70±0.18kg(p=0.002). Data presented as mean weight± standard 
error of mean (kg).	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6.3	  -­‐	  Chronic	  Effects	  of	  Chocolate	  Consumption	  
The data were tested to explore changes from baseline across the whole cohort and 
within groups (Table 6.3.1). This suggested that within the whole population fasting 
insulin fell significantly, in both the milk and control chocolate groups, but not in the 
dark chocolate group. There was also an increase in total cholesterol and HDL 
cholesterol across the whole study population. This was also seen in the control group 
for total cholesterol, and in the dark chocolate group for HDL cholesterol. This did not 
suggest a change compared to control. These relationships were further explored using 
the ANCOVA model (Section 6.3.3.2). 
6.3.2	  -­‐	  Primary	  Outcome	  
The primary outcome for this study was the changes in homeostatic model assessment (HOMA) 
between visit one and visit four. Geometric means for HOMA at initiation of chocolate 
supplementation (Visit One -V1) and the end of the chocolate supplementation (Visit Four-V4) 
and their 95% confidence limits are given in Table 6.3.2.1 for each treatment group. These 
geometric means with the upper and lower quartiles are also displayed in Figure 6.3.2.1. On 
average, the high polyphenol milk chocolate induced the highest decline in HOMA values 
while the dark chocolate had the lowest.  
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Table 6.3.1: Baseline and twelve-week biochemical data for whole study cohort and for each of the 
three chocolate intervention groups. HPMC – High Polyphenol Milk Chocolate, HPDC – High 
Polyphenol Dark Chocolate and LPC – Low polyphenol intake. All data tested for normality using 
Shapiro –Wilks and then difference from baseline calculated using paired t-test. α indicates p<0.05 
and β indicates p<0.01. 
 
The sponsor of the study analysed this data using a Box-Cox transformation and a 
robust ANCOVA model. Table 6.3.2 shows the summary statistics for the primary and 
secondary clinical and biochemical outcome measures. The contrast estimate is the 
estimate of the difference of the active compared to the control. The control is corrected 
to 1.0 and then an estimate of the difference is made following the active intervention, 
e.g. for HOMA in table 6.3.2, the contrast estimate for high polyphenol milk chocolate 
compared to dark chocolate was 0.61, implying a 39% reduction following high 
polyphenol milk chocolate. However this did not reach significance as the 95%CI 0.35-
1.05, resulting in p=0.0754. 
  
 
Whole Cohort Milk Chocolate Dark chocolate Control 
Visit One Visit Four Visit One Visit Four Visit One Visit Four Visit One Visit Four 
HOMA 6.4±4.5 3.4±2.8 β 8.1±5.7 3.4±2.8 α 4.5±2.7 3.5±2.7 6.1±3.8 3.2v3.0 α 
QUICKI 0.51±0.12 0.59±0.13 β 0.48±0.8 0.58±0.11 β 0.58±0.18 0.59±0.15 0.50±0.8 0.61±0.15 β 
Insulin mU/l 20.5±13.7 10.1±8.0 β 24.7±16.7 9.0±5.7 β 15.4±9.4 11.2±9.1 20.5±12.5 10.4±9.4 β 
Glucose 
Mmol/l 7.1±1.4 7.3±1.6 7.5±1.7 7.9±1.4 6.8±0.8 7.0±1.3 6.9±1.2 6.9±1.3 
HbA1c 
mmol/mol 47.3±10.0 48.5±11 α 49.8±13.4 51.4±15.1 44.2±6.8 44.7±6.5 47.0±7.5 48.5±7.5 
Cholesterol 
mmol/l 3.99±1.00 4.27±0.95 α 4.14±1.06 4.37±0.87 3.63±0.91 4.12±0.78 4.13±1.01 4.29±1.17 α 
HDL 
Cholesterol 
mmol/l 
0.98±0.03 1.06±0.26 α 0.99±0.24 1.09±0.25  0.98±0.31 1.09±0.35   0.98±0.27 1.02±0.20 
LDL Cholesterol 
mmol/l 2.32±0.84 2.48±0.90 2.34±0.78 2.52±0.81 2.06±0.78 2.30±0.69 2.46±0.93 2.58±1.14 
Triglycerides 
mmol/l 1.62±0.82 1.69±0.81 1.66±0.77 1.65±0.82 1.78±0.93 1.50±0.59 1.41±0.77 1.88±0.96 
hsCRP mg/l 1.81±1.53 1.92±1.76 2.03±1.62 2.11±2.228 1.36±1.63 1.67±1.59 1.90±1.36 1.93±1.26 
15-F2t-
isoprostane 196.6±235.9 147.7±69.0 170.0±113.6 150.0±59.3 189.3±138.6 173.0±94.0 229.0±361.7 130.1±54.6 
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Table 6.3.2: The summary descriptive and inferential statistics of primary and secondary clinical 
measures. Data presented as contrast estimate based on the robust ANCOVA model. The sponsor 
of the study produced data presented. 
 Comparison of interventions 
between Visits 1 and 4 
Contrast 
Estimate 
Lower 
95%CI 
Upper 
95%CI 
p-value 
HOMA (ITT) High Polyphenol V Low Polyphenol 1.18 0.71 1.96 0.5309 
High Polyphenol V Dark 0.61 0.35 1.05 0.0754 
HOMA (PP) High Polyphenol V Low Polyphenol 0.85 0.43 1.69 0.6439 
High Polyphenol V Dark 0.55 0.30 1.00 0.0518 
HbA1c High Polyphenol V Low Polyphenol 1.00 0.97 1.03 0.8621 
High Polyphenol V Dark 1.00 0.98 1.03 0.8518 
Fasting 
Glucose 
High Polyphenol V Low Polyphenol 1.08 0.99 1.18 0.0795 
High Polyphenol V Dark 1.07 0.98 1.17 0.1096 
Insulin High Polyphenol V Low Polyphenol 0.98 0.86 1.46 0.9243 
High Polyphenol V Dark 0.82 0.56 1.20 0.3134 
Total 
Cholesterol 
High Polyphenol V Low Polyphenol 1.03 0.95 1.12 0.4335 
High Polyphenol V Dark 1.04 0.96 1.13 0.3572 
HDL 
Cholesterol 
High Polyphenol V Low Polyphenol 1.01 0.86 1.18 0.9066 
High Polyphenol V Dark 1.03 0.91 1.16 0.6179 
LDL 
Cholesterol 
High Polyphenol V Low Polyphenol 1.04 0.98 1.16 0.5000 
High Polyphenol V Dark 1.03 0.91 1.16 0.6595 
Triglycerides High Polyphenol V Low Polyphenol 0.91 0.69 1.21 0.5276 
High Polyphenol V Dark 0.90 0.68 1.19 0.4530 
RH-PAT 
Endothelial 
Function 
High Polyphenol V Low Polyphenol 2.72 -5.20 10.64 0.5010 
High Polyphenol V Dark 3.16 -4.84 11.15 0.4391 
hsCRP High Polyphenol V Low Polyphenol 1.06 0.84 1.35 0.6047 
High Polyphenol V Dark 0.53 0.34 0.80 0.0028 
IL-6 High Polyphenol V Low Polyphenol 1.20 0.78 1.86 0.4113 
High Polyphenol V Dark 0.76 0.49 1.20 0.2419 
IL1Ra High Polyphenol V Low Polyphenol 1.02 0.79 1.31 0.8835 
High Polyphenol V Dark 0.94 0.69 1.29 0.7083 
MDA High Polyphenol V Low Polyphenol 1.55 0.85 2.84 0.1536 
High Polyphenol V Dark 0.93 0.54 1.62 0.8071 
Urinary 
Isoprostane 
High Polyphenol V Low Polyphenol 1.16 0.90 1.48 0.2543 
High Polyphenol V Dark 1.05 0.82 1.35 0.6807 
Body Weight  High Polyphenol V Low Polyphenol 1.29 -7.25 9.82 0.7675 
High Polyphenol V Dark -2.10 -10.60 6.39 0.6274 
Table 6.3.2.1: Summary statistics for log transformed data for HOMA at Visit 1 and Visit 4 
 Visit Geometric mean 95% Confidence Intervals 
Upper 
Dark Chocolate 
 Visit 1 4.45 3.19-6.21 
6.21 
Visit 4 2.75 1.72-4.42 
Milk Chocolate 
High Polyphenol 
 Visit 1 6.50 4.14-10.21 
Visit 4 2.82 1.93-4.14 
Control 
 Visit 1 4.63 2.77-7.74 
7.74 
Visit 4 2.21 1.50-3.26 
3.26 
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Figure 6.3.2.1: HOMA measurements by chocolate, mean values ±95% Confidence Intervals 	  
These data were log-transformed as suggested by Box-Cox transformation to reduce the 
degree of skewness. The data then appear to support the raw data analysis that there was 
a reduction in insulin resistance seen across the study population. It is unclear if changes 
in weight may have acted as confounders, masking the effects of the flavanols on 
insulin resistance.  
6.3.2.1.1 - Intention-to-treat (ITT) analysis, (n = 59) 
The ITT analysis comprised all the study participants who were enrolled into the trials and had 
measurements taken at any visit up to and including visit four. The analysis for this endpoint was 
based on the ANCOVA model using the methods of moments (MM)-estimators. The estimated 
treatment ratios are given in Table 6.3.2.1. The estimated ratio between high and low polyphenol 
milk chocolate (primary objective) with respect to HOMA was 1.18 indicating an 18% increase. 
However, this increase was not statistically significant (p = 0.5308). Similarly, high polyphenol 
milk chocolate showed a reduction in HOMA compared to dark chocolate even though this 
reduction was not significant (p = 0.0754). 
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6.3.2.1.2	  -­‐	  Per-­‐Protocol	  (PP)	  analysis,	  (n	  =	  48)	  
The ANCOVA model fitted to the full analysis dataset was also fitted to the PP dataset defined 
in Section 6.1.5. The results suggested there was no difference between the high and low 
polyphenol milk chocolate (p=0.6439) with a 45% reduction in HOMA compared to the dark 
chocolate, which showed a trend towards, but also failed to reach, significance (p=0.0518) as 
the estimated 95% confidence intervals was too close to 1.  
6.3.3	  -­‐	  Secondary	  Outcomes	  
6.3.3.1	  -­‐	  Glycaemia	  	  
Changes in glucose will be considered as part of the acute effect of chocolate as part 
of the meal test in section 6.4. 
6.3.3.1.1	  -­‐	  HbA1c	  	  
HbA1 c was the key secondary endpoint for this trial. Due to the skewness of the data, a log-
transformation was applied as suggested by the Box-Cox transformations. Table 6.3.3.1.1 shows the 
geometric means of HbA1 c percentage and their 95% confidence intervals across the treatment 
groups at each visit. On average, both low and high polyphenol milk chocolate induced an increase in 
the levels of HbA1c.  The levels of HbA1 c under dark chocolate appeared to be constant over the 
duration of the study. 
Table 6.3.3.1.1: Summary log transformed statistics for HbA1c at visit 1 and visit 4. 
  Geometric mean 95% Confidence Intervals 
Dark Chocolate (DCCT %) 
 Visit1 6.33 5.91-6.78 
 Visit4 6.32 6.00-6.65 
Milk Chocolate (DCCT %) 
 Visit1 6.52 6.06-7.01 
 Visit4 6.68 6.12-7.30 
Control (DCCT %) 
 Visit1 6.49 6.08-6.93 
 Visit4 6.62 6.20-7.06 
 
The estimate of effect suggested no difference between the dark chocolate and the milk 
chocolate (p=0.8621) or between the milk chocolate and the control (p=0.8518) 
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6.3.3.2	  	  -­‐	  Lipid	  profile	  
Total cholesterol appeared to increase in all treatment groups with the highest increases observed 
with dark chocolate and high polyphenol milk chocolate. However, treatment comparisons 
based on the log-transformed levels of total cholesterol are shown in table 6.3.3.2.1 and there were 
no statistically significant differences between the treatments in terms of the levels of total 
cholesterol. Treatment comparison data for HDL cholesterol were also log transformed. The 
levels of HDL cholesterol appeared to increase in all treatment groups but there were no statistically 
significant differences between the groups (Table 6.3.3.2.1). 
Summary statistics for LDL cholesterol levels are summarized in Table 6.3.3.2.1, with geometric 
means and 95% confidence intervals for each treatment group at each visit. On average, LDL 
cholesterol levels appeared to increase under high polyphenol milk chocolate and dark chocolate 
while remaining relatively constant under low polyphenol milk chocolate in the duration of the 
trial but the differences were not statistically significant. 
Table 6.3.3.2: Summary statistics of lipid profile and p value from robust ANCOVA model for the 
three chocolates. Note data is log transformed and therefore do not match the absolute values. 
  Geometric mean 95% Confidence Intervals 
 
Total Cholesterol (mmol/l)  
Dark Chocolate Visit1 3.72 3.3-4.2 P-value Vs. Milk 
chocolate =0.3572  Visit4 4.03 3.7-4.4 
Milk Chocolate Visit1 4.05 3.5-4.7  
 Visit4 4.31 3.9-4.8 
Control Visit1 4.03 3.6.4.5 P-value Vs. Milk 
Chocolate = 0.4335  Visit4 4.08 3.6-4.6 
HDL Total Cholesterol (mmol/l)  
Dark Chocolate Visit1 4.45 3.2-6.2 P-value Vs. Milk 
chocolate =0.6179  Visit4 2.75 1.7-4.4 
Milk Chocolate Visit1 6.50 4.1-10.2  
 Visit4 2.82 1.9-4.1 
Control Visit1 4.63 2.8-7.7 P-value Vs. Milk 
chocolate =0.9066  Visit4 2.21 1.5-3.3 
LDL Total Cholesterol (mmol/l)  
Dark Chocolate Visit1 2.10 1.8-2.5 P-value Vs. Milk 
chocolate=0.6595  Visit4 2.22 1.9-2.6 
Milk Chocolate Visit1 2.20 1.8-2.7  
 Visit4 2.41 2.0-2.9 
Control Visit1 2.32 2.0-2.7 P-value Vs. Milk 
chocolate 
=0.5000 
 
Visit4 2.33 1.9-2.8 
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6.3.3.4	  -­‐	  Oxidative	  stress	  
15-F2t-isoprostane: creatinine ratios (mg: mol) measured in the urine at visit one and four are 
given in Table 6.3.3.4.1 (geometric mean with lower and upper 95% confidence limits). Urinary 
15-F2t isoprostane appeared to decrease under dark chocolate and low polyphenol milk chocolate 
while high polyphenol milk chocolate seemed to induce an increase. There were no 
statistically significant differences between the treatments in terms of urinary 15-F2t 
isoprostane (estimate milk compared to control 1.16; 95% confidence interval 0.90, 
1.38; p=0.2543; high compared to dark p=0.6807). 
Table 6.3.3.4.1: Summary log transformed statistics for 15-F2t-sioprostane: creatinine ratios at visit 
1 and visit 4. 
  Geometric mean 95% Confidence Intervals 
Dark Chocolate (mg: mol) 
 Visit1 150.13 115.2-195.6 
 Visit4 134.70 106.6-170.2 
Milk Chocolate (mg: mol) 
 Visit1 139.90 105.4-185.8 
 Visit4 145.07 116.8-180.2 
Control  (mg: mol) 
 Visit1 123.53 96.0-159.0 
 Visit4 108.74 84.2-140.5 	  
No statistically significant differences were seen for malondialdehyde.  
6.3.3.5	  -­‐	  Inflammatory	  markers	  
No significant changes were seen for the interleukins (IL1Ra and IL6). TNF-α was not 
measurable in 90% of cases using the high sensitivity ELISA kit available. 
High sensitivity-C-Reactive Protein (hs-CRP) significantly decreased following milk 
chocolate consumption compared to dark chocolate, with an estimated 47% reduction 
(95% confidence interval 0.35, 0.80; p=0.0028) (figure: 6.3.3.5.1). There was no effect 
when comparing milk chocolate with control. Summary statistics for hs-CRP are shown 
in table 6.3.3.5.1. 
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Table 6.3.3.5.1: Summary for Hs-CRP at visit 1 and visit 4. 
  Geometric mean 95% Confidence Intervals 
Dark Chocolate (mg/l) 
 Visit1 1.57 0.85-2.88 
 Visit4 1.81 0.96-3.38 
Milk Chocolate (mg/l) 
 Visit1 1.70 1.06-2.74 
 Visit4 1.42 0.85-2.37 
Control (mg/l) 
 Visit1 1.84 1.12-3.03 
 Visit4 2.24 1.22-4.12 	  
	  
Figure 6.3.5.5.1: Hs-CRP measurements by chocolate, mean values ±95% Confidence Intervals 
	  
6.3.3.6	  -­‐	  Body	  weight	   
Body weight decreased during the run in phase and increased again after chocolate 
supplementation ceased (Section 6.2.7). 
Weight appeared to be stable during the chocolate supplementation phases of the study. 
Figure 6.3.3.6.1 shows body weight by chocolate group and figure 6.3.3.6.2 shows 
individual weight changes over the course of the 12-week study. It is notable that in the 
dark chocolate arm, two participants lost greater than 5% of bodyweight during the trial 
despite no recordable change in energy intake. 
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Figure 
6.3.3.6.1: Body weight over time (mean and 95% confidence intervals) by chocolate. Weight at the 
screening visit (V0) was not included in the analysis due to protocol restrictions. 
	  
Figure 6.3.3.6.2: Individual body weight over time by individual participant. Weight at the screening 
visit (V0) was not included in the analysis due to protocol restrictions. 
There were no statistical differences between the chocolate groups with respect to body 
weight during the intervention.  
Table 6.3.3.6.1 Estimated treatment differences in terms of body weight 
 Est imate  Lower  Upper  p -va lue  
Mi lk  Vs .  
Contro l  
1 .29  -7 .25  9 .82  0 .7675  
Milk  Vs .  Dark  -2 .10  -10 .60  6 .39  0 .6274  
6.3.3.7	  	  -­‐	  Participant	  reported	  outcomes	  
No significant differences were seen between the three groups either at visit one or four 
for any of the questionnaire scores. There were no significant changes in questionnaire 
scores from visit one to four between groups, descriptive statistics for the questionnaires 
are presented in table 6.3.3.7. 
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Table 6.3.3.7: Summary descriptive statistics from the participant reported outcomes. 
 Scales Treatment n Geomean Lower Upper  n Geomean Lower Upper 
V1       V4     
 Alert Dark Chocolate 20 17.5 11.8 25.9  19 29.6 19.6 44.5 
  High Polyphenol 20 19.5 11.9 31.8  20 13.6 8.5 21.9 
  Low Polyphenol 20 19.3 13.9 26.8  19 15.6 9.2 26.4 
 Amicable Dark Chocolate 20 13.1 8.7 19.7  20 8.3 3.6 19.2 
  High Polyphenol 20 9.3 4.9 17.8  20 8.5 5.5 13.0 
  Low Polyphenol 21 13.1 7.0 24.6  21 8.0 3.7 17.5 
 Attentive Dark Chocolate 20 19.3 12.9 28.7  19 20.9 14.3 30.6 
  High Polyphenol 20 15.7 8.6 28.6  20 14.1 8.4 23.5 
  Low Polyphenol 20 16.3 11.3 23.5  18 14.4 8.9 23.4 
 Calm Dark Chocolate 20 12.6 9.0 17.6  19 13.6 10.0 18.4 
  High Polyphenol 20 9.0 5.4 15.0  20 10.1 6.7 15.2 
  Low Polyphenol 20 14.1 10.2 19.4  19 11.6 7.5 18.0 
 Clear-headed Dark Chocolate 20 19.9 13.8 28.8  19 23.0 16.1 32.8 
  High Polyphenol 20 18.4 11.8 28.8  20 12.0 8.3 17.5 
  Low Polyphenol 20 19.3 13.0 28.8  19 18.2 12.7 26.2 
 Contentedness Dark Chocolate 20 12.9 9.3 18.0  20 10.7 5.2 22.2 
  High Polyphenol 20 9.7 5.6 16.7  20 6.7 4.6 10.0 
  Low Polyphenol 21 10.5 5.3 21.0  21 6.9 3.1 15.1 
 Energetic Dark Chocolate 20 29.0 21.4 39.4  19 30.3 22.1 41.6 
  High Polyphenol 20 25.6 16.5 39.5  20 16.5 10.9 25.2 
  Low Polyphenol 20 35.2 25.7 48.3  19 23.8 16.9 33.6 
 Gregarious Dark Chocolate 20 21.5 14.9 31.0  19 23.8 17.4 32.7 
  High Polyphenol 20 18.0 11.8 27.4  19 12.9 8.4 19.9 
  Low Polyphenol 20 25.6 18.5 35.5  19 25.8 17.9 37.3 
 Happy Dark Chocolate 20 13.0 8.8 19.1  19 17.1 11.2 25.9 
  High Polyphenol 20 10.6 6.6 17.2  19 8.6 5.1 14.7 
  Low Polyphenol 20 12.2 8.0 18.6  19 12.4 8.2 18.8 
 Interested Dark Chocolate 20 13.2 8.5 20.3  19 15.3 9.6 24.3 
  High Polyphenol 20 9.5 5.9 15.2  20 7.6 4.6 12.5 
  Low Polyphenol 20 12.2 7.8 19.2  19 11.7 7.4 18.4 
 Proficient Dark Chocolate 20 23.0 17.0 31.2  20 14.8 7.5 29.3 
  High Polyphenol 20 13.4 6.7 27.0  20 11.2 7.0 17.8 
  Low Polyphenol 21 17.5 9.1 33.9  21 10.3 4.5 23.7 
 Relaxed Dark Chocolate 20 15.2 10.9 21.1  20 13.7 7.2 26.1 
  High Polyphenol 20 11.7 6.0 22.9  20 11.5 7.9 16.7 
  Low Polyphenol 21 14.0 7.4 26.3  21 10.1 4.5 22.7 
 Strong Dark Chocolate 20 17.9 12.0 26.9  19 23.0 15.9 33.3 
  High Polyphenol 20 14.6 9.0 23.8  20 12.0 7.8 18.6 
  Low Polyphenol 20 22.9 16.4 32.0  19 13.5 8.4 21.6 
 Tranquil Dark Chocolate 20 17.7 12.4 25.1  19 21.7 15.1 31.3 
  High Polyphenol 20 11.2 7.7 16.5  20 11.7 7.8 17.4 
  Low Polyphenol 20 19.6 13.7 28.0  19 16.7 11.9 23.6 
 Well-coordinated Dark Chocolate 20 14.5 10.1 20.8  19 18.7 12.8 27.4 
  High Polyphenol 20 12.6 8.0 19.9  20 9.8 6.5 14.7 
  Low Polyphenol 20 12.4 9.0 17.2  19 10.6 6.8 16.6 
 Witted Dark Chocolate 20 22.7 16.3 31.7  20 20.2 10.2 40.3 
  High Polyphenol 20 14.2 6.8 29.7  20 14.1 8.8 22.8 
  Low Polyphenol 21 20.8 10.8 40.3  21 12.0 5.2 27.9 
 Samn-Perelli 
questionnaire score 
Dark Chocolate 20 13.8 6.0 20.0  20 12.4 0.0 18.0 
 High Polyphenol 20 13.3 6.0 20.0  20 12.0 2.0 20.0 
 Low Polyphenol 20 12.6 2.0 18.0  19 13.7 7.0 17.0 
 Stanford sleepiness 
scale score 
Dark Chocolate 20 1.8 1.0 3.0  19 2.1 1.0 6.0 
 High Polyphenol 18 1.8 1.0 3.0  20 2.3 1.0 5.0 
  Low Polyphenol 20 1.8 1.0 3.0  19 1.8 1.0 3.0 
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6.4	  –	  Acute	  Feeding	  Effects	  of	  Chocolate	  	  
6.4.1	  -­‐	  Acute	  Consumption	  of	  Chocolate	  
6.4.1.1	  -­‐	  Endothelial	  function	  	  
6.4.1.1.1	  -­‐	  Reactive	  hyperaemia	  index	  
Reactive Hyperaemia Index (RHI) also defined as Reactive Hyperaemia-Peripheral 
Artery Tonometry (RH-PAT) was measured at visits one (V1) and four (V4), in each 
case, both before the consumption of 40g of chocolate and 180minutes later.  
As a whole cohort, an improvement of endothelial function prior at V1 following eating 
40g of chocolate was apparent (1.855±0.510 compared to 2.146±0.585 3 hours later, 
p=0.007) with the trend repeated at V4 at the end of the 12-week period of 20g of 
chocolate daily (1.906±0.510 compared to 2.092±0.468 3 hours later, p=0.060), but at 
visit four this trend did not reach significance (n=47). No difference was seen in arterial 
stiffness as measured by augmentation index. 
The ANCOVA model did not show any significant effects of time on endothelial 
function, although the milk chocolate did show the lowest changes in RH-PAT (table 
6.4.1.1.1). 
Table 6.4.1.1.1: Treatment contrast estimates for RH-PAT on the robust ANCOVA 
 Est imate  Lower  Upper  p -va lue  
Mi lk  Vs .  
Contro l  
-0 .15  -0 .62  0 .31  0 .5166  
Milk  Vs .  Dark  -0 .21  -0 .64  0 .23  0 .3509  
	  
6.4.2.1	  -­‐	  Glucose	  
Glucose measurements (mmol/l) were taken at visit 4 on four occasions (0, 60, 120 and 180 
minutes). These are summarized in Table 6.4.2.1.1. Figure 6.4.2.1.1, shows the profiles of the 
measurements for each participant. On average, the highest glucose concentrations were 
observed with milk chocolate. The peak concentrations appeared at 60 minutes on average. 
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Table 6.4.1.2.1: Summary log transformed statistics for insulin at visit 4 
 Treatment Geometric mean 95% Confidence Intervals 
0 mins. 
 Dark Chocolate 6.76 6.20-7.40 
 High Polyphenol 7.59 6.75-8.50 
 Low Polyphenol 6.72 6.03-7.50 
60 mins. 
 Dark Chocolate 7.59 7.02-8.20 
 High Polyphenol 8.87 7.92-9.90 
 Low Polyphenol 7.74 6.96-8.60 
120 mins. 
 Dark Chocolate 6.77 6.23-7.40 
 High Polyphenol 8.00 7.04-9.10 
 Low Polyphenol 6.99 6.31-7.80 
180 mins. 
 Dark Chocolate 6.26 5.84-6.70 
 High Polyphenol 6.59 5.79-7.50 
 Low Polyphenol 5.94 5.39-6.50 
	  
Figure 6.4.1.2.1: Individual glucose over time at visit 4 following feeding 40g of chocolate at 0 
minutes. High polyphenol chocolate refers to the milk chocolate, which contains 20mg 
epicatechin; dark chocolate also contained 20mg epicatechin. The low polyphenol chocolate 
contained 1mg epicatechin. 	  
Table 6.4.1.2.2: Estimated treatment ratio differences in terms of plasma glucose over the course 
of the 180 minutes following consuming 40g chocolate at visit 4. 
 Es t imate  Lower  Upper  p -va lue  
Mi lk  Vs .  Contro l  1 .08  0 .99  1 .18  0 .0795  
Milk  Vs .  Dark  1 .07  0 .98  1 .17  0 .1096  
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A linear mixed model with treatment, linear and quadratic effects of time as fixed effects was used 
while adjusting for age and glucose measurements at baseline. A random subject intercept was also 
included in the model to account for the variability at time zero. Glucose measurements were log-
transformed to correct for the distributional assumptions. The estimated overall treatment ratios are 
given in Table 6.4.1.2.2. Overall, no statistically significant differences were observed between the 
treatment comparisons of interest. The 95% confidence interval for the estimated ratio between 
the glucose levels under milk chocolate and control chocolate was [-1.1%, 18%] while that 
between milk chocolate and dark chocolate was [-2%, 17%]. 
6.4.1.3	  -­‐	  Insulin	  	  
At visit one and four, insulin (µU/l) measurements were taken on four occasions (0, 60, 120 and 180 
minutes), at the same time as the glucose measurements. These are summarized in table 
5.4.1.2.1. All the treatment groups exhibited an increase in insulin levels, which peaked after 60 
minutes before decreasing gradually. The rates of change in insulin levels over time seemed to be 
similar in the three treatment groups. A linear mixed model with treatment, linear and 
quadratic effect of time as fixed effects while adjusting for age and glucose measurements at 
baseline was used. 
Table 6.4.1.3.1: Summary log transformed statistics for insulin at visit 4 
 Treatment Geometric mean 95% Confidence Intervals 
0 mins. 
 Dark Chocolate 9.18 5.94-14.20 
 High Polyphenol 7.73 5.25-11.40 
 Low Polyphenol 7.43 5.15-10.70 
60 mins. 
 Dark Chocolate 23.42 14.90-36.80 
 High Polyphenol 19.35 11.51-32.50 
 Low Polyphenol 17.87 11.38-28.10 
120 mins. 
 Dark Chocolate 18.12 13.56-24.20 
 High Polyphenol 15.00 9.56-23.50 
 Low Polyphenol 11.02 6.61-18.40 
180 mins. 
 Dark Chocolate 9.67 6.45-14.50 
 High Polyphenol 11.37 8.03-16.10 
 Low Polyphenol 8.21 5.23-12.90 
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A random subject intercept was also included in the model to account for the variability at time 
zero. A natural log transformation was applied to the insulin measurements to correct for the 
distributional assumptions. The estimated overall treatment ratios in terms of insulin levels are given 
in Table 6.4.1.3.2. Overall, no statistically significant differences were observed between the 
treatment groups. 
Table 6.4.1.3.2: Treatment contrast estimates for insulin at visit 4 on the robust ANCOVA 
 Est imate  Lower  Upper  p -va lue  
Mi lk  Vs .  Contro l  0 .98  0 .66  1 .46  0 .9243  
Milk  Vs .  Dark  0 .92  0 .56  1 .20  0 .3134  
6.4.1.4	  -­‐	  Triglycerides	  
A linear mixed model with treat and linear effect of time as fixed effects of time (hours) while 
adjusting for age and triglyceride levels at visit one was applied to the log-transformed triglyceride 
levels at visit four. A random subject intercept and slope was also included in the model. The 
estimated overall treatment ratios are given in Table 6.4.1.4.1. No significant differences were 
seen between the treatments. 
Table 6.4.1.4.1: Treatment contrast estimates for triglycerides on the robust ANCOVA 
 Est imate  Lower  Upper  p -va lue  
Mi lk  Vs .  Contro l  0 .91  0 .69  1 .21  0 .5276  
Milk  Vs .  Dark  0 .90  0 .68  1 .19  0 .4530  
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6.5	  –	  Discussion	  
This is the first report using a pragmatic study design of the effect of chocolate 
consumption (as defined by EU regulations (European Union, 2004), including milk 
chocolate, given for a period of longer than two months, on a range of  biomarkers in  
individuals with T2DM. The chocolate consumption in this study was approximately 
compatible with nutritional guidelines in terms of sugar and fat.  
The data provide evidence that milk chocolate can reduce inflammatory markers with a 
significant reduction in hs-CRP (p=0.0028). This effect did not appear to be linked to 
insulin mediated mechanism since HOMA did not significantly improve (although a 
trend was observed p=0.0754 ITT analysis, and p=0.0518 PP analysis). 
Curtis et al. (2012) using a cohort females alone with medicated T2DM, demonstrated 
modest changes in lipid parameters, followed by improvements in cardiovascular risk as 
estimated using the UKPDS risk engine. Curtis et al. (2012) employed a longer 
intervention period of 12 months, compared to the 12 weeks in the present study and the 
‘active’ chocolate also contained 100mg of isoflavones, and therefore not comparable 
with the study here. However, the present study confirms that normal (in terms of sugar) 
chocolate, although in this study did not demonstrate a beneficial effect in individuals 
with T2DM, in accord with the other experimental work presented in this thesis showed 
no negative effects on body weight or glycaemia. This has not previously been 
demonstrated other than in my previous published work (Mellor et al., 2010b; 2012). 
Limitations of this data are the small sample size and the potential confounding of 
apparent acute phase responses associated with frequent upper respiratory tract 
infections seen during the study. This may have resulted in the dark chocolate not 
showing any effect on insulin resistance or on lipid profiles; contrary to other reports in 
participants with T2DM following chocolate consumption (Curtis et al., 2012; Mellor et 
al., 2010b).  
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A key strength of this work is that it is one of very few studies since that of Fraga et al. 
(2005), to investigate the health effects of milk chocolate, and the first in a population 
with the significant cardiovascular risk of T2DM. The lack of studies using milk 
chocolate formulations may be due to the influence of Serafini et al. (2003; 1996), who 
suggested that milk had an inhibitory effect upon flavon-3-ol metabolism; a position 
since widely disputed as described in section 1.3.5.1. This is important, since products 
based upon milk chocolate are more palatable to consumers in the UK, potentially 
extending benefits of chocolate to everyone who enjoys the product. 
The apparent universal effect of chocolate on insulin resistance is of interest since it 
mainly occurs through a reduction in fasting insulin levels, although this is less clear 
when an ANCOVA model is applied. Hooper et al. (2012) in a meta-analysis reported 
that flavanol rich chocolate reduced HOMA significantly by 0.67. In the present study 
there was no effect of dark chocolate on HOMA, though in the per protocol analysis 
there was a trend towards a reduction in insulin resistance with milk chocolate 
(p=0.0518). The data suggest that regular consumption of chocolate for twelve weeks 
has no negative effects on the health of individuals with T2DM and may have the 
potential to reduce insulin resistance.  
It is possible that the lack of any clear outcomes in respect to insulin resistance, may be 
a reflection of the relatively low epicatechin and flavanol levels, since the chocolates 
contained significantly less than the 200mg cocoa flavanols recently been accepted by 
EFSA  (2012a) as having health benefits on endothelial function. This observation may 
explain the lack of a clear effect on insulin resistance and endothelial function in this 
study. It is possible that any positive effects seen, e.g. in terms of the general 
improvement in HOMA, could be attributed to a placebo effect.  
This is the first study to provide evidence of an ability of milk chocolate to reduce 
inflammation as measured by hs-C-Reactive Protein following 12 weeks of 
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supplementation. This effect was not seen with dark chocolate with the same 
epicatechin content, and it is possible this effect might not be associated with cocoa 
content but reflect the effects of the milk content. Further work with higher flavanol 
content milk chocolate is required to explore whether a synergistic effect of milk with 
cocoa flavanol compounds exists. However the present results may be a reflection of the 
adverse event rate (upper respiratory tract infections) and represent type 1 error.  
The findings of this study indicate that modest reductions in insulin resistance and 
cardiovascular risk across all groups are apparent following 12 weeks of chocolate 
supplementation with no evidence of harm. More research is required to explore if this 
effect of chocolate is independent of the flavanols, as proposed by Mursu et al. (2004) 
or due to a placebo effect. Supplementation with milk chocolate enriched with flavanols 
showed trends towards additional effects beyond those seen for the control or dark 
chocolate; there was a trend seen towards an improvement for HOMA for milk 
chocolate compared to dark chocolate (p=0.0754) in the ITT analysis. This trend was 
further supported by the PP analysis (p=0.0518).  
This study also highlighted the potential challenges of working with an industrial 
sponsor, as this set limits with respect to the products used and the type of analysis 
conducted. Although, this was necessary to allow the work to take place, it could have 
resulted in the findings of the study not being as fully explored as there was a tendency 
for a robust but cautious approach to the analysis of data. Also unlike the initial work of 
Taubert et al. (2003) and Grassi et al. (2005a; 2005b; 2008) it attempted to use a smaller 
chocolate bar with a lower dose of polyphenols as this was considered to be 
commercially and poltically more acceptable as a health message than the studies which 
used 100g per day, which ultimately could have accounted for the lack of positive 
findings. 
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6.5.1	  -­‐	  Conclusion	  
The dose of epicatechin and hence flavanols used in this study was considerably lower 
than that accepted by EFSA to improve endothelial function and lower than in my 
previous work (Mellor et al., 2010b; 2012). This may explain the lack of a clear effect 
of the flavanol rich chocolate (both milk and dark formulations) in the present study 
although there was a trend towards a benefit of milk chocolate enriched with flavanols 
and no evidence of harm. The work highlights the challenge of providing an efficacious 
dose of epicatechins and flavanols in a product palatable to the consumer (Ried et al., 
2010a), but not in the form of a calorific formulation as in the early studies of the health 
benefits of chocolate (Taubert et al., 2003; Grassi et al., 2005a; 2005b; 2008). Whilst at 
the same time suggesting that there may be potential for benefit of milk chocolate 
enriched with flavanols for individuals with T2DM, and at the very least it does not 
cause harm. 
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Chapter	  Seven:	  	  General	  Discussion	  and	  Conclusions	  
7.1	  –	  Primary	  Findings	  of	  this	  Thesis	  
Nutritional	   management	   is	   viewed	   as	   a	   key	   intervention	   in	   the	   management	   and	  prevention	  of	  type 2 diabetes mellitus (T2DM) (Dyson, et al., 2011; Franz, et al., 2008). 
Over the past decade there has increasingly been a demand for an evidence-based 
approach to healthcare, including dietary approaches in diabetes. In the UK, this has 
been acknowledged by the Diabetes UK Nutrition Working Group (of which I was a 
member) in their most recent nutrition guidelines (Dyson, et al., 2011). Dyson et al. 
(2011) used a rating system based on the hierarchy of evidence presented in figures 
1.4.1 and 2.2.1.1, using the scale of Petrie, Grimshaw and Bryson (1995). This scale 
gave an ‘A’ rating for guidelines which were based on either data from meta-analyses of 
randomised controlled trials (RCTs) or at least one RCT (Petrie, Grimshaw & Bryson, 
1995), down to a ‘D’ rating for guidance based on expert or consensus opinion. For the 
16 recommendations for T2DM and management of cardiovascular risk, only half 
claimed to be linked to the strongest experimental evidence and given an ‘A’ grade. In 
the 1990s the dietetic profession considered that chocolate should be avoided or if 
consumed, limited to a post-meal snack to moderate the glycaemic response. However, 
the data presented in this thesis provides potentially ‘A’ grade evidence for health 
benefits of flavanol rich chocolate for individuals with T2DM. It is suggested that the 
data presented in this thesis are based on more scientifically sound data (albeit limited 
by the study population size) of the published nutritional recommendations for T2DM 
(Dyson et al., 2011). 
7.1.1	  –	  Original	  Nature	  of	  Work	  
This thesis represents the first systematic study of the effects of chocolate containing 
cocoa polyphenols in individuals with T2DM. The inspiration for this work came from 
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the comments of Cesar Fraga (2005), who posed the question ‘cocoa, diabetes and 
hypertension: should we eat more chocolate?’ a question suggested without the support 
of any experimental data on the effects of cocoa or chocolate in diabetes! This thesis 
represents the sum total of the published data investigating the effects of chocolate (not 
as cocoa or without additional isoflavones) in individuals with T2DM to the end of 2012. 
7.1.2	  -­‐	  Chocolate	  or	  Cocoa	  
The exploratory review with meta-analysis reported in Chapter Three explored the 
beneficial effects of chocolate identified in the literature review of Chapter One, when 
compared to cocoa supplementation as the optimal matrix for delivery of epicatechins. It 
was found that chocolate had greater beneficial effects upon blood pressure and fasting 
glucose than cocoa. The positive effects of chocolate and cocoa supplementation with 
respect to blood pressure and endothelial function were in accordance with other recent 
meta-analyses (Hooper, et al., 2012; Shrime et al., 2011). However, these findings need 
to be treated with caution due to the limitations of the search strategy and statistical 
methodology. 
7.1.3	  –	  Beneficial	  Effects	  in	  Continuous	  and	  Acute	  Feeding	  of	  Chocolate	  
The work presented in Chapters Four and Five, provide evidence for the beneficial 
effects of chocolate consumption in reducing markers of cardiovascular risk. The proof 
of concept work (Chapter Four) demonstrated an improvement in HDL cholesterol 
(5.9% or 0.07mmol/l, p =0.04) and HDL cholesterol: total cholesterol ratio (-9.8 % or    
-0.3, p =0.03) following eight weeks of consuming 45g of high polyphenol (flavanols) 
chocolate containing 55.3mg of epicatechins and 783mg of total flavanols. These 
beneficial effects of continued consumption over a two-month period extend the work 
of Mursu et al. (2004), on healthy individuals to those with T2DM; a population group 
with greater cardiovascular risk than used in their study.  
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In the second clinical trial (Chapter Five), a single bar of chocolate containing 472.5mg 
of flavanols administered 60 minutes prior to a 75g oral glucose load, ameliorated the 
increase in oxidative stress (p = 0.02) and endothelial dysfunction (p =0.01) which had 
been reported following acute transient hyperglycaemia (Ceriello et al., 1998; 2008; 
Wright, Scism-Bacon, & Glass, 2006). These data extend the previous work of Balzer et 
al. (2008), in terms of demonstrating the beneficial effects on endothelial function 
following a significant carbohydrate load and in the ability to link an improvement in 
endothelial function to a reduction in urinary 15-F2t-isoprostane (oxidative stress).  
The work in Chapter Five was accepted for publication at the same time as a similar 
study by Grassi et al. (2012), but went further as this group who fed a larger weight 
(100g) of chocolate for three days, limited their study population to 12 healthy young 
adults. Grassi et al. (2012) also undertook the assessments from a fasting baseline, so no 
chocolate was given immediately before the 75g Oral Glucose Tolerance Test Solution. 
As the work presented in Chapter Five, was in subjects with T2DM, my data 
demonstrated a maintained effect of chocolate flavanols at a greater degree of 
hyperglycaemia in subjects at a greater cardiovascular risk and hence endothelial 
dysfunction. The findings of both pieces of work imply that further investigation of how 
dietary factors, including cocoa flavanols might modulate postprandial metabolism 
stress is required. 
7.1.4	  –	  Dose	  Required	  for	  Effect	  and	  Potential	  Health	  Claim	  for	  the	  Role	  
of	  Chocolate	  in	  T2DM?	  
Chapter Six investigated whether the beneficial effects of chocolate flavanols observed 
with dark chocolate formulations extended to milk chocolate, but failed to show any 
clear beneficial effects, either with dark chocolate containing 19mg epicatechin, or milk 
chocolate containing 19mg epicatechins. The lack of efficacy seen in this study may be 
due to the relatively low levels of epicatechins, although Taubert et al. (2007) 
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demonstrated a significant reduction in blood pressure in untreated pre-hypertensive 
elderly participants with a chocolate containing only 5.1mg of epicatechins. It is 
plausible that having T2DM or taking medication including antihypertensive agents 
may require a higher dose of epicatechins to demonstrate efficacy. 
With regard to the beneficial effects of cocoa and chocolate, the Dietetic products, 
Nutrition and Allergies (NDA) Committee of the European Food Safety Agency 
(EFSA, 2012a) provided a positive opinion for an Article 13(5) claim by Barry 
Callebaut BV. Potentially, this could mean chocolate being labelled with a health claim. 
This may present set precedence, for a future Article 14 claim linked to modification of 
disease risk associated with T2DM using the findings of this thesis. Such a claim would 
require further work including dose response data from people with T2DM. Data from 
Chapter Six suggested that 60mg polyphenols per daily dose (estimated from the 19mg 
of epicatechin) was insufficient to show a significant effect in individuals with T2DM. 
This dose was also far less than the 783mg (55.4mg of epicatechins) and 472.5mg of 
total polyphenols provided as supplements in Chapters Four and Five, which 
demonstrated positive outcomes.  
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7.2	  	  -­‐	  Similarities	  Between	  Studies	  
Overall only three participants across the three studies (which were made up of 83 
participants and totalled 17.56 participant years of daily chocolate intake) withdrew; 
two because of being unable to consume the chocolate or feeling weak and a third on 
the advice of their general practitioner.  
7.2.1	  -­‐	  Chocolate	  is	  Not	  Harmful	  in	  Type	  2	  Diabetes	  
In the final study there were a number of adverse events, all of which were expected in 
view of the population. The most common of these were upper respiratory tract 
infections and gastroenteritis. In terms of concomitant medication, over 80% of 
participants reported being given the influenza vaccine and over 50% had the swine flu 
vaccine due to the time when the study was undertaken (2009-10). 
One participant following having had their diabetes medication increased by their 
general practitioner was advised that the study chocolate was having a detrimental 
effect on their diabetes. This was despite a 0.2% decrease in their HbA1C whilst they 
had been consuming chocolate and was withdrawn. This highlights a common 
perception within both the general population and healthcare communities that diabetes 
is a condition of ‘sugar’ as discussed in Chapter One, and the work Peters et al. (1990). 
They suggested that isocalorific substitution of potato with chocolate cake results in no 
significant variation in postprandial glycaemia. This has been extrapolated and 
interpreted as meaning that high sugar foods should only be consumed as part of a 
starch rich meal. This ignores subsequent work that has defined the concept of 
glycaemic index and has been extended to include the idea of a glycaemic load. 
The combination of the concepts of carbohydrate ‘quality’ as defined by rate of 
absorption and uptake and ‘quantity’ means that it is possible to predict the glycaemic 
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response of a food portion consumed, and in the present work, there were no adverse 
effects on acute glycaemia or longer term assessments in the form of HbA1c. 
7.2.2	  -­‐	  Weight	  	  
Weight was deemed a key outcome measure, both in the proof of concept study 
(Chapter Four) and the parallel study (Chapter Six) which involved at least three months 
of eating chocolate on a daily basis. Both studies had at least 95% compliance. For the 
proof of concept study, that meant that an extra 240 kcal of energy per day, could, if not 
compensated for in terms of change in diet or physical activity, result in a 3.84kg weight 
gain the five months of the study. For the final parallel study participants were asked to 
consume an additional 110 kcal per day, which gave a potential risk of participants 
gaining 1.32kg over the 12 weeks of the study. 
The studies presented in Chapters Four and Six did not demonstrate any weight gain, in 
accordance with the data of O’Neil, Fulgoni and Nicklas (2011a; 2011b) and the meta-
analysis data presented in Chapter Three (Figure: 3.3.7.1). Notably, there was a 
significant reduction in weight between the screening visit and the first administration 
of chocolate at visit one, which appeared to be a type of ‘Hawthorne effect’, with the 
reduction in weight appearing to be an effect of mere participation in the study. This 
was despite participants being asked not to make any changes to their eating or other 
lifestyle behaviours, apart from abstaining from chocolate or cocoa, which according to 
their dietary recalls resulted in no difference in energy or macronutrient intake.  
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7.3	  	  -­‐	  Limitations	  	  
There	  were	  a	  number	  of	   critical	   limitations	   to	   the	   exploratory	   review	  and	  meta-­‐analysis	  which	  need	   to	  be	   revised	   should	   this	  work	  be	   further	  developed	  with	   a	  view	  to	  publish.	  The	  search	  strategy	  for	  the	  exploratory	  review	  was	  limited,	  in	  its	  completeness	   and	   ability	   to	   restrict	   to	   randomised	   studies,	   in	   part	   this	   was	  corrected	   by	   a	   hand	   search	   and	   review	   of	   clinical	   trial	   registries,	   but	   any	   future	  study	   should	   address	   its	   literature	   searching	   strategy.	   This	   should	   include	   the	  correct	  use	  of	   indexing	  to	  reduce	  missed	  studies.	  The	  search	  strategy	  would	  then	  be	   developed	   using	   Boolean	   operators,	   and	   then	   test	   words	   and	   synonyms	  (including	  truncation	  e.g.	  diabet*	  or	  $	  depending	  on	  the	  database).	  Finally	  limiters	  would	  be	  introduced	  to	  refine	  the	  search	  to	  randomised	  clinical	  trials	   in	  humans.	  The	  search	  strategy	  would	  be	  trialled	  and	  reviewed	  to	  see	  if	  it	  could	  be	  enhanced.	  The	   meta-­‐analysis	   was	   limited	   by	   the	   data	   selected,	   only	   using	   published	  numerical	  data	  and	  not	  using	  graphical	  data	  and	  contacting	  authors.	  Further	  work	  should	  attempt	  to	  include	  this	  data	  and	  contact	  authors	  to	  verify	  aspects	  of	  study	  design	  and	  missing	  data.	  Where	   this	   is	  not	  possible,	   the	   estimates	  of	   variance	  of	  mean	  difference	  could	  be	  refined	  to	  include	  aspects	  of	  the	  paired	  nature	  of	  the	  data	  e.g.	  correlations	  to	  allow	  for	  the	  use	  of	  the	  sum	  of	  variance	  law	  2.	  The	   lack	   of	  measurements	   of	   nitric	   oxide	  metabolites	   is	   one	   that	   future	   studies	  should	   consider.	   This	  would	  help	   to	   try	   and	   identify	   the	  potential	  mechanism	  of	  the	   chocolate,	  which	   although	   it	   has	   been	  widely	   described	   in	   healthy	   volunteer	  studies,	  has	  not	  been	  assessed in T2DM. This has made it necessary to assume that the 
mechanism seen in healthy individuals also occurs in T2DM. This would be important 
in studies exploring the effects of milk chocolate compared to dark chocolate, as there 
may be subtle differences in time of absorption (Mullen et al., 2009). 
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The formulation is a potential issue; the funding of the studies meant that although one 
corporation provided the chocolate for two studies, in fact all three studies used 
different chocolates. This also meant that as found in Chapter Three, and commented 
upon by Cooper et al. (2008), there was a lack of consistency of chocolate formulation 
and assessment of polyphenol, flavanols or epicatechin content. Although ideal, it is 
unlikely due to commercial and intellectual property interests that a common study 
formulation of chocolate, with a known nutritional composition in terms of energy, 
macronutrients and flavanols will be made available. This is perhaps the only way to 
define precisely the physiological effects of chocolate and its components within a 
multi-centre randomised trial. However, although a criticism of having to use different 
chocolates in each study, it is also a potential strength that there were positive findings 
seen in the same population group with different formulations of chocolate. This might 
suggest a greater degree of robustness and generalizability of the findings to clinical 
practice.  
Despite these limitations a number of reviews have complimented the quality of the 
study design (Shrime et al., 2011) and conduct of the study reported in Chapter One and 
included the data in reviews and meta-analyses (Ellinger et al., 2012; Hooper et al., 
2012; Shrime, et al., 2011; Tokede, Gaziano, & Djoussé, 2011)  
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7.4	  -­‐	  Implications	  
Chocolate appears to be the most biologically effective way of delivering cocoa 
flavanols and potentially polyphenols, although its energy content needs to be 
considered before it can be widely recommended as part of a healthy diet by nutrition 
professionals. Further work needs to be undertaken to assess the most effective 
chocolate formulations for the delivery of flavanols. The dose of flavanols appears to be 
critical; a total polyphenol content of 500mg or 55mg of epicatechins per day were 
shown in this thesis to produce positive benefits for individuals with T2DM.  
The data presented in this thesis suggest that beneficial effects may be seen across a 
range of cardiovascular risk factors, including individuals receiving medication. This 
may imply that the effects on endothelial function and HDL cholesterol may be at least 
in addition to the effects of pharmaceutical agents and could potentially be synergistic. 
This avenue would benefit from further investigation both in in vitro and in vivo studies.  
It is likely that many individuals with T2DM would benefit from the consumption of 
flavanol rich chocolate. The prior belief held by many health professionals was that the 
consumption of chocolate is harmful in terms of weight or glycaemic control and should 
therefore be excluded from the diet of individuals with T2DM. This belief has failed to 
stand up to the scrutiny of the RCTs presented in this thesis. 
The findings of this thesis should be considered, interpreted and then if meeting the 
critical scrutiny requirements of the profession, added to nutritional guidelines. If 
accepted, such recommendation would probably be included with the caution and 
caveats stated above, to avoid excessive consumption of chocolate. Then subsequent 
research, as part of clinical practice, would be required to assess the best way of 
incorporating flavanol rich chocolate in an individual’s dietetic care plan.  
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7.5	  -­‐	  Directions	  for	  Future	  Work	  
The evidence from previously published epidemiological and clinical studies of healthy 
participants is that cocoa flavanols can have health benefits. Potentially, the key 
question is what is the best way to consume these health maintaining and potentially 
disease modifying compounds? Thus, leading to the question what formulation is 
required to achieve the optimal biological activity of cocoa flavanols? The requirement 
is for a palatable product, which is not too bitter nor too energy dense or high in 
carbohydrates, especially sugar (Faridi et al., 2008), with the caveat that too little sugar 
may reduce bioavailability and uptake in the gut.  
The next steps therefore is to: 
1. Develop formulations which are palatable and have the optimal sugar 
and energy content either as cocoa drinks or chocolate; 
2. Undertake pharmacokinetic and pharmacodynamics studies to assess 
bioavailability; 
3. Undertake further clinical trials to assess the optimal formulation or 
matrix for the delivery and effect of cocoa flavanols. 
Considering chocolate is a food containing potentially multiple biologically active 
compounds, it is possible that the epicatechins and flavanols are not the only ‘actives’, 
which are responsible for the biological effects reported in this thesis. For example, 
there is potential for the peptides in chocolate to have beneficial biological effects, 
especially those found in milk chocolate (Erdmann, Cheung, & Schröder, 2008). A 
further possibility is that 100g dark chocolate can provide 115mg magnesium, over a 
third of the Reference Nutrient Intake (Department of Health, 1991), which a recent 
meta-analysis has linked to reducing the risk of developing diabetes (Dong, Xun, He, & 
Qin, 2011). Finally, the manufacturing of the chocolate starting with the agricultural 
origin of the cocoa (Caligiani et al., 2007) and how its processed (Jolić et al., 2011) 
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could also be significant since Barry Callebaut BV, claim to have increased the flavanol 
content of the ActicoaTM used in Chapter Five (Bernaert, 2007) by altering how it is 
processed.  
Future work should therefore attempt to clarify what the active compounds are, and if a 
number of biological relevant compounds are identified, whether these compounds have 
synergistic effects. These should then be investigated in combination with common 
medications (both in vitro and in vivo), as knowledge of drug-nutrient interactions is 
very limited (Hu, 2007; Boullata & Hudson, 2012; Heuberger, 2012). This is of vital 
importance if the initial findings of this work are to be extended to the wider population 
of people with diabetes and so to avoid the risk of adverse interactions with medication.  
Learning	  Points	  from	  thesis:	  
If type of work were to be revisited or undertaken again, the following should be 
considered during the planning phases and conduct: 
1. For the meta-analysis, work as part of a team which includes an experienced 
reviewer. Insure at all points, search strategy, study selection, data extraction 
and data analysis is initially for the first four undertaken separately prior to 
cross-checking and then the data analysis checked for accuracy. To broaden the 
available data, enough time and finance for this would be required along with 
the contacting of authors to minimise the need to undertake estimate of mean 
change and variance of change. This could include use of different approaches to 
estimating the variance of the change, and using sensitivity analysis to assess the 
effects. 
2. It is necessary to fund the clinical trials, this means working with industry. A 
carefully designed contract needs to be drawn up, otherwise there is a potential 
risk to the researcher (including potentially their degree if they are a student). 
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This should include an agreement regarding allowing the researcher to 
independently analyse their data. 
7.6	  –	  Key	  Questions	  	  
Following the work presented in this thesis three key questions appear to still require 
investigational work. These being: 
1. What is the optimal dose of cocoa polyphenols needed to demonstrate improved 
endothelial function in T2DM? 
Aim: To define the optimal polyphenol/ epicatechin dose in a chocolate bar for 
individuals with T2DM with respect to improved endothelial function. 
 Although it is plausible that the health effects resulting from supplementation 
with cocoa polyphenols are not solely due to the effect of epicatechins, this is 
the molecule which has been identified post ingestion and linked to beneficial 
effects in vivo and in vitro, it is logical that this should be level assessed in 
chocolates developed to provide potential health benefits to individuals with 
T2DM. The work presented in Chapter Six, suggested about 20mg epicatechin 
was not enough to produce an effect, where as the 55mg used in Chapter Four 
appeared to have demonstrated beneficial effects. 
This work would require three phases;  
I. Product development, to develop a 15-20g chocolate bar 
containing approximately 100kcal and less than 10g of sugar 
containing <2mg, 20mg, 40mg, 60mg and 80mg of epicatechin. 
These will be matched for macronutrients, taste and appearance. 
II. Taste test, using the approach reported in Chapter Five. 
III. A clinical trial would then be undertaken in a group of medically 
stable individuals with T2DM using a crossover design. The 
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work presented in Chapter Five and Balzer et al. (2008) suggests 
a sample size of 10 should be adequate. The work of Grassi et al., 
(2012) and the data in this thesis suggest that both acute and three 
day feeding of chocolate can improve endothelial function.  
Following screening individuals and baseline assessment of 
endothelial function, will be randomised to one of the five 
chocolates for three days, then after three days, endothelial 
function will be reassessed. Following one weeks wash out, 
individuals will return for baseline assessment (this will allow a 
true assessment of change and more robust analysis of the 
crossover study), this will be followed by three days of chocolate 
and reassessment of endothelial function. This will be repeated 
until all the chocolates had been tested. As there are five arms, 
around 20 individuals with T2DM would need to be recruited to 
allow for group out and concurrent illnesses that could act as a 
source of confounding. 
 
2. Can supplementation with cocoa polyphenols lead to drug nutrient interactions? 
Aim: To investigate the potential of cocoa polyphenols as inhibitors of CYP4a 
and its potential effect on drug pharmacokinetics. 
Although there is an increasing body of evidence to support a potential health 
benefit of cocoa and chocolate in healthy individuals, to the extent that the NDA 
of EFSA (2012) have approved at Article 13.5 health claim. The potential 
problem of supplementation with polyphenols, including those from chocolate is 
that they may lead to food/nutrient- drug interactions. These have been poorly 
defined. It has been suggested that epicatechins and other flavanols can act on 
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cytochrome P450, including CYP3A4 (Muto et al., 2001). These are responsible 
for the conjugation of many organic compounds including a wide range of 
drugs, thus any compounds altering the action of this and similar enzyme 
systems can affect circulating levels of drugs, their half-life and ultimately 
increase risk of side effects.  
The methodology would be based upon the methods initially described by Lown 
et al. (1997) and Bailey et al. (2003) who undertook pharmokinetic studies of 
felodipine. Although this work initially aimed to investigate the effects of 
alcohol upon drug metabolism, it discovered grapefruit juice, which contain a 
number of polyphenolic compounds including naringin and hesperidin increased 
the AUC for the drug. As such interactions can lead to serious complications 
including torsades des pointes affecting cardiac function, it is vital for the ageing 
populations in Westernised countries who are increasingly on chronic 
prescriptions of multiple drugs that we gain a better understanding of how 
polyphenols may interact with common drugs. 
In a group of 12 healthy mean would be used as part of an oral pharmacokinetic 
study of felodipine and dehydrofelopidine (its primary metabolite). In a 
crossover design, an initial study will be undertaken with felodipine and water 
followed by felodipine with 250ml of grapefruit juice. These will act as control 
and a demonstration of an interaction effect. This will be followed in a 
randomised designed study where 60mg of epicatechins/500mg of polyphenols 
(or a low polyphenol placebo) are given as a cocoa drink. A drink would be 
used, as solid chocolate may influence pharmacokinetics by altering gut transit 
time and not being comparable to the juice. This would then be with the 
alternative cocoa. This should provide evidence to suggest whether cocoa 
polyphenols can have an effect upon drug metabolism and thus, should the 
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supporting evidence for their efficacy in populations with chronic diseases be 
accepted, mean that advice to include cocoa polyphenols as part of their diet, 
along with their potential to interact with cardiovascular drugs. 
 
3. Which dietary interventions can demonstrate a reduction postprandial 
dysregulation, including endothelial dysfunction and oxidative stress? 
Aim: Can a protocol used to investigate the acute effects of high polyphenol 
chocolate in T2DM be adapted to assess the efficacy of other nutritional 
interventions on improving postprandial dysregulation. 
Following on from the findings of Chapter Five, it was demonstrated that cocoa 
polyphenols in the form of chocolate could ameliorate postprandial oxidative 
stress and endothelial dysfunction. This was shown to be both very acutely in 
this study, and following three days consumption of chocolate by healthy 
individuals  (Grassi et al., 2012).  
This protocol was based on the work of Ceriello et al., (1998; 2008) who 
demonstrated that varying plasma glucose could adversely affect oxidative stress 
and endothelial function. This is an area where a range of dietary interventions 
can be further investigated. This forms the basis for a number of proposals I am 
currently developing. These range from the effect of different macronutrient 
restrictions on postprandial metabolism to other dietary sources of polyphenols. 
The first step is to use a standard mixed meal test to investigate if the 
combination of macronutrients which Ceriello et al. (1998) demonstrated a 
metabolic disturbance, then following a crossover study design investigate if 
cocoa polyphenols can ameliorate these negative effects. 
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7.7	  -­‐	  Conclusion	  and	  Summary	  
The data presented in this thesis provides evidence to support the statement of Cesar 
Fraga (2005) suggesting a beneficial effect of chocolate in individuals with diabetes 
with the addition of two key findings. Firstly, that chocolate may provide a better 
formulation than cocoa and secondly, that the health benefits reported in healthy 
volunteers, can be demonstrated in individuals with T2DM. This aspect was further 
extended by the study reported in Chapter Five, where additional metabolic stress was 
induced using a 75g oral glucose load and the endothelial dysfunction and oxidative 
stress often seen in the postprandial state were successfully ameliorated by pre-feeding 
chocolate rich in flavanols. It was not possible to demonstrate an extension of these 
benefits to milk chocolate enriched with cocoa flavanols, highlighting the challenge to 
chocolatiers of producing a palatable chocolate with enough flavanols, but not too much 
fat and sugar, to have health benefits. It will also be important to overcome the 
widespread notion that chocolate is ‘naughty but nice’ when moderate amounts of 
chocolate are consumed as part of a sensible nutritional management plan for 
individuals with diabetes is clearly not harmful and may be beneficial.  
So, for dietitians working in clinical practice, the data means that advice regarding the 
consumption of chocolate by individuals with T2DM can now be balanced with an 
experimental evidence base. Too high an intake may lead to positive energy balance and 
worsening glycaemic control, whereas smaller amounts of flavanol rich chocolate 
(although hard to identify from shop bought brands) may have beneficial effects in 
reducing cardiovascular risk.  
To paraphrase Hippocrates, ‘let food of the Gods (Theobroma cacao) be thy medicine’, 
but only in moderation. 
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Appendix	  I	  –	  Search	  Terms	  and	  Strategy	  for	  Review	  and	  Meta-­‐
Analysis	  (Including	  Harvard	  style	  citations	  for	  papers	  used	  in	  
review).	  
	  
Medline (PubMed), EMBASE, Cochrane and WHO international trials database search 
strategy run to June 2012.  
1. Chocolate 
2. Cocoa 
3. Cacao 
4. Flavanols  
5. Randomised controlled trial OR RCT  
6. Cardiovascular disease OR diabetes OR hypertension OR blood pressure OR 
dyslidaemia OR cholesterol OR endothelial dysfunction OR oxidative stress OR 
inflammation 
7. 5 AND 1 OR 2 OR 3 OR epicatechin 
8. Controlled trial OR 5 AND 1 OR 2 OR 3 OR epicatechin 
9. Placebo AND 7 
10. 8 and Human NOT animal 
11. 10 and 6 
Studies were checked along with systematic reviews and meta-analysis published up 
until June 2012 to check for the completeness of the review 
The addition of the WHO international trials database was to screen for potential 
studies, which have reported a study design, which met the criteria for publication to 
search for early reports/ articles in press. 
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Full Search Strategy for Medline (Ovid) 
 
 
Note: For future systematic reviews, the limitation and logic of this search strategy need 
to be considered, including use of indexing and limiting terms (e.g. randomised 
controlled trials).  
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Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  111 – Refers to 
Exploratory 
Systematic 
Reviewrather 
than  
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic 
review registration number.  
Not done as 
part of chapter, 
referred to in 
thesis abstract 
– 13-14 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already 
known.  
111-120 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
Table 3.0: 112 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration information 
including registration number.  
Not done as 
part of thesis 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
121-122 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
123 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
123 and 
Appendix I 302-
303 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 
included in systematic review, and, if applicable, included in the meta-
analysis).  
123-124 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
123 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  
122 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data 
synthesis.  
122-124 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in 
means).  
125 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
125 
 
Page 1 of 2  
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.  
Appendices	  
	   303	  
 
 
 
 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-­‐statement.org.  
Page 2 of 2  
	  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may 
affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
124 
Additional analyses  16 Describe methods of additional analyses (e.g., 
sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
125 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for 
eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow 
diagram.  
126-129 
Study characteristics  18 For each study, present characteristics for which 
data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
130-134 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if 
available, any outcome level assessment (see item 
12).  
134-135 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
137-156 
Synthesis of results  21 Present results of each meta-analysis done, 
including confidence intervals and measures of 
consistency.  
137-156 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias 
across studies (see Item 15).  
134-135 
Additional analysis  23 Give results of additional analyses, if done (e.g., 
sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
137-156 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength 
of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, 
users, and policy makers).  
As part of the 
discussion 157-160 
Limitations  25 Discuss limitations at study and outcome level (e.g., 
risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
160 
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
161 
FUNDING   
Funding  27 Describe sources of funding for the systematic 
review and other support (e.g., supply of data); role 
of funders for the systematic review.  
None define, 
done as part of 
PhD studies  
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Harvard	  Style	  References	  supporting	  Table	  3.1.1	  
Lead Author Year Harvard Style Reference 
Allgrove 2011 (Allgrove et al., 2011) 
Almoosawi (overweight) 2012 (Almoosawi, Tsang, Ostertag, Fyfe, & Al-Dujaili, 2012) 
Almoosawi (obese) 2012 (Almoosawi et al., 2012) 
Baba 2007 (Baba et al., 2007) 
Balzer 2008 (Balzer et al., 2008) 
Davison, K. 2008 (Davison, Coates, Buckley, & Howe, 2008) 
Davison, K. 2010 (Davison et al., 2010) 
Davison, G. 2012 (Davison et al., 2012) 
Engler 2004 (Engler et al., 2004) 
Faridi  (Chocolate) 2008 (Faridi, Njike, Dutta, Ali, & Katz, 2008) 
Faridi (Cocoa) 2008 (Faridi et al., 2008) 
Farouque (Long-term) 2006 (Farouque et al., 2006) 
Farouque (acute) 2006 (Farouque et al., 2006) 
Flammer (acute) 2011 (Flammer et al., 2011) 
Flammer (Long-term) 2011 (Farouque et al., 2006) 
Flammer 2007 (Flammer et al., 2007) 
Fraga 2005 (Fraga et al., 2005) 
Grassi 2005a (Grassi et al., 2005a) 
Grassi 2005b (Grassi et al., 2005b) 
Grassi 2008 (Grassi et al., 2008) 
Heiss 2005 (Heiss et al., 2005) 
Monahan 2011 (Monahan et al., 2011) 
Muniyappa 2008 (Muniyappa et al., 2008) 
Murphy 2003 (Murphy et al., 2003) 
Mursu 2004 (Mursu et al., 2004) 
Njike 2011 (Njike et al., 2011) 
Sathyapalan 2010 (Sathyapalan et al.,  2010) 
Shiina 2009 (Shiina et al., 2009) 
Taubert 2003 (Taubert, Berkels, Roesen, & Klaus, 2003) 
Taubert 2007 (Taubert et al., 2007) 
Tzounis 2011 (Tzounis et al., 2011) 
Wang-Polagruto 2006 (Wang-Polagruto et al., 2006) 
Westphal 2011 (Westphal & Luley, 2011) 
Wiswedel 2004 (Wiswedel et al., 2004) 
  
Appendices	  
	   305	  
Appendix	  II–	  Dietary	  Advice	  Provided	  to	  Participants	  
Concomitant diet and treatment 
Permitted	  concomitant	  diets/treatments/medications	  
During	  the	  study	  participants	  will	  be	  asked	  to	  refrain	  from	  altering	  their	  intake	  of	  polyphenol	  rich	  foods	  including:	  
• Black	  or	  green	  tea	  
• Coffee	  
• Onions	  
• Apples,	  	  
• Cabbage	  
• Wine	  	  
• Cocoa	  products.	  
	  Just	  before	  and	  during	  the	  blood	  test	  and	  other	  investigations,	  participants	  will	  be	  asked	  to	  abstain	  from	  these	  foods	  all	  together.	  	  
Diet	  was	  monitored	  in	  each	  of	  the	  three	  studies,	  in	  Chapter	  Four,	  by	  the	  study	  dietitian	  and	  in	  Chapters	  Five	  and	  Six	  by	  dietary	  recall.	  A	  conscious	  decision	  was	  made,	  not	  to	  use	  a	  food	  diary	  as	  this	  might	  alter	  food	  intake	  and	  behaviour.	  	  
Unauthorized	  concomitant	  diets/treatments/medications	  
More	  than	  the	  dose	  of	  supplied	  chocolate	  	  
A	  very	  high	  polyphenol	  content	  in	  diet	  (from	  recall	  or	  dietetic	  assessment)	  
High	  dose	  antioxidant	  supplements	  including	  single	  and	  multivitamin	  preparations	  including	  A,C,E.	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Appendix	  III–	  Consort	  Checklist	  (Non-­‐pharmacological	  Trial)	  of	  
Study	  Reported	  in	  Chapter	  Six	  
 
Checklist of Items for Reporting Trials of Nonpharmacologic Treatments* 
Section Item Standard CONSORT 
Description 
Extension for 
Nonpharmacologic Trials 
Reported 
on Page 
No. 
Title and 
abstract† 
1 
 
How participants were 
allocated to interventions 
(e.g., “random allocation,” 
“randomized,” or “randomly 
assigned”) 
In the abstract, description of 
the experimental treatment, 
comparator, care providers, 
centers, and blinding status 
Included in 
abstract  
13-14 
Introduction     
Background 2 Scientific background and 
explanation of rationale 
 206-208 
Methods     
Participants† 3 Eligibility criteria for 
participants and the settings 
and locations where the data 
were collected 
When applicable, eligibility 
criteria for centers and those 
performing the interventions 
209 
Interventions† 4 Precise details of the 
interventions intended for 
each group and how and 
when they were actually 
administered 
Precise details of both the 
experimental treatment and 
comparator  
215-218 
 4A  Description of the different 
components of the 
interventions and, when 
applicable, descriptions of the 
procedure for tailoring the 
interventions to individual 
participants 
215-218 
 4B  Details of how the 
interventions were 
standardized 
210 
 4C  Details of how adherence of 
care providers with the 
protocol was assessed or 
enhanced 
213-215 
Objectives 5 Specific objectives and 
hypotheses 
 205, 212 
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Outcomes 6 Clearly defined primary and 
secondary outcome 
measures and, when 
applicable, any methods 
used to enhance the quality 
of measurements (e.g., 
multiple observations, 
training of assessors) 
 205 
Sample size† 7 How sample size was 
determined and, when 
applicable, explanation of any 
interim analyses and 
stopping rules 
When applicable, details of 
whether and how the 
clustering by care providers or 
centers was addressed 
220 
Randomization– 
sequence 
generation† 
8 Method used to generate the 
random allocation sequence, 
including details of any 
restriction (e.g., blocking, 
stratification) 
When applicable, how care 
providers were allocated to 
each trial group 
211, 222 
Allocation 
concealment 
9 Method used to implement 
the random allocation 
sequence (e.g., numbered 
containers or central 
telephone), clarifying whether 
the sequence was concealed 
until interventions were 
assigned 
 211 
Implementation 10 Who generated the allocation 
sequence, who enrolled 
participants, and who 
assigned participants to their 
groups 
 211 
Blinding 
(masking)† 
11A 
 
Whether or not participants, 
those administering the 
interventions, and those 
assessing the outcomes were 
blinded to group assignment 
Whether or not those 
administering co-interventions 
were blinded to group 
assignment 
211 
 11B  If blinded, method of blinding 
and description of the similarity 
of interventions† 
215 
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Statistical 
methods† 
12 Statistical methods used to 
compare groups for primary 
outcome(s); methods for 
additional analyses, such as 
subgroup analyses and 
adjusted analyses 
When applicable, details of 
whether and how the 
clustering by care providers or 
centers was addressed 
220-222 
Results     
Participant flow† 13 Flow of participants through 
each stage (a diagram is 
strongly recommended)---
specifically, for each group, 
report the numbers of 
participants randomly 
assigned, receiving intended 
treatment, completing the 
study protocol, and analyzed 
for the primary outcome; 
describe deviations from 
study as planned, together 
with reasons 
The number of care providers 
or centers performing the 
intervention in each group and 
the number of patients treated 
by each care provider or in 
each center 
220, 213 
Implementation 
of intervention† 
New 
item 
 Details of the experimental 
treatment and comparator as 
they were implemented 
217-218 
Recruitment 14 Dates defining the periods of 
recruitment and follow-up 
 211 
Baseline data† 15 Baseline demographic and 
clinical characteristics of 
each group 
 
When applicable, a description 
of care providers (case 
volume, qualification, 
expertise, etc.) and centers 
(volume) in each group 
224-225 
Numbers 
analyzed 
16 Number of participants 
(denominator) in each group 
included in each analysis and 
whether analysis was by 
“intention-to-treat”; state the 
results in absolute numbers 
when feasible (e.g., 10/20, 
not 50%) 
 222 
Outcomes and 
estimation 
17 For each primary and 
secondary outcome, a 
summary of results for each 
group and the estimated 
effect size and its precision 
(e.g., 95% confidence 
interval)  
 235 
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Ancillary 
analyses 
18 Address multiplicity by 
reporting any other analyses 
performed, including 
subgroup analyses and 
adjusted analyses, indicating 
those prespecified and those 
exploratory 
 235-247 
Adverse events 19 All important adverse events 
or side effects in each 
intervention group 
 231 
Discussion     
Interpretation† 20 Interpretation of the results, 
taking into account study 
hypotheses, sources of 
potential bias or imprecision, 
and the dangers associated 
with multiplicity of analyses 
and outcomes 
In addition, take into account 
the choice of the comparator, 
lack of or partial blinding, and 
unequal expertise of care 
providers or centers in each 
group 
248-249 
Generalizability† 21 Generalizability (external 
validity) of the trial findings 
Generalizability (external 
validity) of the trial findings 
according to the intervention, 
comparators, patients, and 
care providers and centers 
involved in the trial 
Study had 
no 
definitive 
results 
250 
Overall 
evidence 
22 General interpretation of the 
results in the context of 
current evidence 
 250-251 
*Additions or modifications to the CONSORT checklist. CONSORT = Consolidated Standards of Reporting 
Trials. 
†This item was modified in the 2007 revised version of the CONSORT checklist. 
 
